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Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the 
second most frequent cause of cancer-related mortality worldwide. HCC predomi-
nantly arises in cirrhotic livers as a consequence of underlying chronic diseases in-
cluding viral hepatitis, alcoholic liver disease and non-alcoholic steatohepatitis. 
Treatment options for advanced HCC are limited. Sorafenib (Nexavar®) has been 
the only approved drug for the management of advanced HCC for the past ten years. 
Recently, additional multikinase inhibitors entered the clinic, however, without signifi-
cantly improving overall survival as compared to sorafenib. Major advancements are 
expected to be achieved with the introduction of immune checkpoint inhibitors such 
as nivolumab (Opdivo®), but biomarkers to identify patients who may benefit from 
the treatment are currently missing. Moreover, several additional drugs have failed to 
meet clinical end points in large phase III trials, indicating a need for new drug dis-
covery for HCC.  
 
A major obstacle for the development of new therapies is the lack of suitable pre-
clinical animal models or cell culture systems that allow a faithful translation of basic 
research findings into the clinical setting. This thesis describes the generation of or-
ganoids derived from needle biopsies of HCCs. The use of tumor biopsies instead of 
surgically resected HCC specimens is important because it allows to generate or-
ganoids from all tumor stages, whereas surgical resection of HCCs is limited to a mi-
nority of patients with small, early stage tumors. These tumors are typically not treat-
ed with systemic therapies, and material derived from them might have limited value 
for developing new treatments for advanced HCCs.  
 
Because of the very limited amount of tissue that can be obtained with a needle bi-
opsy, generation of HCC organoids was technically challenging. A key to our suc-
cess was the immediate sample processing. The biobank of tumor organoids de-
scribed in this study encompasses different etiologies and, most importantly, all clini-
cal tumor stages. Our study design also allowed to compare the organoids with the 
originating tumor biopsies. We found that HCC organoids preserve the morphological 
characteristics and tumor marker expression of their originating tumors. Moreover, a 
comprehensive analysis of the genetic landscape in both, primary tumors and corre-
sponding organoids, revealed a high concordance of the molecular alterations and 
the genetic heterogeneity, confirming that the organoids are a genuine representa-
tion of the originating tumors. In addition, tumor organoids can be successfully trans-
planted and propagated in immunodeficient mice to generate xenografts. Finally, in a 
proof of concept study, we show that tumor organoids can be used to test sensitivi-
ties to clinically-relevant drugs and provide a promising novel tool for developing tai-
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3.1. The human liver 
The liver is one of the largest and micro-anatomically most complex organs of the 
human body given its numerous functions required for maintaining whole-body ho-
meostasis. Liver function can be summarized in five classes: (I) uptake of nutrients 
derived from the intestines, supplied by the portal vein; (II) metabolic biosynthesis, 
conversion, and degradation of endogenous compounds; (III) detoxification of exog-
enous compounds; (IV) supply of the body with essential metabolites and nutrients; 
and (V) excretion of compounds with the bile1,2. All these functions are carried out by 
the main cell type in the liver, the hepatocyte. An estimate of 2.4×1011 hepatocytes 
are present in the liver, accounting for ~80% of its total mass3. Cholangiocytes or bile 
duct cells build up the whole intra- and extrahepatic biliary tree and represent the 
second most frequent cell type in the liver, accounting for ~3% of the total cell num-
ber4. Bile produced by the hepatocytes is transported via the bile ducts to the 
gallbladder where it is stored until its controlled release during digestion1. Kupffer 
cells represent the macrophages of the liver and function as scavengers of foreign as 
well as endogenous material4. The hepatic stellate cells only account for ~1.4% of 
the total cell number in the liver but play a central role in the maintenance of the ex-
tracellular matrix (ECM) and the regenerative response upon liver injury (discussed 
below)4.  
The functional unit of the liver is the liver lobule2,4. The rough shape of a lobule is 
hexagonal with every corner harboring a portal triad, consisting of one hepatic artery, 
one portal vein, and one bile duct, respectively (Figure 1). The lobule is constituted of 
hepatocytes lined towards the center where a central vein is located. The hepato-
cytes within a lobule can be divided into three zones from the portal space towards 
the central space. Liver zonation is based on the spatial distribution of different met-
abolic enzymes along the three zones due to oxygen- and nutrient gradients from the 
periportal to the pericentral space2,5 (Figure 1). Nutrient-rich blood from the intestine 
and oxygen-rich blood enter the liver through the portal vein and hepatic artery, re-
spectively. From each portal triad, the blood flows through the hepatocyte plates in 
so-called sinusoids towards the central vein (Figure 1). During its flow, the blood 
comes in close contact with the hepatocytes thanks to the fenestrated endothelium of 
the sinusoids4. On the other hand, bile acids and salts are released into bile canalicu-
li — formed between adjacent hepatocytes — and flow in retrograde direction into 
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the bile duct of the portal triad for further transport into the gallbladder (Figure 1). The 
three-dimensional architecture of the liver lobule is central to liver function but also 




Figure 1. Architecture of the liver lobule and the basic organization of the periportal-to-pericentral axis. Nutrient-rich, 
mildly-oxygenated blood enters the liver through the portal vein and flows towards the central vein. Oxygen-rich blood 
enters the liver through the hepatic artery and flows in the same direction where it mixes with portal blood inside the 
sinusoids. Bile produced by the hepatocyte flows in the retrograde direction towards the bile duct. The portal vein 
contributes to 80% of the total blood flow entering the liver, the remaining 20% are supplied by the hepatic artery. 
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3.1.1. Liver development 
Knowledge about the mechanisms underlying the development of an organ is fun-
damental for the understanding of its maintenance and regeneration in the adult 
stage. Like all the other organs of the digestive tract, the liver is formed from cells 
arising from the endodermal germ layer (Figure 2A)6,7. The definitive endoderm — 
initially a monolayer of cells at the ventral side of the developing embryo — forms a 
tube that is patterned into three different regions: foregut, midgut, and hindgut2,8. The 
foregut endoderm will later give rise to the liver, specifically to hepatocytes and chol-
angiocytes (Figure 2A)8.  
 
 
Figure 2. Schematic representation of fetal liver development. (A) Schematic lineage from definitive endoderm to 
hepatocytes and cholangiocytes. The factors indicated within the cells are needed for the transition in that specific 
developmental stage. (B) Liver diverticulum and bud formation. (C)  Hepatoblast maturation into hepatocytes and 
cholangiocytes. Abbreviations: ST: septum transversum; EC: endothelial cell; HE: hepatic endoderm. Figure obtained 
and modified from Gordillo et al.8 
 
Liver development is initiated with the formation of a diverticulum that is followed by 
the outgrowth of the liver bud (Figure 2B)8,9. These tissue remodeling steps are pre-
cisely coordinated by surrounding cells of the septum transversum and cardiac mes-
oderm that both provide the required morphogens such as Bone Morphogenetic Pro-
teins (BMPs) and Fibroblast Growth Factor (FGF)8,9. The transition from diverticulum 
to liver bud consists in the differentiation of foregut endodermal cells into bipotent 
hepatoblasts, the progenitor cells of hepatocytes and cholangiocytes8,9. Hepatoblasts 
are marked by the expression of two specific hepatic transcription factors, Hepato-
cyte Nuclear Factor 1b and 4a (HNF1b and HNF4a, respectively), as well as Alpha-


































































Fetoprotein (AFP), the most abundant plasma protein in the fetus8. With continuing 
embryonic growth, the hepatoblasts increase in number and start to differentiate into 
hepatocytes, that will exclusively express HNF4a, and cholangiocytes, that will ex-
clusively express HNF1b8. The generation of hepatocytes and cholangiocytes from 
hepatoblasts is spatially regulated by the portal mesenchyme (Figure 2C). Hepato-
blasts that are close to the portal mesenchyme will differentiate into cholangiocytes, 
in particular under the influence of the NOTCH- and Transforming Growth Factor b 
(TGFb) signaling pathways, while the hepatoblasts located further away will differen-
tiate into hepatocytes2,8,9. 
 
3.1.2. Facultative stem cells and liver regeneration 
The regenerating capability of the liver is by far its most intriguing feature that has 
fascinated researchers for decades. As for every other organ, the liver also needs to 
maintain and repair its tissue to endure for long time intervals. Under homeostatic 
conditions the proliferation rate of hepatocytes is very low and they usually persist for 
weeks to months without cell division10. However, upon tissue injury, e.g. due to tox-
ins, viruses, or physical damage, the liver is able to initiate a potent proliferative pro-
gram that replenishes the lost cell pool within a very short time frame. Since dec-
ades, partial hepatectomy — a procedure by which up to two thirds of the liver mass 
are surgically removed — has been the most widely used model to study liver regen-
eration10. This type of experiments, already performed in the rat model decades ago, 
highlight the massive regenerative potential because the missing liver mass is recov-
ered within only a week after surgery11. 
The source of regenerating hepatocytes following liver injury is a controversial topic 
and not completely understood. Some organs, such as the small intestine, harbor a 
very well established and characterized stem cell niche12. The short-lived epithelium 
of the small intestine is constantly replenished by the rapidly proliferating stem cells 
residing in the crypts13. Regarding the liver, two main ideas dominate the field of liver 
regeneration: (i) the presence of facultative stem cells that repopulate the liver upon 
injury, and (ii) the proliferation of pre-existing hepatocytes re-entering the cell cycle. 
The truth lays in between. Depending on the type of injury, pre-existing hepatocytes 
are able to re-enter the cell cycle and rapidly replenish the missing cell pool14-16. This 
type of proliferative response is mostly observed in partial hepatectomy-based injury 
models. On the other hand, several groups reported the injury-mediated emergence 
of a facultative stem cell population that replenishes the organ10. These facultative 
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stem cells share some phenotypic characteristics of bile duct cells and were initially 
referred to as “oval cells” because of their atypical appearance compared to the ac-
tual ductal cells10. Oval cells were described to appear following toxin-mediated liver 
injury and to reside at the interface between hepatocytes and cholangiocytes within 
the Canal of Hering10,17 (Figure 1). They display bipotential progenitor features be-
cause of their ability to differentiate into hepatocytes as well as cholangiocytes, anal-
ogous to hepatoblasts during embryonic liver development14. Recently, increasing 
number of research groups refined the definition of oval cells or proposed new con-
cepts of liver regeneration: generation of hepatocytes from SOX9+ bile duct cells18, 
later refuted by another study19; generation of hepatocytes from bile duct-derived 
“buds” in cirrhotic livers20; proliferative ducts derived from dedifferentiated chronically-
injured hepatocytes21; bipotent progenitors of biliary origin that repopulate hepato-
cytes and cholangiocyte pools22; hybrid hepatocytes with ductal features23; and direct 
lineage conversion of bile duct cells into hepatocytes24. The above-mentioned stud-
ies all share one characteristic: the facultative stem cell pool resides at the periportal 
side of the liver lobule (i.e. adjacent to the portal triad). Facultative because all the 
described putative stem cells only appear after injury. Only one study so far de-
scribed a putative liver stem cell population residing at the pericentral (i.e. adjacent to 
the central vein) side25, however, the stem cell features attributed to these cells are 
most probably shared by all hepatocytes independently of their zonal position within 
the liver lobule15.  
In conclusion, liver regeneration is a very robust process and includes different pro-
grams of cell cycle reactivation. Whether this is occurring in terminally differentiated 
hepatocytes or bipotent progenitors may depend on the type of injury and/or the in-
sulted cell type. 
 
3.2. Hepatocellular carcinoma 
Cancer is a major global health burden and a leading cause of death worldwide. In 
2016, 8.9 million people died of cancer worldwide, with primary liver cancer (PLC) 
representing the fourth most common cause of cancer-related deaths26. Of all PLCs, 
hepatocellular carcinoma (HCC) accounts for about 75%–85% of the cases, whereas 
10%–15% are intrahepatic cholangiocellular carcinomas (CCC)27. Each year about 
1’000’000 people are diagnosed with HCC and about 830’000 people die as a con-
sequence26. The incidence increases with age, reaching a peak at 70 years28. More-
over, the prevalence is four times higher in men compared to women26. In the past 
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25 years, the incidence of HCC doubled and was paralleled by increasing mortality 
rates26,29. A recent projection of the worldwide HCC incidence rate until 2030 using 
age-period-cohort models, revealed that the overall incidence is predicted to rise in 
both sexes, however, geographical exceptions are expected27. For Asian countries 
like China, Japan and Singapore — currently accounting for over 50% of HCC cases 
worldwide — the incidence rates are predicted to decline due to better control of the 
related underlying risk factors, mostly hepatitis B and C virus infections27. On the 
other side, HCCs associated with obesity and its metabolic complications are pre-
dicted to increase, in particular in the United States and western European 
countries27. A better understanding of the factors and pathogenic mechanisms con-
tributing to HCC development is therefore of crucial importance for improving disease 
control rates and reducing the growing incidence and mortality rates.   
 
3.2.1. Etiologies and risk factors 
Chronic liver disease (CLD) is closely associated with the development of HCC. 
About 90% of HCCs occur in the background of CLD30. The risk factors leading to 
CLD, and consequently the same responsible for HCC development, are well de-
fined: hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcoholic 
liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), exposure to aflatoxin 
B1 (AFB1) and to a minor extent genetic disorders such as Morbus Wilson and he-













Table 1. Geographical distribution of the main risk 
factors of HCC. AAIR: Age-adjusted incidence rate. 
Table obtained from the EASL-EORTC clinical prac-
tice guidelines30.  
 
Most of these risk factors lead to liver cirrhosis, present in 90% of all HCCs32. World-
wide, the incidence of HCC is heterogeneous because of the geographical variation 
in the prevalence of the various risk factors (Table 1; Figure 3). Most of the HCC 
cases occur in eastern Asia and sub-Saharan Africa, where HBV infection and afla-
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toxin B1 represent the major risk factors. In contrast, the main cause of HCC in 
Western Europe and the United States is attributed to HCV infection and alcohol 
abuse30,33 (Table 1). In developed countries, NAFLD and its more advanced and se-
vere form NASH (non-alcoholic steatohepatitis) are emerging causes of HCC com-





Figure 3. Age-standardized global incidence of HCC. Figure obtained from Llovet et al.33 
 
Hepatitis B virus. Chronic hepatitis B (CHB) infection, occurring in 5-10% of infected 
individuals, is the major risk factor for the development of HCC, accounting for 54% 
of all cases worldwide30. The highest prevalence of CHB can be found in Asian and 
sub-Saharan countries33,35 (Figure 3), although the incidence is decreasing due to 
improved socioeconomic status and the implementation of broad vaccination pro-
grams36.    
HBV belongs to the Hepadnaviridae family of DNA viruses and harbors a partially 
double-stranded circular genome with a total size of 3.2 kb37. Upon hepatocyte entry 
through the Sodium Taurocholate Cotransporting Polypeptide (NTCP) receptor, the 
viral genome is converted to covalently closed circular DNA (cccDNA) that serves as 
template for the transcription of viral RNA from its four open reading frames 
(ORF)37,38. The virus replicates itself through a pre-genomic RNA intermediate. The 
four proteins encoded by HBV are the surface envelope protein S (HBs); the core 
protein C (HBc, forming the viral capsid); the viral polymerase P; and the X protein 
Age-standardized liver cancer
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(HBx)37,38. The latter was shown to alter several of the host’s cellular processes, but 
the exact function and its presumed direct carcinogenic properties have been a mat-
ter of debate for years39.  
The molecular pathogenesis underlying HBV-associated HCC development can be 
divided into direct and indirect mechanisms. Direct carcinogenesis can be a result of 
insertional mutagenesis and/or the alteration of cellular pathways by HBV-encoded 
proteins. Because of its DNA nature, HBV can integrate into the host genome and 
potentially alter (cancer) gene expression40,41. The fact that HBV integration events 
were initially detected in HCC tissues of HBV-infected patients and HCC cancer cell 
lines lead to the initial hypothesis that virus integration was the cause of HCC tumor-
igenesis42-45. However, whole genome sequencing of HCCs from HBV-positive pa-
tients revealed a random HBV integration pattern at many different sites in the ge-
nome with only a few recurrent hotspots46. This notion, therefore, does not fully sup-
port a classic cis-acting insertional mutagenic mechanism as the main driving event 
of HCC47,48. On the other hand, viral proteins — expressed from integrated or non-
integrated HBV — were shown to contribute to HCC carcinogenesis by directly af-
fecting oncogenic pathways in the host cell41,49. The most acclaimed one, HBx, has 
been shown to alter gene expression, increase proliferation and prevent apoptosis, 
however, direct evidence from human tissue samples is missing since most of these 
observations were made in cell culture and/or animal models39,41,49.  
Indirect mechanisms of HBV-induced HCC pathogenesis are generally immune me-
diated. The immune response to HBV-infected cells results in hepatocyte death and 
inflammation of the surrounding tissue38,49. Thus, chronicity of hepatitis B, leads to 
persistent inflammation that combined with increased hepatocyte proliferation can 
contribute to cirrhosis and accumulation of oncogenic mutations ultimately leading to 
HCC49,50.  
 
Hepatitis C virus. HCV is the second most frequent risk factor of HCC, accounting 
for 31% of all cases30. Chronic hepatitis C (CHC) infection is the leading cause of 
HCC development in Japan, Western Europe and North America30. The recent intro-
duction of highly effective direct-acting antivirals (DAA) markedly improved HCV 
treatment outcome which may, in principle, result in complete eradication of the dis-
ease51-53. 
HCV belongs to the Flaviviridae family of RNA viruses and harbors a 9.6 kb long, 
positive sense, single-stranded genome encoding a large polyprotein from one single 
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ORF52. The ORF is flanked by untranslated regions on both ends, which function as 
regulatory units for the synthesis of viral RNA and proteins. The polyprotein is co- 
and post translationally modified by host cellular and viral proteases to yield structur-
al proteins such as viral capsid and envelope, and non-structural proteins such as 
viral proteases and RNA polymerase52.  
The pathogenesis of HCCs associated with HCV is also based on direct and indirect 
mechanisms. Compared to HBV and its progression to CHB, HCV results in chronic 
infection in a much larger proportion of infected individuals, with 60%–80% of all pa-
tients developing chronic disease38.  
Direct carcinogenic mechanisms are mainly a result of altered cellular processes, 
such as activation of oncogenic signaling pathways, interaction with tumor suppres-
sors like TP53 and/or RB, interference with the DNA damage repair machinery, in-
duction of oxidative stress and inhibition of apoptosis49. 
As for CHB, indirect mechanisms of CHC-associated HCC carcinogenesis are medi-
ated by the host immune system49. The immune response to chronic infection leads 
to liver inflammation and, as a result, increased hepatocyte proliferation that elevates 
the risk to accumulate oncogenic mutations eventually leading to HCC 
development49,50. 
 
Alcoholic liver disease. Heavy use of alcohol for prolonged time is a frequent risk 
factor for HCC development28,33. Depending on the geographic area, 10%–20% of 
HCCs can be attributed to alcohol abuse and its consequences30. Daily alcohol con-
sumption in the range of 40–80 g ethanol (EtOH) intake is a strong predictor of ALD, 
however, only 35% of heavy drinkers will eventually display a severe disease course 
that includes hepatitis, fibrosis and cirrhosis54,55. 
The expression of enzymes involved in EtOH detoxification, most importantly Alcohol 
Dehydrogenase (ADH) and Cytochrome P450 2E1 (CYP2E1), are highest in hepato-
cytes54. EtOH breakdown generates byproducts that deregulate the intracellular re-
dox potential and favors the generation of fatty acids (FA)54,56. Increased amounts of 
FA are deposited as triglycerides within lipid droplets and contribute to the progres-
sion to alcoholic steatosis54,56. The further pathogenic mechanisms leading to pro-
gression from alcoholic steatosis towards hepatitis, fibrosis, cirrhosis and eventually 
HCC, are associated with immune cell-mediated liver inflammation50,54,56. As in the 
case of chronic viral hepatitis, the permanently inflamed tissue results in an environ-




Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Several 
large-scale cohort studies showed that the risk to develop cancer, including HCC, is 
higher in overweight/obese individuals57. NAFLD is an emerging cause of HCC de-
velopment related to obesity, diabetes and the metabolic syndrome. The disease 
presents as non-physiological, increased fat accumulation in the hepatocytes that, in 
a subset of the cases, can progress to a hepatitis and cause NASH34,57. In a recent 
European study, nearly all (= 94%) obese patients were found to have NAFLD, and 
about 25% had NASH57. Moreover, because of the rising prevalence of obese indi-
viduals, NAFLD is close to become the main risk factor for HCC development in the 
United States and Europe, offsetting the reduction of CHC-related HCC mortality 
reached with year-long global public health programs34,57,58.   
NAFLD-associated HCCs might be the exception of the general rule that HCC is 
generally associated with advanced fibrosis or cirrhosis57. Indeed, different groups 
reported that up to ~50% of patients with NAFLD or NASH did not have a back-
ground of cirrhosis34,59,60. The pathophysiology of the progression from NAFLD to 
NASH, cirrhosis and eventually HCC is a result of tissue inflammation and oxidative 
stress mediated by lipid accumulation34,57. For NAFLD patients that progress to HCC 
without cirrhosis development, the pathophysiologic mechanisms are less clear but 
likewise involve insulin resistance associated with oxidative stress and inflammation 
of the liver parenchyma34,57,61. 
 
Aflatoxin B1. AFB1 is a toxin produced mainly by two fungal species, Aspergillus 
flavus and Aspergillus parasiticus62. Unproperly stored food may cause fungal growth 
and contamination by their toxins. Most HCC cases associated with AFB1 can be 
found in sub-Saharan Africa and southeast Asia, because of the local climatic condi-
tions that favor the growth of fungal species63. In Africa, particularly in Sudan, AFB1 
is a frequent cofactor in HBV-induced HCCs33,63,64. 
The pathogenicity of AFB1-induced carcinogenesis can be explained by the toxin’s 
ability to produce DNA adducts and therefore induce DNA damage, strand break and 
ultimately mutations63. Moreover, the specific liver toxicity is due to the biotransfor-
mation and conversion of AFB1 to a reactive compound by Cytochrome P450, which 
is highly expressed in hepatocytes63.  The most common mutation associated with 




Inherited diseases. Together with extrinsic (HBV, HCV, EtOH, AFB1) and intrinsic 
(e.g. lipids in NAFLD and NASH) etiological agents, inherited disorders that cause 
liver fibrosis, cirrhosis or inflammation can also potentially lead to the development of 
HCC.  
Hereditary haemochromatosis (HH), an autosomal recessive condition that results in 
iron overload within hepatocytes, increases the risk to develop HCC65,66. The in-
creased amount of intracellular iron favors the formation of free radicals and oxida-
tive stress that consequently damage the tissue and lead to inflammation that does 
not necessarily culminate in the development of fibrosis or cirrhosis65,66. 
Morbus Wilson is an autosomal recessive disease that manifests with hepatic and 
neurologic symptoms due to excessive copper depositions in liver and brain of af-
fected individuals, as a result of abnormal copper metabolism in hepatocytes67. The 
association between Morbus Wilson and HCC is not very firm because of the very 
low number of cases66,68. The mechanisms leading to HCC development in patients 
with Morbus Wilson can be attributed to persistent liver damage as a consequence of 
copper overload within the hepatocytes and the associated cycles of regeneration 
that may lead to fibrosis and cirrhosis in the long-term66,68. As a summary, these and 
other rarely occurring hereditary disorders account for less than 10% of all HCC cas-
es worldwide30,33. 
 
3.2.2. The conceptual framework of HCC pathogenesis 
The etiological factors described above share common ground on how they contrib-
ute to the progression from a diseased liver to HCC development. As outlined before, 
most of the HCCs occur on the setting of chronic liver disease, that can develop be-
cause of different agents such as viruses, toxins, ethanol or hereditary diseases. In 
the majority of cases, the risk factors culminate in the development of cirrhosis, a 
process taking several years to decades, explaining why HCC typically occurs in old-
er patients50. The pathophysiology of HCC can be summarized in a conceptual 
framework involving the progressive gain of cancer hallmarks69. The progression 
from a healthy liver to HCC starts with hepatocyte injury by the etiological agent fol-
lowed by hepatocyte death and regeneration33,50 (Figure 4). Sustained hepatocyte 
injury due to chronic liver disease and persistence of the etiological factors results in 
repetitive cycles of hepatocellular necrosis and compensatory proliferation33,50. This 
process is accompanied by an increment of tissue inflammation mediated by the in-
nate and adaptive immune system33,50. Year-long liver damage reduces the hepato-
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cyte’s regenerative potential and leads to tissue scarring through excessive collagen 
deposition, eventually resulting in the progression from fibrotic scars to complete cir-
rhosis33,50. Throughout this process, somatic mutations and epigenetic modifications 
in driver and passenger genes are acquired and selected, resulting in a stepwise se-
quence from initially low-grade dysplastic nodules to high-grade dysplastic nodules 




Figure 4. Pathogenesis of HCC development. Despite different insults such as viruses or toxins, the pathophysiology 
of HCC is comparably similar. Chronic hepatocyte damage results in compensatory proliferation and tissue scarring 
followed by genetic and epigenetic alterations that induce cancer formation. Figure obtained from Farazi et al.50 
 
3.2.3. Prevention – Diagnosis – Treatment 
In the past years most of the progress in the HCC field was made in its prevention, 
diagnosis and treatment. The following sections recapitulate the most important as-
pects.   
 
Prevention. HCC belongs to those cancers for which prevention is possible. As pre-
viously described, patients with CLD display high risks to develop HCC, and there-
fore, controlling the progress to CLD could prevent HCC tumorigenesis28. The best 
example is the vaccination program against HBV that reduced the incidence of HCC 
in countries with high prevalence of HBV-infected individuals33,70. Furthermore, inter-
feron- and/or DAA-based therapies against HCV infection can lead to the cure of 
CHC, however, when patients already progressed to cirrhosis before virus eradica-






































moderate alcohol intake, can contribute to reduce the risk to develop diabetes, 
NAFLD and ALD respectively72. 
 
Surveillance and diagnosis. Beside the prevention of HCC, by avoiding the risk 
factors, or by early treatment of the underlying liver diseases, surveillance of patients 
affected by CLD plays an equal central role in reducing HCC-related morbidity. HCC 
typically causes symptoms only in patients with advanced disease. At this pro-
gressed stage, patients usually can’t undergo curative treatments anymore. Howev-
er, because HCCs have relatively long sub-clinical incubation periods, patients with 
known CLD can be included in surveillance programs that aim at detecting HCCs at 
early-stage.  In general, both the American- and European Associations for the Study 
of the Liver (AASLD and EASL, respectively) recommend the surveillance of patients 
with cirrhosis, owing to any cause, because previous studies clearly demonstrated 
improved survival rates73,74. Both associations also recommend the surveillance in 
patients with HBV or HCV infections associated with advanced fibrosis or cirrhosis, 
or in a subset of HBV patients without cirrhosis but with specific ethnical character-
stics73,74. Currently, patients with ALD or NAFLD/NASH are included in surveillance 
programs only in cases with associated cirrhosis73,74. Generally, surveillance consists 
of ultra-sound (US) alone or in combination with serum AFP measurements, a com-
mon biomarker of HCC, whose expression normally restricts to the fetal developmen-
tal stage73,74. 
 
Once a nodule is detected in the liver of a patient with CLD by US modality, two main 
diagnostic procedures can be used to confirm the finding, (i) non-invasive radiologi-
cal imaging, such as contrast-enhanced computer tomography (CT) or magnetic res-
onance imaging (MRI) — with or without complementary AFP measurements — and 
(ii) tissue biopsy collection. 
Radiological diagnosis can be of high specificity and sensitivity in patients with cir-
rhosis73,74. This is due to the dual blood supply of the liver and the particular vascular 
profile of HCCs. The majority of the blood in the liver enters through the portal vein, 
that carries nutrient-rich and oxygen-poor blood, while the remaining minority is sup-
plied by the hepatic artery that provides oxygen-rich blood75. HCCs are predominant-
ly vascularized through neoangiogenesis from the hepatic artery because of the high 
oxygen demand by tumor cells75. This feature can be used to specifically recognize 
an HCC nodule due to its dense contrast enhancement in the arterial phase, i.e. indi-
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cating arterial blood supply, followed by a decreased signal in the portal venous 
phase75. However, not every HCC nodule can be diagnosed with this procedure. In 
such cases, especially in non-cirrhotic patients, tumor biopsies represent the diag-
nostic standard33,70. Histological diagnosis requires examination by experienced 
pathologists, particularly for early-stage HCCs that usually don’t present many visible 
tumorigenic abnormalities. Nevertheless, the use of specific markers (see below) and 
the comparison of tumor biopsies with those of adjacent non-tumor liver tissue can 
increase the specificity and ensure a precise diagnosis76. 
 
Treatment. After confirmed diagnosis of a HCC, the tumor is staged according to the 




Figure 5. The BCLC classification system. Figure obtained from Forner et al.70 
 
The BCLC staging system links tumor stage with appropriate treatment options and 
provides an evidence-based guide for the management of HCCs. HCC patients can 
be stratified into five different groups according to their disease stage: BCLC 0; A; B; 
C; and D77. Treatment modalities differ according to the disease stage.  
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Very early- to early-stage disease patients, i.e. BCLC 0 and A respectively, benefit 
from potentially curative treatments such as surgical resection of the tumor or liver 
transplantation (Figure 5). The requirements for these treatment options however, 
are a well-preserved liver function, e.g. no cirrhosis; and the absence of portal hyper-
tension70,77. Because several HCCs are detected at later stages and/or with underly-
ing CLD, only a minority of patients are surgically treated. This important circum-
stance is also a major limitation for the collection of tumor tissue for research pur-
poses (discussed in more detail below). Patients with early-stage HCCs that don’t 
meet the criteria for surgery, are then usually treated with thermal ablation, either 
with radiofrequency thermal ablation (RFTA) or more recently with microwave-
mediated ablation33,70,77.  
Tumors of patients with intermediate-stage disease, i.e. BCLC B, are predominantly 
treated with transcatheter arterial chemoembolization (TACE, Figure 5). Treatment 
consists of small beads loaded with a chemotherapeutic agent, typically doxorubicin, 
that are administered through the main tumor-supplying artery, resulting in the embo-
lization of the tumor by obstruction of the vessels combined with local release of the 
drug33,70. Alternatively, patients can be treated with selective internal radiation thera-
py (SIRT), whereby the beads are loaded with compounds containing b-radiation-
emitting isotopes such as yttrium-9033,70. 
Patients with advanced-stage disease, i.e. BCLC C, receive systemic treatments in 
the form of targeted therapies33,70,78 (Figure 5). Sorafenib (Nexavar®), a multikinase 
inhibitor targeting cancer cells as well as angiogenesis79, was shown to increase sur-
vival from 7.9 months in the control group to 10.7 months in the treated group in a 
landmark clinical trial taking place ten years ago80. The survival benefit in sorafenib-
treated patients is obviously marginal and the efficacy is limited due to side effects 
and the occurrence of drug resistance. Nevertheless, sorafenib is still the primary 
choice for the first-line treatment of HCC patients, given the fact that for ten years 
following its approval no additional targeted therapy met the desired clinical end-
point81. Very recently, lenvatinib (Lenvima®) resulted non-inferior to sorafenib in the 
first-line setting82, while four additional drugs — regorafenib (Stivarga®)83; cabozan-
tinib (Cabometyx®)84; ramucirumab (Cyramza®)85; and nivolumab (Opdivo®)86 — 
improved the clinical outcome as second-line treatments in patients progressing un-
der sorafenib. However, the manageability of advanced HCCs using these new ther-
apies will require further evaluation in the daily clinical setting. 
Lastly, patients with end-stage disease, i.e. BCLC D, have very short life expectancy 
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and are supported with palliative care33,70 (Figure 5). 
 
3.2.4. Histopathological features of HCC 
Heterogeneity is a known feature of HCCs, either at the molecular level (discussed 
below) as well as at the histological level. The pathological evaluation of HCC biop-
sies or surgically-resected tumor specimen includes the determination of the growth 
pattern; differentiation grade; presence of immune cell infiltrates; necrosis; and other 
important histopathological features that can strongly differ between patients. 
 
 
Figure 6. The three main morphological growth patterns of HCC. (A) solid growth pattern; (B) pseudoglandular 
growth pattern; and (C) trabecular growth pattern. Scale bar: 50 µM. (D) Micrographs displaying the four differentia-
tion grades according to Edmondson and Steiner. Micrographs obtained and adapted from Iavarone et al.87. 
  
HCCs can display different growth patterns that emphasize their heterogeneity. The 
most common are: solid; pseudoglandular or acinar; and trabecular88 (Figure 6 A-C). 
The differentiation or histologic grade describes the degree of abnormality between 
tumor and normal cells. Tumor cells within a low-grade tumor display few histologic 
abnormalities and closely resemble the normal tissue. The most common grading 
system for HCC was developed by Edmondson and Steiner in 195489. The Edmond-
son grading comprises a four-scale system from grade I to IV (Figure 6D)89. Grade I 
HCCs are difficult to diagnose because of their high similarity to normal hepatocytes. 
A B C
D I II III IV
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Grade II HCCs show more nuclear irregularity and pronounced nucleoli. Grade III 
HCCs display more variability in cellular size and shape compared to grade II and 
can harbor angulated nuclei. Grade IV HCCs show the highest degree of cellular var-
iability and in some cases can contain anaplastic giant cells. In cases of low-grade, 
difficult to recognize HCCs, a combination of immunohistochemical markers — 
Glypican-3; Glutamine Synthetase; and Heat Shock Protein 70 — was shown to in-
crease the specificity of diagnosis and helping in discriminating low-grade HCCs from 
benign dysplastic nodules76.  
 
3.2.5. The molecular landscape of HCC 
The development of HCC involves a long process of tumorigenesis typically starting 
from liver cirrhosis caused by different etiological factors. Cirrhotic nodules are non-
neoplastic regenerative nodules surrounded by scar tissue, mostly collagen. These 
nodules can develop into low-grade dysplastic nodules followed by high-grade dys-
plastic nodules, finally giving rise to very early- to early-stage (BCLC 0 and A) 
HCCs33 (Figure 7).  
 
 
Figure 7. Progression of cirrhosis to early-stage HCC. TERT promoter mutations occur early during HCC carcino-
genesis and are present in >50% of early-stage HCCs. Alterations in several pathways and cellular processes (right 
panel) occur during the progression from cirrhotic nodules to HCC. Figure obtained and modified from Llovet et al.33.  
 
This multistep process is accompanied by the accumulation of somatic genetic and 
epigenetic alterations that induce malignant transformation. HCCs contain between 
40 and 100 somatic non-synonymous mutations90, however, the number of mutated 
cancer driver genes within each tumor is typically ≤890,91. The different combinations 
of driver gene mutations together with the various etiological routes to hepatocarcin-
ogenesis, explains the complexity and heterogeneity of HCCs. 
The early mechanism of malignant transformation of hepatocytes is likely based on 
the activation of the Telomerase Reverse Transcriptase (TERT) gene92 (Figure 7) 
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resulting from mutations in the promoter region that lead to its constitutive expres-
sion92. These early mutations, already occurring within low- and high-grade dysplas-
tic nodules, are required to initiate hepatocarcinogenesis by enabling unlimited prolif-
eration of cirrhotic hepatocytes that would normally display a reduced regenerative 
potential or even replicative senescence. Indeed, TERT overexpression, either by 
promoter mutation or focal amplification, is observed in ~68% of HCCs93. 
In progressed HCC, the most commonly mutated genes are TP53 and CTNNB1 
found in 31% and 27% of the cases, respectively90 (Figure 8). Other frequently al-
tered genes (also including gene amplifications and deletions) belong to members of 
the WNT pathway (AXIN1 in 8% of the cases); the Retinoblastoma or cell cycle 
pathway (RB1, CDKN2A in 4% and 2% of the cases, respectively); and the family of 
chromatin remodelers (ARID1A, ARID2 in 7% and 5% of the cases, respectively)90. 
Interestingly, inactivating mutations in the Albumin (ALB) and Apolipoprotein B 
(APOB) genes were found in 13% and 10% of the cases, respectively90 (Figure 8). 
The hypothesized underlying rationale for mutations in the ALB and APOB genes is 
related to the fact that Albumin expression can account for up to 20% of cellular 
mRNA in hepatocytes and Very-low-density Lipoprotein (VLDL) secretion supported 
by APOB consumes great quantities of cellular energy90. Therefore, inactivating mu-
tations in ALB and APOB results in an increase of the tumor cell’s energetic re-
sources. Finally, frequently detected amplifications on chromosome 11 result in the 
overexpression of CCND1 and FGF19, that act as oncogenes by increasing cell 
growth and proliferation90. 
 
The analysis of transcriptomic data from large HCC cohorts revealed different mo-
lecular classifications of HCC94-97. Importantly however, none of the proposed molec-
ular classifications could be translated to daily clinical practice so far. The classifica-
tion systems reported by the different laboratories comprise distinct numbers of sub-
classes, from two to six, that don’t share characteristics between each other. This is 
why no consensus molecular classification system could be established so far. Some 
of the published molecular classification systems94,96 can be partially summarized 
into two main classes: the proliferation and the non-proliferation class78,98. The prolif-
eration class is characterized by the activation of the RAS/MAPK-, mTOR-, NOTCH-, 
and IGF signaling pathways; the amplification of the FGF19 locus; and the correla-
tion with poor histologic differentiation and worse outcome98. On the other hand, the 
non-proliferation class is characterized by the activation of the WNT pathway and by 
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a correlation with better outcome98. However, as before, also this attempt to merge 
different transcriptomic studies did not result in their translation into clinical practice. 
One critical limitation of the above-mentioned transcriptomic-based classifications is 
the use of surgically resected HCCs as tissue source. As outlined in section 3.2.3, 
surgical resection is only an option for a minority of HCC patients that usually don’t 
have cirrhosis. The bias introduced with this sample collection protocol might there-




Figure 8. The mutational landscape of HCC. The top panel shows the mutation rate for each tumor (total: 363 pa-
tients). The middle panel includes information about ethnicity, tumor differentiation grade, gender, and the underlying 
liver disease. The bottom panel shows the significantly altered genes and copy number alterations. Figure obtained 
from the TCGA consortium90. 
 
In an attempt to generate a meaningful molecular classification, our lab established a 
classification for HCCs based on needle biopsy specimens99. The use of needle bi-
opsies enabled the inclusion of a broad spectrum of HCCs in terms of disease stage, 
etiologies, and the presence and absence of cirrhosis. Paired non-tumor liver biop-
sies from each patient were used as control samples, in addition to a set of 5 normal 
liver biopsies from unrelated patients without history of HCC. The expected reduction 
of inter-individual variability with the use of paired biopsies as matched gene expres-
sion controls was not observed, yet the opposite happened as additional variations 
were introduced. Interestingly, when normalizing the HCC dataset to the 5 normal 
livers, the signature genes defining the different subclasses were equally differential-
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ing the normalization protocol to previously published HCC classification systems. 
This observation led to the conclusion that the different subclasses in current classifi-
cation systems are defined by expression level changes in a group of tumor-specific 
genes rather than subclass-defining genes. Finally, because of the heterogeneous 
nature of HCCs and the relatively low information content of single omics analyses, 
classification studies aiming at integrating different datasets (genomics, transcriptom-
ics, phospho-proteomics, metabolomics, etc.) could potentially culminate in a clinical-
ly meaningful classification system. 
 
3.2.6. Experimental models for the study of HCC 
Despite the broad heterogeneity of HCCs within and between patients, the possibili-
ties to study the biology of this cancer are currently limited to a variety of in vivo 
mouse models and a few frequently-used in vitro cancer cell lines as outlined below. 
 
Animal models. As for most of the biomedical research fields, current animal mod-
els of HCC rely on the versatility of the mouse (mus musculus) model system. Mouse 
models of HCC can be derived by chemical induction through toxins; genetic engi-
neering; and by xenotransplantation of tumor tissues100-102. 
HCCs in mice can be induced by different hepatotoxic/carcinogenic agents that are 
administered at young age. The underlying tumorigenic mechanism involves the he-
patic metabolic conversion of such compounds into reactive metabolites that in turn 
exert their carcinogenic activity, usually by directly affecting DNA integrity100-102. The 
same mechanism underlies the development of aflatoxin B1-related HCCs in human 
patients as described above. The most commonly used compounds are carbon tet-
rachloride (CCl4), diethylnitrosamine (DEN), and dimethylnitrosamine (DMN)100-102. 
Genetically-engineered mouse models offer the possibility to (partially) reproduce the 
molecular background of human HCCs in a tailored manner. The advancements in 
the field of genetic engineering, allowed the generation of hepatocyte-specific onco-
gene activation and tumor suppressor inactivation, respectively, e.g. by driving the 
Cre recombinase under the Albumin promoter102. So far, a large number of transgen-
ic mouse models of HCC was generated by targeting cellular processes such as the 
cell cycle machinery (TP53; c-MYC; E2F-1; SV40 T-antigen) and a variety of cellular 
signaling pathways (WNT; PI3K/AKT; EGF; IGF; HGF)102. Another option to induce a 
carcinogenic process within hepatocytes consists in the overexpression of viral pro-
teins originating from HBV and/or HCV that cause hepatocellular damage100-102.  
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Despite the advantages offered by transgenic mouse models, the major drawback 
remains the inability to reflect the process of tumorigenesis from hepatocyte insult to 
fibrosis, cirrhosis and eventually HCC, as it is occurring in patients. On the other 
hand, chemically-induced tumors follow the common path of HCC tumorigenesis by 
inducing inflammation and fibrosis. However, they typically fail to reproduce the mo-
lecular background of human HCCs. 
Patient-derived xenografts (PDX), are perhaps the closest in vivo models represent-
ing human cancer biology. To generate xenograft models, tissue fragments or cell 
lines derived from tumors are transplanted into immunodeficient mice, either subcu-
taneously or orthotopically102,103. Subcutaneous xenograft models facilitate tumor 
growth monitoring and measurement while orthotopic models might be necessary to 
enable growth of tumors with higher microenvironmental demands. Moreover, the 
use of primary tumor specimens rather than immortalized cancer cell lines allows to 
reproduce the complexity and heterogeneity of the primary tumor103. Therefore, PDX 
models have the potential to overcome the limitations of chemically-induced- and ge-
netically-engineered mouse models. Indeed, several groups reported the generation 
of HCC-derived PDX mouse models, however, they were all generated using surgi-
cally-resected HCC specimens104-108. In our group, we recently generated a collection 
of PDX mouse models derived from needle biopsies of HCCs with different disease 
stages and from patients with different etiologies, thereby reflecting the broad spec-
trum of patients, and the histological features and molecular landscape of the primary 
tumors (unpublished data).  
Current improvements in the PDX field aims at developing humanized PDX models 
that enable the generation of PDX mouse models with the presence of some compo-
nents of the immune system, such as tumor-reactive T cells103. This will enable the 
study of the interactions between the tumor and the immune system and support the 
evaluation of novel immunotherapies. 
 
Cell culture models. Cancer cell lines represent the workhorse of biomedical re-
search and pre-clinical drug development. They are easy-to-handle, broadly applica-
ble and generate low costs in terms of reagent usage, however, their generation is 
rather inefficient and requires selection and adaptation to 2D culture. About 30 HCC-
derived cell lines are publicly-available to the research community and most of them 
were recently characterized at the genomic level within the frame of the Cancer Cell 
Line Encyclopedia (CCLE) project109. All these cell lines were derived from surgically 
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resected HCCs and thus suffer from the same drawbacks outlined above that limits 
their representability of the HCC patients’ spectrum. Moreover, the most common 
cancer cell lines used in HCC research, HepG2 and HuH-7, were established dec-
ades ago, in 1979 and 1982, respectively110-112. A direct comparison of these cell 
lines to their primary tumors, especially in terms of genomic alterations, is therefore 
missing and the question how well they represent the original tumors remains unan-
swered. Importantly, the genetic evolution of these cell lines over time was not doc-
umented, thus, their original identity might have been remarkably altered since their 
establishment. Nevertheless, HuH-7 and HepG2 cells have demonstrated a remark-
able broad utility in basic hepatological research due to the retention of several 
hepatocyte-specific features as, among others, the expression of a variety of meta-
bolic enzymes, e.g. members of the Cytochrome P450 family, or the secretion of 
hepatocyte-specific proteins such as Albumin112. In addition, further adaptations and 
modifications to these cell lines rendered them permissive to infection with hepato-
tropic viruses such as HBV and HCV112. 
Recently, new cell lines were established, deeply characterized at the genomic and 
transcriptomic level, and compared to the primary tumor to evaluate the degree of 
representation113. Despite these efforts, they only partially represented the original 
tumor and their establishment did not add increasing value to the currently existing 
models. Most importantly, novel in vitro models will have to recapitulate the three-
dimensional architecture and cellular and genetic heterogeneity to provide novel 
possibilities for a better understanding of HCC biology. 
 
3.3. Organoid models in biomedical research  
The term “organoid” first appeared half a century ago in the context of classical de-
velopmental biology experiments, that involved simple dissociation and reaggrega-
tion experiments to study the mechanisms of organogenesis114. After several years of 
“silence”, the scientific community is now witnessing a revival of the organoid sys-
tem115. However, the current definition of an organoid has changed from what devel-
opmental biologist initially described. An organoid — as recently defined by Lancas-
ter and Knoblich — is a three-dimensional multicellular structure that, (i) contains 
multiple organ-specific cell types, (ii) recapitulates at least some of the organ-specific 
functions, and (iii) is spatially organized in a similar way as the original organ114. Or-
ganoids can be derived from pluripotent embryonic stem cells (ESCs); induced plu-
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ripotent stem cells (iPSCs); and organ-restricted multipotent adult stem cells 
(aSCs)114,116. 
 
3.3.1. Stem cell- and multipotent progenitor cell-derived organoids 
Back in 2007, Barker and colleagues succeeded in identifying and describing the 
stem cell niche of the small intestine and the colon13. The Wnt target gene Leucine-
rich repeat-containing G-protein coupled receptor 5 (Lgr5) was shown to be specifi-
cally expressed at the surface of cells residing at the bottom of the intestinal crypt 
and, to mark rapidly-dividing cells that could give rise to all differentiated cell types of 
the intestinal epithelium13. This discovery paved the way for the development of the 
organoid culture system, as we know it nowadays. 
Two years later, in an attempt to culture Lgr5+ stem cells in vitro, Sato and colleagues 
described the first organoid culture protocol that was entirely derived from single 
adult stem cells117. The protocol involved the isolation of Lgr5+ stem cells from the 
mouse intestine, their suspension in Matrigel droplets to allow 3D outgrowth and, im-
portantly, the addition of a highly specialized growth factor-enriched culture 
medium117 (Figure 9A). Alternatively, and more convenient, the culture can also be 
initiated by isolating single crypts, without the need to select for Lgr5+ stem cells117. 
The growth factors in the culture medium recapitulate the signals provided by the 
stem cell niche. The most important ones among these are Wnt3a and the Wnt-
agonist R-Spondin 1 (R-Spo1), two ligands that both drive the proliferation of stem 
cells in the intestine; Noggin, an inhibitor of BMP-mediated cell differentiation and cell 
cycle arrest; and Epidermal Growth Factor (EGF), a potent mitogen that activates the 
Mitogen-activated Protein Kinase (MAPK) pathway (Figure 9B). Interestingly, the mo-
lecular mechanisms of R-Spo1 activity were not known when the first organoid model 
was described but two years later the same group discovered that Lgr5 was actually 
the receptor of R-Spondins118. The organoid technology could be rapidly applied to 
other murine organs such as the liver119, pancreas120, stomach121, prostate122,123 and 
the esophagus124. Most of these organoid systems also rely on Lgr5+ stem or Wnt-
responsive multipotent progenitor cells and therefore, depending on the organ, the 
culture medium required only little modification, like for example the addition of single 
tissue-specific factors116,125. Remarkably, every organoid model described so far re-
capitulated some of the tissue-specific functions, e.g. albumin secretion and metabol-
ic activity in liver organoids119 or the expression of lysozyme and mucin in intestinal 
organoids117. The real breakthrough came with the protocol adaptations and modifi-
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cations that allowed the culture of human aSC-derived organoids. Human 
prostate122,123, intestine126, colon126, esophagus126, liver127, and pancreas128 could be 
readily reproduced as mini-organs using refined culture media recipes. The utility of 
the organoid models was further demonstrated by their ability to model human dis-
eases such as hepatic disorders127, gastric bacterial infection129, and cystic fibro-





Figure 9. The intestinal organoid culture system. (A) Single Lgr5+ stem cells are embedded in Matrigel and overlaid 
with growth factor-enriched medium. Organoids form within one week and self-organize to resemble the in vivo epi-
thelium with crypt and villus structure. (B) The crucial niche signals that are essential for the maintenance and ex-
pansion of Lgr5+ stem cells in vivo. Figure obtained and modified from Date et al.131. 
 
Importantly, because the growth of organoids relies on self-renewing stem- or pro-
genitor cells, they can be stably maintained in culture for several months without loss 
of their proliferative potential. In addition, deep sequencing studies revealed a re-
markable genetic stability, because only very few newly-acquired somatic mutations 
were detected in protein-coding genes116,127.  
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As of today, all the organoid systems derived from aSCs — isolated from tissue bi-
opsies — are of epithelial nature116,125 and the current culture conditions do not allow 
the simultaneous expansion of other cell types present in the tissue biopsy, e.g. fi-
broblasts or immune cells116,125. This represents a current limitation of this in vitro 
system. 
 
The majority of the organoid models can be derived from aSCs, however, the reper-
toire can be further expanded with the use of ES- or iPS cells as the cell of 
origin116,125. The culture workflow is more complex as it implies the initial differentia-
tion of pluripotent stem cells into the required germ layer, followed by further differen-
tiation steps into the desired tissue lineage116,125,132. Nevertheless, this procedure en-
abled the generation of highly complex and fascinating organoid models of the kid-
ney133 and the brain134. Importantly, there is currently no way to derive kidney or brain 
organoids directly from aSCs. The protocols to grow organoids from aSCs are (cur-
rently) only applicable for endoderm-derived organs as listed above, but not for mes-
oderm- (kidney) or ectoderm (brain)-derived organs132.  
 
3.3.2. Tumor-derived organoids 
The observation that single stem cells isolated from biopsies of healthy tissues could 
give rise to organoids in vitro raised the question whether the technique would be 
also applicable to patient tumor tissues. However, one problem arising in tumor or-
ganoid cultures is their cellular heterogeneity, and in particular the presence of non-
tumor tissue in a given tumor biopsy. Indeed, the initially-described organoid proto-
cols allowed the growth of tumor cells but at the same time also of the normal, non-
tumor tissue counterpart leading to mixed tumor/non-tumor cultures. For some tumor 
types this problem could be elegantly solved. In colorectal cancer (CRC) for exam-
ple, about 90% of the tumors harbor mutations that aberrantly activate the Wnt path-
way135. Because the growth of non-tumor organoids relies on the exogenous addition 
of Wnt and R-Spo1 ligands, removal of these components from the CRC organoid 
medium results in a pure tumor organoid culture126,136. This simple manipulation 
could be applied to additional tumor types and molecular alterations in a similar 
manner. The Mouse double minute 2 homolog (MDM2) inhibitor nutlin-3a for exam-
ple can be used to positively selected tumor cells that harbor mutant TP53, while 
TP53 proficient cells are driven into apoptosis137. To date, as for CRC, the refinement 
of culture media recipes allowed the generation of patient-derived organoids (PDO) 
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from cancers of the pancreas128, stomach138, prostate139, breast137, bladder140, and 
liver (this study)141,142. Importantly, the success rate of tumor organoid generation is 
currently between 15%–100% depending on the tumor type143. Moreover, the collec-
tion protocols for these organoid models were mostly based on tissues derived from 
surgical resections that, for some tumors, can have implications for the representabil-
ity of the patient cohort. Nevertheless, the spectrum of tumor patients can be excep-
tionally represented as in the case of CRC136,144.  
When compared to the primary tumor, organoids markedly reproduced most of the 
histological features. Strikingly, several different histological tumor subtypes can be 
modeled in organoids136,137. However, because they are purely composed of tumor 
cells they consequently lack immune-, endothelial- and other stromal cells143. Never-
theless, recent reports described the first co-culture protocols that aimed to repro-
duce the tumor microenvironment by co-culturing tumor organoids with autologous 
cancer associated fibroblasts145 or immune cells146. On the other hand, epithelial and 
mesenchymal organoid components can be directly obtained by culturing organoids 
at the air-liquid interface147. 
 
Beside the recapitulation of the primary tumors’ histology, deep sequencing of tumor 
organoids and their primary tumor counterpart revealed a high degree of concord-
ance in the number of genetic alterations such as mutations and copy number varia-
tions. Indeed, in all tumor organoid models, the vast majority of mutations in the pri-
mary tumors were maintained in the corresponding organoids143. Notably, analysis of 
the cancer cell fraction (CCF) revealed the presence of intratumor genetic heteroge-
neity, emphasizing the advantage of organoid cultures compared to typically clonal 
cancer cell lines136,143. Finally, the derivation of paired healthy organoids for each pa-
tient provides the ideal in vitro control tissue143.  
Despite the numerous advantages of PDOs given their robust recapitulation of the 
primary tumor, the ultimate proof of their utility for the clinical setting came from re-
cent studies that correlated patients’ response to therapy to the one observed in the 
corresponding organoids, providing evidence that PDOs can serve as a model to re-
capitulate but also possibly predict the clinical response to therapy140,148.  
 
Finally, the advancements in genome editing, especially with the rise of the CRISPR-
Cas9 system and its broad applicability, allowed the simple manipulation of the ge-
nomes of cellular systems149. This methodology was recently used for the step-wise 
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generation of tumor organoids from initially non-tumor healthy organoids, thereby 
modeling the sequential accumulation of mutations, a process that is thought to oc-
cur in a similar manner in human patients150,151. Such studies are now possible with-
out the need of artificially-transformed cell lines and will help in validating and identi-





4. AIMS OF THE PHD THESIS 
 
Liver cancer research suffers from a lack of adequate in vivo and in vitro models that 
faithfully recapitulate the biology of hepatocellular- and cholangiocellular carcinomas. 
This circumstance is reflected by the scarcity of effective therapies for patients with 
advanced liver cancer. Therefore, new models that enable the translation of basic 
research findings to the pre-clinical and clinical setting would significantly advance 
the understanding as well as the clinical management of this malignancy. 
 
Our laboratory follows a truly translational approach combining both, basic- and clini-
cally-oriented research, aiming to better understand liver pathophysiology, with the 
ultimate goal of providing more effective treatments to patients. One of our ap-
proaches includes the collection of valuable primary tissue specimens from needle 
biopsies and their use for research purposes. Thanks to these precious samples, I 
was able to establish a protocol for the generation and characterization of a new pa-
tient-derived liver cancer model based on the organoid system.  
 
The first part of this thesis focuses on the generation of liver organoid cultures from 
small biopsy fragments. Our starting material was much smaller than the resected 
specimens previously used for the establishment of the liver organoid protocol. 
Therefore, my first aim was to adapt the protocol to accommodate the isolation of 
organoid-initiating cells from biopsies, in particular by minimizing tissue loss due to 
the given specimen size. The resulting organoid cultures were then characterized in 
terms of hepatic markers and functional properties. 
In the second part of this thesis, I describe my main PhD project, namely the genera-
tion of patient-derived organoid models obtained from needle biopsies of liver can-
cers. Because of my personal interest in cancer biology and the availability of tumor 
tissue it was obvious to apply the organoid technology also to biopsies derived from 
liver cancer patients. The aim was to comprehensively characterize the model (i) his-
tologically, for the analysis of the phenotypic features, as well as (ii) molecularly, for 
the analysis of the genetic landscape and assessment of the genomic stability in cul-
ture. Importantly, these analyses were always conducted in comparison to the prima-
ry tissue biopsy to evaluate the degree of similarity between organoids and primary 
tumor. This approach resulted in the establishment of a biobank currently comprising 
more than 20 tumor organoid lines from hepatocellular carcinomas, cholangiocellular 
carcinomas and, to a smaller extent, from liver metastases of other primary tumors.  
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5. MATERIALS AND METHODS 
 
5.1. Collection of human tissues and biopsy procedure 
All human tissues used in this study were obtained from patients undergoing diag-
nostic liver biopsy at the Clinic of Gastroenterology and Hepatology of the University 
Hospital Basel. Written informed consent was obtained from all patients. The study 
was approved by the ethics committee of the north-western part of Switzerland (pro-
tocol number: EKNZ 2014-099). Biopsy collection was performed by Prof. Dr. Markus 
Heim and Dr. Tujana Boldanova. US-guided needle biopsies were obtained from tu-
mor lesions with a coaxial liver biopsy technique that allows taking several biopsy 
samples through a single biopsy needle tract. After local anesthesia, the introducer 
needle was advanced 2-3 cm into the liver parenchyma. In case of a focal lesion, the 
needle was positioned precisely at the tumor border. The trocar of the introducer 
needle was removed, and up to five cylindrical biopsies of ~1 mm diameter and 10–
30 mm in length were obtained with an automatic spring-loaded biopsy needle (Bio-
Pince™). The introducer needle was kept in place during the entire procedure to en-
sure that all specimens came from the same area of the tumor. One cylinder was 
fixed in formalin and paraffin-embedded for diagnosis and staging by the pathologist. 
Additional cylinders were immediately snap-frozen in liquid nitrogen for later use in 
DNA and RNA extraction or embedded in O.C.T. (Tissue-Tek) and frozen using 
standard procedures. For organoid generation, biopsy pieces were placed in 1 ml 
advanced DMEM/F-12 (Gibco, Thermo Fisher Scientific) on ice. For control tissue, all 
patients that underwent US-guided HCC biopsy also got a biopsy of the liver paren-
chyma at a site distant from the tumor. Finally, the needle tract was filled with ab-
sorbable gelatin sponge before removal of the introducer needle. The biopsy collec-
tion procedure was identical for non-tumor patients. 
 
5.2. Organoid culture 
Tumor biopsy fragments designated for organoid generation typically measured ~1 
mm in diameter and 5–10 mm length. All other (non-tumor) biopsies typically meas-
ured ~1 mm in diameter and 30 mm length. They were transported to the laboratory 
and further processed for organoid generation within 20 min after collection. The dif-




• Isolation medium: advanced DMEM/F-12 supplemented with 1:50 B-27, 1:100 N-
2, 10 mM Nicotinamide, 1.25 mM N-acetyl-L-cysteine, 10 nM [Leu15]-Gastrin, 10 
μM Forskolin, 5 μM A83-01, 50 ng/ml EGF, 100 ng/ml FGF10, 25 ng/ml HGF, 
10% RSPO1-conditioned medium, 30% WNT3A-conditioned medium, 25 ng/ml 
NOGGIN and 10 μM Y-27632. 
 
• Expansion medium: advanced DMEM/F-12 supplemented with 1:50 B-27, 1:100 
N-2, 10 mM Nicotinamide, 1.25 mM N-acetyl-L-cysteine, 10 nM [Leu15]-Gastrin, 
10 μM Forskolin, 5 μM A83-01, 50 ng/ml EGF, 100 ng/ml FGF10, 25 ng/ml HGF, 
10% RSPO1-conditioned medium. 
 
• Differentiation medium: advanced DMEM/F-12 supplemented with 1:50 B-27, 
1:100 N-2, 10 nM [Leu15]-Gastrin, 500 nM A83-01, 50 ng/ml EGF, 100 ng/ml 
FGF19, 25 ng/ml HGF, 25 ng/ml BMP7, 10 μM DAPT and 30 μM Dexame-
thasone. 
 
Commercial reagent sources: advanced DMEM/F-12, B27 and N-2 all from Gibco 
(Thermo Fisher Scientific); BMP7, EGF, FGF10, FGF19, HGF and NOGGIN all from 
Peprotech; DAPT, Dexamethasone, [Leu15]-Gastrin, N-Acetyl-L-Cysteine, Nicotina-
mide and Y-27632 all from Sigma; A83-01 and Forskolin both from Tocris; RSPO-1 
and WNT3A conditioned media were both homemade. 
 
Non-tumor liver organoid generation and expansion. Organoid cultures from non-
tumor liver biopsies of HCC patients or biopsies from non-tumor patients with other 
diseases (e.g. HBV, HCV, cirrhosis, NAFLD, ALD, genetic diseases) were generated 
with a previously-described, slightly modified protocol127. Briefly, biopsy tissue was 
minced to small pieces of ~1 mm3 size and placed in 2 ml digestion solution (2.5 
mg/ml collagenase D, 0.1 mg/ml DNase I in EBSS) in a water bath at 37°C for 10 
min. Undigested tissue fragments were further disrupted by repetitive pipetting. The 
tube was filled with 10 ml DMEM+10%FBS and centrifuged at 400 ×	g for 4 min. This 
washing step was repeated twice. After the last washing, the supernatant was re-
moved completely, and the tube pre-cooled on ice. The digested tissue was resus-
pended in the required amount of BME2 (Basement Membrane Extract, Type 2, 
Amsbio) and droplets of 15–50 μl (depending on the experiment) were pipetted on 
pre-warmed suspension cell culture plates (Greiner Bio-one). Plates were placed in a 
37°C incubator for 20 min to allow the BME2 to polymerize before adding the re-
quired amount of pre-warmed organoid isolation medium (IM). After 3 days, isolation 
medium was switched to expansion medium (EM). Liver organoids were passaged 
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by mechanical dissociation through a fire-polished Pasteur-pipette or incubation in 
0.25% Trypsin-EDTA (Gibco, Thermo Fisher Scientific) for 2 min. Disrupted or di-
gested organoids were subsequently seeded in EM as described above. Cryovials 
were prepared by dissociating organoids and resuspending in Recovery Cell Culture 
Freezing Medium (Gibco, Thermo Fisher Scientific) prior to freezing. Presence of 
Mycoplasma contamination was regularly tested with the MycoAlert™ Mycoplasma 
Detection Kit (Lonza) according to the manufacturer’s instructions. 
 
Differentiation of liver organoids into hepatocyte-like cells. Liver organoids are 
composed of bipotent progenitors127. For differentiation into hepatocyte-like cells, or-
ganoids were first expanded as described above. To induce differentiation, EM was 
switched to differentiation medium (DM) and the organoids cultured for 11 days with 
medium changes every 3 days.  
 
Tumor organoid generation and expansion. For tumor organoid generation, biop-
sies underwent a limited digestion to small cell clusters. Complete digestion into sin-
gle cells was intentionally avoided because it has been reported that preservation of 
cell-cell contacts enhances derivation efficiency of tumor cultures153. Therefore, tu-
mor tissue was minced and placed, for max. 2-4 min, in digestion solution (2.5 mg/ml 
collagenase D, 0.1 mg/ml DNase I in EBSS) at 37°C. The digestion step was com-
pletely skipped in case of very small and/or fragmented biopsy pieces. Instead the 
tissue was further disrupted by repetitive pipetting and washed with 
DMEM+10%FBS. The total yield of cells/cell clusters varied due to differences in the 
size of the tumor biopsy available for the generation of organoids and the variable 
content of viable tumor cells in the biopsies. This was different for each case and the 
result of variable degrees of necrotic areas in each tumor biopsy. Cells and cell clus-
ters were seeded into BME2 as described above for non-tumor liver organoids. After 
polymerization of BME2, EM was added to the wells. Tumor organoids were pas-
saged after dissociation with 0.25% Trypsin-EDTA (Gibco, Thermo Fisher Scientific). 
In the few cases for which enough biopsy material was available, we tried an 
adapted version of the culture medium in comparison to the standard one. The 
adapted medium lacked some of the original components reported to have a nega-
tive effect on HCC cell proliferation (i.e. Forskolin154, N-Acetyl-L-Cysteine155, Nico-
tinamide156, HGF157) and contained FGF19 due to the frequent amplification of the 
FGF19 gene detected in HCCs and its positive effect on proliferation of HCC cells158. 
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However, these attempts did not result in the establishment of additional HCC or-
ganoid lines. Frozen stocks of early (≤P4) passages could be prepared as described 
for non-tumor liver organoids. All tumor organoid lines could be kept in long-term cul-
tures with regular splitting for at least 1 year. Presence of Mycoplasma contamination 
was regularly tested with the MycoAlert™ Mycoplasma Detection Kit (Lonza) accord-
ing to the manufacturer’s instructions. 
 
5.3. Generation of tumor organoid xenografts 
All experiments involving organoid transplantations into mice were performed in strict 
accordance with Swiss law and were approved by the ethics committee of the north-
western part of Switzerland (protocol number: EKNZ 2014-099) and the animal care 
committee of the canton Basel-Stadt, Switzerland. Tumor organoids, corresponding 
to 1×106 cells, were released from BME2 by incubating in Cell Recovery Solution 
(Corning) or Dispase II solution (Sigma) for 30 min on ice or at 37°C respectively. 
After washing in DMEM+10%FBS, organoids were resuspended in 100 μl 50:50 (v/v) 
BME2:EM and injected subcutaneously into immunodeficient NOD scid gamma 
(NSG) mice (The Jackson Laboratory) at young age (6-8 weeks). Paired non-tumor 
liver organoids from the same patient were used as control. Tumor xenograft growth 
was measured every two weeks using a caliper. When tumors reached the size of at 
least 500 mm3 (maximal volume allowed: 1’500 mm3), mice were euthanized by CO2 
inhalation and tumors surgically excised. One half of the xenograft tissue was used 
for paraffin-embedding and further histological analysis, the other half was divided in 
equal parts that were snap-frozen in liquid nitrogen and embedded in O.C.T. (Tissue-
Tek) respectively. Mice that did not show any sign of tumor growth 8 months after 
injection were euthanized and the xenografting considered unsuccessful.  
 
5.4. Histology and immunohistochemistry 
Biopsies from tumor and non-tumor tissue, as well as tumor organoid xenografts 
were fixed in 4% phosphate buffered formalin and embedded in paraffin using stand-
ard procedures. Tumor and non-tumor liver organoids were released from BME2 by 
incubating in Cell Recovery Solution (Corning) following the manufacturer’s instruc-
tions or by incubating in Dispase II solution (Sigma). Organoids were then fixed in 
freshly prepared 4% formalin solution in PBS for 30 min at room temperature (RT) 
following dehydration and paraffin embedding. Sections were subjected to Hema-
toxylin and Eosin (H&E), Masson’s Trichrome, Alcian Blue-PAS as well as immuno-
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histochemical staining using standard procedures. Histopathological evaluation was 
assessed by two board-certified pathologists, Dr. Matthias S. Matter and Prof. Dr. 
Luigi M. Terracciano, at the Institute of Pathology of the University Hospital Basel. 
Tumors were classified based on architecture and cytological features and graded 
according to the Edmondson grading system89. 
For immunohistochemistry, the following primary antibodies were used for automated 
staining on a Benchmark XT device (Ventana Medical Systems, Inc.): Alpha-
Fetoprotein (Ventana Cat. Nr. 760-2603), Glutamine Synthetase (Ventana Cat. Nr. 
760-4898), Glypican 3 (Ventana Cat. Nr. 790-4564), Heat Shock Protein 70 (Biocare 
Medical CM407A), Keratin 7 (Ventana Cat. Nr. 790-4462), Keratin 19 (Ventana Cat. 
Nr. 760-4281), KI-67 (Ventana Cat. Nr. 760-4286). 
 
5.5. Transmission electron microscopy (TEM) 
For TEM, undifferentiated as well as differentiated organoids were fixed with 3% glu-
taraldehyde in PBS over night at 4°C. Organoids were then washed in PBS and fixed 
with 1% OsO4 in PBS for 20 min at RT. After a dehydration series in 70%, 80%, 96% 
and 100% EtOH for 5 min each, the organoids were submerged in propylene oxide 
for 5 min, then in propylene oxide:epoxy resin (1:2) for 30 min and finally in propyl-
ene oxide:epoxy resin (1:3) for 4 hrs. Polymerization of the resin was carried out at 
60°C for 48 hrs. Semi-thin sections (3 µm) were prepared for orientation purposes 
followed by ultra-thin (80 nm) sections that were placed on a copper grid. Contrasting 
was carried out with uranyl acetate and lead nitrate before acquisition. 
 
5.6. Drug treatments 
Drugs used in this study were dissolved in DMSO at 10 mM and stored in aliquots at 
-20°C. Sorafenib tosylate (Cat. Nr. S-8502) was purchased from LC Laboratories. 
For regular dose-response experiments with sorafenib, tumor organoids were plated 
at a density of 5×103 cells in 15 μl BME2 droplets in 300 μl EM. Medium was re-
placed with 250 μl fresh EM containing sorafenib or vehicle (=100% DMSO) after 6 
days, when organoids were fully formed. All tumor organoid lines were subjected to a 
7-point dilution series of sorafenib. The dose range was chosen based on pharma-
codynamic data obtained from HCC patients159. Cell viability was measured after 6 
days using CellTiter-Glo 3D reagent (Promega) according to the manufacturer’s in-
structions. Luminescence was measured on a Synergy H1 Multi-Mode Reader (Bio-
Tek Instruments). Results were normalized to vehicle. Curve fitting was performed 
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using Prism (GraphPad) software and the nonlinear regression equation. All experi-
ments were performed at least two times in duplicate. Results are shown as mean ± 
SEM.  
 
5.7. Functional hepatocyte studies 
Glycogen production and Albumin secretion were assessed on liver organoids at day 
11 of the differentiation protocol. For glycogen production, organoids were embedded 
in paraffin and histological sections stained with Periodic Acid-Schiff (PAS, Sigma, 
Cat. Nr. 395B-1KT). One liver biopsy section was used as control. Albumin secretion 
was measured in the supernatant collected during the last day of differentiation. Pro-
tein measurement was carried out using a human Albumin-specific Sandwich ELISA 
kit (Assaypro, Cat. Nr. EA3201-1). Supernatant from HepG2 cells was used as con-
trol. 
 
5.8. DNA and RNA extraction 
Genomic DNA from organoids was extracted using the DNeasy Blood & Tissue kit 
(Qiagen) following the manufacturer’s instructions, with the following modification of 
the protocol: Instead of using H2O, DNA was eluted in 100 μl of a 5 mM Tris/HCl, pH 
8.5 solution. Total RNA from organoids was extracted using Trizol® reagent (Invitro-
gen, Thermo Fisher Scientific) according to the manufacturer’s instructions. Genomic 
DNA and total RNA from biopsies was extracted using the ZR-Duet DNA/RNA Mini-
Prep Plus kit (Zymo Research) following the manufacturer’s instructions. Prior to ex-
traction, biopsies were crushed in liquid nitrogen to facilitate lysis. For next genera-
tion sequencing (NGS) applications, the extracted DNA and RNA was quantified us-
ing the Qubit Fluorometer (Invitrogen).  
 
5.9. Real-time quantitative PCR 
Reverse transcription of 1 mg RNA was performed using M-MLV reverse transcrip-
tase (Promega, Cat. Nr.  M1701) following DNase I (Promega, Cat. Nr. M6101) 
treatment. RT qPCR was performed on 40 ng cDNA using FastStart Universal SYBR 
Green Master Mix (Roche, Cat. Nr. 04 913 850 001) and the ABI 7500 detection sys-
tem (Applied Biosystems, Thermo Fisher Scientific). Primer sequences are listed be-





 Gene Forward primer (5’ – 3’) Reverse primer (5’ – 3’) 
ALB TGCCAAAGTGTTCGATGAAT AGCGCATTCTGGAATTTGTA 
CYP3A4 TGTGCCTGAGAACACCAGAG GTGGTGGAAATAGTCCCGTG 
EpCAM CGCAGCTCAGGAAGAATGTG TGAAGTACACTGGCATTGACG 
KRT19 CGCGGCGTATCCGTGTCCTC AGCCTGTTCCGTCTCAAACTTGGT 
 
Table 2. RT qPCR primer sequences. 
 
5.10. Whole exome sequencing 
DNA extracted from eight HCC biopsy-derived organoid lines (Patients 1, 2, 5-A, 5-B, 
9, 12-I, 12-II and 25), three CCC biopsy-derived organoid lines (Patients 13, 16 and 
20) the corresponding original biopsies and the control paired non-tumor biopsies 
were sequenced using whole-exome sequencing. The eight HCC biopsies were de-
rived from six patients and for three of the biopsies, early and late passage organoids 
were profiled. The tumor biopsy sample corresponding to Patient 1 had to be exclud-
ed from further analyses because of low tumor cell content in the biopsy. Whole-
exome capture was performed using the SureSelectXT Clinical Research Exome 
(Agilent) platform according to the manufacturer’s guidelines. Sequencing was per-
formed on an Illumina HiSeq 2500 at the Genomics Facility Basel according to the 
manufacturer’s guidelines. Paired-end 101bp reads were generated.  
 
5.11. Analysis of whole exome sequencing data 
Sequence reads were aligned to the reference human genome GRCh37 using Bur-
rows-Wheeler Aligner (BWA, v0.7.12)160. Local realignment, duplicate removal and 
base quality adjustment were performed using the Genome Analysis Toolkit (GATK, 
v3.6)161 and Picard (http://broadinstitute.github.io/picard/). Somatic single nucleotide 
variants (SNVs) and small insertions and deletions (indels) were detected using Mu-
Tect (v1.1.4)162 and Strelka (v1.0.15)163, respectively. We filtered out SNVs and in-
dels outside of the target regions, those with variant allelic fraction (VAF) of <1% 
and/or those supported by <3 reads. We excluded variants for which the tumor VAF 
was <5 times that of the paired non-tumor VAF, as well as those found at >5% glob-
al minor allele frequency of dbSNP (build 137). We further excluded variants identi-
fied in at least two of a panel of 123 non-tumor samples, including the 4 non-tumor 
samples included in the current study, captured and sequenced using the same pro-
tocols using the artifact detection mode of MuTect2 implemented in GATK. All indels 
were manually inspected using the Integrative Genomics Viewer164. To account for 
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the presence of somatic mutations that may be present below the limit of sensitivity 
of somatic mutation callers, we used GATK Unified Genotyper to interrogate the po-
sitions of all unique mutations in all samples from a given patient to define the pres-
ence of additional mutations. 
 
Allele-specific copy number alterations (CNAs) were identified using FACETS 
(v0.5.5)165 as previously described166, which performs a joint segmentation of the to-
tal and allelic copy ratio and infers allele-specific copy number states. Somatic muta-
tions associated with the loss of the wild-type allele (i.e. loss of heterozygosity, LOH) 
were identified as those where the lesser (minor) copy number state at the locus was 
0. All mutations on chromosome X in male patients were considered to be associated 
with LOH. All gene amplifications and homozygous deletions were visually inspected 
using plots of raw Log2 and allelic copy ratios. Copy number states were collapsed to 
the gene-level based on the median values to coding gene resolution based all cod-
ing genes retrieved from the Ensembl (release GRCh37.p13). 
  
The cancer cell fraction (CCF) of each mutation on the autosomes was inferred using 
the number of reads supporting the reference and the alternate alleles and the seg-
mented Log2 ratio from WES as input for ABSOLUTE (v1.0.6)167. Solutions from AB-
SOLUTE were manually reviewed as recommended162,167. A mutation was classified 
as clonal if its clonal probability, as defined by ABSOLUTE, was >50%, or if the up-
per bound of the 95% confidence interval of its CCF crosses 1. Mutations that did not 
meet the above criteria were considered subclonal. 
 
Cancer genes were annotated according to the cancer gene lists described by Kan-
doth et al. (127 significantly mutated genes)168, Lawrence et al., (Cancer5000-S gene 
set)169, Fujimoto et al.170 or the TCGA90. Mutations affecting hotspot residues171,172 
were annotated. Pathogenicity of missense mutations was predicted using CHASM 
(liver cancer predictor, viral or non-viral as appropriate)173 and FATHMM (cancer 
predictor)174. 
 
Decomposition of the mutational signature was performed using deconstructSigs175, 
based on the set of 30 mutational signatures (“signature.cosmic”, based on the sig-




5.12. RNA sequencing 
RNA extracted from all HCC biopsies (n=38) and the paired non-tumor biopsies were 
sequenced using RNA sequencing (RNA-seq). Tumor samples corresponding to Pa-
tients 1, 7-B (C959), 15-B and 29-A had to be excluded from further analyses be-
cause of low tumor cell content in the biopsy. 200 ng total RNA were used for RNA-
seq library prep with the TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero 
Gold (lllumina) according to manufacturer’s specifications. SR126 sequencing was 
performed on an Illumina HiSeq 2500 using v4 SBS chemistry at the Ge-
nomics Facility Basel according to the manufacturer’s guidelines. Primary data anal-
ysis was performed with the Illumina RTA version 1.18.66.3.  
 
5.13. Analysis of RNA sequencing data 
Sequence reads were aligned to the human reference genome GRCh37 by STAR178 
using the two-pass approach. Transcript quantification was performed using 
RSEM179. For unsupervised cluster analysis, we retrieved the TCGA Liver dataset 
RNA-seq data (“V2_MapSpliceRSEM”) from the Genomics Data Commons Data 
Portal90. We performed gene-level upper quartile normalization of the combined da-
taset to the fixed threshold 1000 as described in the TCGA study90. Genes whose 
expression was quantified to zero by RSEM in >75% of the samples were removed. 
RSEM values were subsequently log2-transformed, adding 0.5 to RSEM values prior 
to transformation. To identify genes with variable expression for clustering, genes 
with standard deviation <2 were excluded. Batch correction using the edgeR pack-
age180 was performed to correct for systematic biases between the datasets. Cluster 
analysis was performed using hierarchical clustering using the Ward method and 
with a 1-Pearson correlation distance90.  
For the TCGA HCC cohort90, images of diagnostic H&E slides were retrieved from 
the cbioportal (http://www.cbioportal.org; accessed December 2017)181 and reviewed 
by two board-certified pathologists, Dr. Matthias S. Matter and Prof. Dr. Luigi M. Ter-
racciano, according to the Edmondson grading system89 for comparison purposes. 
Differential expression analysis between biopsies that yielded organoids and did not 
was performed using the edgeR package180. Specifically, genes with counts-per-
million <1 in more than 5 HCC biopsies were removed. Normalization was performed 
using the “TMM” (weighted trimmed mean) method and differential expression was 




5.14. Statistical analysis 
P values were calculated with Student’s t-test, Fisher’s exact test or Mann-Whitney 
test using Prism (GraphPad) software, as specified in the results section and in the 







6.1. Establishment of a patient-specific liver organoid biobank 
The culture conditions to generate liver organoids from human tissue have been pre-
viously established with the use of surgically-resected liver specimens127. In our lab, 
we aimed to generate liver organoids from significantly smaller tissue pieces derived 
from needle biopsies. For this purpose, we modified the original protocol to avoid 
over-digestion and loss of tissue. 
 
From March 2015 to June 2018, we established a biobank of liver organoids from 
patients undergoing diagnostic biopsy procedure. The biobank comprises more than 
100 organoid lines encompassing all major liver disease backgrounds, namely, alco-
holic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infections, primary biliary cirrhosis (PBC), drug-
induced liver injury (DILI), and autoimmune hepatitis (AIH). In addition, we were able 
to generate organoids from two patients with Morbus Wilson, a rare genetic disease 
resulting in copper accumulation in liver and other organs. Among all liver organoids, 
some were obtained from the non-tumoral parenchyma of HCC patients142 (see also 
section 6.2.).  
 
 
Figure 10. Generation of liver-derived organoids from needle biopsies. (A) Biopsy fragments are digested, and the 
resulting cell suspension embedded in BME2 as described in materials and methods (left side). Scale bar: 2 mm. 
Representative time-course of organoid growth from a single cell (right side). Scale bar: 200 µm (B) Representative 
images of organoids from patients with different disease backgrounds. Scale bar: 500 µm. 






The success rate for generating liver organoids was 100%, and as expected they 
grew as single-cell layered cysts resembling the ductal epithelium when cultured in 
EM127 that promotes their proliferation (Figure 10 and 11A). All liver-derived organ-
oids are morphologically similar independently of their etiology. 
 
 
Figure 11. Differentiation of liver organoids into hepatocyte-like cells. (A) Left side: schematic representation of the 
differentiation protocol: organoids are cultured in EM supplemented with BMP7 for 7 days before switching to DM for 
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11 days. Right side: representative H&E images of undifferentiated (EM) and differentiated (DM) organoids. Scale 
bar: 100 µm. (B) RT qPCR analysis of common hepatocyte markers. EM: undifferentiated organoids; DM: differenti-
ated organoids; PHH: primary human hepatocytes. Every dot represents one organoid line from a different patient, 
one biopsy, or biological replicate in case of HepG2 cells, respectively. (C) Glycogen production in undifferentiated 
and differentiated organoids assessed by Periodic Acid-Schiff (PAS) stain. Scale bar: 100 µm. Albumin secretion 
assessed by Sandwich ELISA in two different organoid lines (#1 and #2). (D) RT qPCR analysis of common cholan-
giocyte markers. n = 3–9 for RT qPCR experiments. 
 
As described before, proliferating organoids are bipotent, since they can be differen-
tiated into hepatocyte- and cholangiocyte-like cells. We used differentiation medium 
to direct the maturation of proliferating organoids into hepatocyte-like cells (HLCs)127, 
a process that requires 11 days (Figure 11A). We then assessed the expression of 
hepatocyte-specific genes on proliferating, undifferentiated organoids and the corre-
sponding differentiated organoids. Differentiated organoids were characterized by the 
induction of mature hepatocyte markers such as ALB, PROX1 and CYP3A4 (Figure 
11B). Despite the strong upregulation, the expression levels of the different markers 
remained below the ones measured in PHH, liver biopsy or the HepG2 cell line, re-
spectively. The strong upregulation of Albumin in differentiated organoids was further 
confirmed by measuring its secretion in the culture supernatant by sandwich ELISA. 
Interestingly, one organoid line secreted more Albumin than the HepG2 cells, despite 
the higher transcript expression levels measured by RT qPCR in the latter. We also 
detected glycogen synthesis in differentiated organoids (Figure 11C), another hall-
mark of hepatocyte function.  
In the original report, liver-derived organoids were shown to originate from cells ex-
pressing EpCAM127. In the liver, only cholangiocytes express EpCAM implicating that 
liver organoids could originate from ductal cells or other cells within the biliary tree 
that have the ability to proliferate in vitro and differentiate into hepatocyte- or cholan-
giocyte-like cells, similarly to hepatoblasts during fetal liver development. We found a 
sustained expression of EpCAM even after differentiating organoids into the hepato-
cyte fate (Figure 11D). The same was true for another cholangiocyte marker, KRT19, 
suggesting that, despite the presence of liver-specific functions and expression of 
major hepatocyte markers, the differentiation efficiency of our current protocol for the 
hepatocyte fate is not optimal.  
Because of the unique three-dimensional architecture of hepatocytes, we performed 
transmission electron microscopy (TEM) on undifferentiated as well as differentiated 
organoids to reveal microstructural details. We found common structural features be-
tween differentiated organoids and the originating liver tissue such as well-defined 
plasma membranes, tight junctions, desmosomes, rough endoplasmic reticulum, in-
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tact mitochondria and the presence of microvilli (Figure 12). We could also detect 
glycogen, in line with the PAS staining. Interestingly, TEM revealed the presence of 
structures between adjacent cells that resembled bile canaliculi in the liver (Figure 
12). These structures are only found between hepatocytes and this observation is in 
line with the detection of bile acid secretion by differentiated organoids as previously 
described127. In conclusion, we demonstrate the feasibility of deriving liver organoids 
from small biopsy specimens that retain similar characteristics of those derived from 
surgical resections.  
 
 
Figure 12. Transmission electron microscopy of liver organoids and primary liver tissue. (A) TEM images show the 
polarized organization of organoid-forming cells with microvilli facing the luminal side of the organoid cyst. (B) Undif-
ferentiated- and (C) differentiated organoids form bile canaliculi-like structures between cells, morphologically similar 
to authentic bile canaliculi in liver tissue (D-F). Bc: bile canaliculi; ck: cytokeratin; des: desmosomes; gly: glycogen; 

























6.2. Organoid models of liver cancers derived from tumor needle biopsies 
The results for this part are presented in the following publication:  
 
Nuciforo, S., Fofana, I., Matter, M.S., Blumer, T., Calabrese, D., Boldanova, T., 
Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., Terracciano, L.M., Ng, 
C.K.Y., Heim, M.H., 2018. Organoid Models of Human Liver Cancers Derived from 
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Hepatocellular carcinoma (HCC) is themost common
primary liver cancer and the second most frequent
cause of cancer-related mortality worldwide. The
multikinase inhibitor sorafenib is the only treatment
option for advanced HCC. Due to tumor heterogene-
ity, its efficacy greatly varies between patients and is
limited due to adverse effects and drug resistance.
Current in vitro models fail to recapitulate key fea-
tures of HCCs. We report the generation of long-
term organoid cultures from tumor needle biopsies
of HCC patients with various etiologies and tumor
stages. HCC organoids retain the morphology as
well as the expression pattern of HCC tumor markers
and preserve the genetic heterogeneity of the origi-
nating tumors. In a proof-of-principle study, we
show that liver cancer organoids can be used to
test sensitivity to sorafenib. In conclusion, organoid
models can be derived from needle biopsies of liver
cancers and provide a tool for developing tailored
therapies.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary
liver cancer, accounting for 90% of all liver cancers, and is the
second most frequent cause of cancer-related mortality world-
wide (Marquardt et al., 2015). Main risk factors include infection
with hepatitis B virus, hepatitis C virus, alcoholic liver disease,
nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis.
Intrahepatic cholangiocellular carcinoma (CCC) represents the
second most common primary liver cancer with main risk factors
including primary sclerosing cholangitis, cysts of the biliary duct,
and parasitic infection with liver flukes (Marquardt et al., 2015).
Currently available treatment options for HCC are unsatisfac-
tory. In the past, conventional chemotherapies have been exten-
sively tested, but none of them have improved survival (Chen
et al., 2015). Major progress came with the introduction of the
multikinase inhibitor sorafenib in 2008. In a landmark trial, sorafe-
nib was found to significantly prolong median survival from 7.9 in
the control group to 10.7 months in the sorafenib treatment group
(Llovet et al., 2008). In the following years >10 additional targeted
drugs were tested, but all failed to meet clinical endpoints in
phase III trials (Llovet and Hernandez-Gea, 2014). More recently,
the sorafenib derivative regorafenib (Bruix et al., 2017) and the im-
mune-checkpoint inhibitor nivolumab (El-Khoueiry et al., 2017)
showed efficacy in second-line treatments for advanced HCC.
However, given the limited efficacy of current HCC treatment op-
tions, there is an urgent need for new therapies for HCC.
A major obstacle in preclinical drug development is the lack of
appropriate cell culture model systems. Current in vitro cell cul-
ture models of HCC are based on conventional hepatoma and
hepatocarcinoma cell lines that fail to recapitulate key features
of tumor tissues such as three-dimensional tumor architecture,
cellular heterogeneity, and cell-cell interactions. The recently
developed organoid technology could overcome these limita-
tions because it allows differentiation of tissue stem cells into
functional organ-like structures (Clevers, 2016). Indeed, the gen-
eration of three-dimensional organoid cultures from patient-
derived tumors has been a major breakthrough in cancer
biology. Over the past 3 years, tumor-derived organoids have
been described for prostate (Gao et al., 2014), pancreatic (Boj
et al., 2015), colorectal (van de Wetering et al., 2015), breast
(Sachs et al., 2018), and bladder cancers (Lee et al., 2018).
In this study, we report the successful generation of tumor or-
ganoid cultures fromneedle biopsies obtained frompatients with
HCC. We demonstrate that HCC organoids recapitulate the his-
tological features of the originating tumor in vitro. Moreover, in-
jection of HCC organoids into immunodeficient mice results in
the formation of tumors that also recapitulate the histological
features of the original biopsy. Additionally, we show that HCC
organoids maintain the genomic features of their originating tu-
mors during long-term culturing for up to 32 weeks. Finally, we
demonstrate that HCC organoids respond to sorafenib treat-
ment with variable sensitivity.
RESULTS
Establishment of HCC Organoid Cultures
We obtained tumor and non-tumor liver samples from patients
undergoing diagnostic needle biopsies for suspected HCCs
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(Figures 1A and 1B). Biopsies were performed under ultrasound
guidance using a coaxial needle biopsy technique that allows for
obtaining up to five samples from the same location in a tumor
(described in the Experimental Procedures). This multiple
sampling procedure allowed a comprehensive characterization
of all samples by histopathology for clinical diagnosis and
Edmondson staging (Edmondson and Steiner, 1954), by immu-
nohistochemical staining to identify tumor markers, and by
whole-exome sequencing and RNA sequencing (RNA-seq) for
molecular analysis. In total, we established 10 HCC-derived or-
ganoid lines from eight patients (Table 1). For patient 5, we
generated organoid lines from two different tumor nodules (5-A
and 5-B). For patient 12, we established two tumor organoid
lines from two different locations of the same large tumor nodule
(12-I and 12-II; Table 1). We also established organoid cultures
from non-tumor liver biopsies in all patients (Figures 1C and
S1A; Table S1). HCC organoids present morphologically as
compact spheroids without a lumen but occasionally forming
pseudoglands (Figure 1C), whereas non-tumor liver-derived or-
ganoids, originating from cholangiocytes, grow as single-cell
layered cysts resembling the ductal epithelium (Huch et al.,
2015) (Figure S1A). The underlying disease spectrum of our pa-
tient cohort encompasses the major risk factors for HCC, viral
hepatitis, nonalcoholic fatty liver disease (NAFLD), and alcoholic
liver disease (ALD) (Table 1). Furthermore, the cohort represents
all different clinical stages of HCC according to the Barcelona
Clinic Liver Cancer (BCLC) staging system (Llovet et al., 1999)
(Table 1).















































Figure 1. Establishment of Organoid Cul-
tures from Needle Biopsies of Hepatocellu-
lar Carcinoma and Paired Non-tumor Liver
Tissues
(A) Schematic workflow of organoid generation
from needle biopsies.
(B) Representative biopsy pieces of tumor and
liver tissue used for organoid generation.
(C) Representative bright-field images of tumor
and paired non-tumor liver tissue organoids from
three different patients. Tumor organoids form
compact spheroids, whereas liver organoids from
non-tumor liver tissue grow as cystic structures.
Organoids were imaged at the indicated passage
numbers. Scale bar: 500 mm.
The success rate for the generation of
HCC organoids was 26% based on the
number of cultured tumor biopsies (10
out of a total of 38 HCC biopsies). HCC
organoids were obtained in 8 of the 24
HCC patients included in the study
(33%) (Table S1). We did not find a corre-
lation between a number of clinically
relevant patient characteristics and the
success or failure to generate HCC orga-
noids from their tumors (Figure 2A). On
the other side, there was a strong correla-
tion with the histopathological grading of
the HCCs: all HCC organoids are derived
from poorly differentiated tumors (Edmondson grades III and IV)
(Figure 2A; Table 1). Furthermore, KI-67 staining of tumor bi-
opsies showed significantly higher cancer cell proliferation rates
in samples that could be propagated as tumor organoids
compared with samples that failed (Figures S2A and S2B).
The transcriptome data of the tumor biopsies were used to
analyze the distribution of our samples within a reference set
from The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas
Research Network, 2017) using an unsupervised hierarchical
clustering analysis. Overall, our samples distributed evenly in
the entire reference dataset, but the eight samples from which
we could derive HCC organoids preferentially located in a sub-
class located at the left end of the clustering tree (Figure 2B).
Because all of our HCC organoids originated from poorly differ-
entiated HCCs (Edmondson grades III and IV), we also per-
formed the clustering analysis using the subset of poorly differ-
entiated HCCs from TCGA HCC database as a reference. In
this analysis, our samples distributed over the entire spectrum
of the tree (Figure 2C).We conclude that the organoidmodel sys-
tem strongly selects for Edmondson grade III and IV HCCs, but
within this group of poorly differentiated HCCs, there seems to
be no further selection of a specific molecular subtype.
HCC Organoids Recapitulate the Histopathological
Characteristics of the Originating Tumor
To investigate whether the histological characteristics of the
originating tumors were preserved in the HCC organoids,
two expert pathologists with expertise in hepatopathology
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performed histological analysis and diagnostic evaluation on
the original biopsies and their tumor organoids on paraffin-
embedded sections. Notably, HCC organoids maintained the
growth pattern and differentiation grade of the originating
primary tumors (Figure 3A). For example, HCC organoids
derived from patient 2 displayed a solid growth pattern with an
Edmondson differentiation grade III as in the originating tumor
(Figure 3A). Likewise, tumor organoids from patient 12 formed
pseudoglands (Figure 3A), a feature that was also present in
the original HCC of this patient. Importantly, long-term culturing
up to 1 year did not alter the histological properties of the HCC
organoids (Figure S1B). As expected, immune cell infiltrates
and tumor stromal cells were not propagated in the organoids.
Wenext assessedwhether the expression of alpha-fetoprotein
(AFP), a tumor marker for HCC (Table 1), was maintained in the
corresponding organoids. Immunohistochemical analysis re-
vealed consistent distribution and expression intensity of AFP
between organoids and their original tumor biopsy tissue (Fig-
ure 3B). The same was true for three additional biomarkers
commonly used for histological HCC diagnosis, Glypican 3,
glutamine synthetase, and heat shock protein 70 (GPC3, GS,
andHSP70, respectively) (Di Tommaso et al., 2009) (Figure S1C).
Someof theHCCsalso stainedpositive for thebiliary cellmarkers
Keratin 7 (KRT7) andKeratin 19 (KRT19). Again, the expression of
these markers was maintained in the organoids (Figure 3C).
Taken together, these results demonstrate that HCC organoids
retain the phenotypic characteristics of their originating tumors.
HCC Organoids Give Rise to Tumors upon Injection into
Immunodeficient Mice
To assess whether HCC organoids retained the ability to form
bona fide tumors in mice, we injected HCC organoids subcuta-
neously into immunodeficient mice. So far, 6 of the 10 HCC orga-
noids could be stably propagated in mice (Figures 4A and 4D).
Two organoids failed to grow despite repeated transplantations.
Two organoidswere injected recently and the outcome could not
yet be determined (Figure 4D). Of note, all successfully trans-
planted organoids gave rise to xenograft tumors that recapitu-
lated the histopathological features and the tumor marker
expression (Figure 4B) of the originating organoids and the orig-
inal tumors. In contrast, and as expected, none of the paired
non-tumor liver organoids gave rise to neoplasms.
HCC Organoids Retain the Somatic Genetic Alterations
of the Originating Tumor
To assess whether the HCC organoids recapitulate the genetic
alterations of the originating tumor, we subjected DNA from
seven HCC organoid lines, their originating tumor biopsies,
as well as the paired non-tumor biopsies to whole-exome
sequencing (WES). WES was performed to median depths of
853, 953, and 503 in the organoids, biopsies, and non-tumor
counterparts, respectively (Table S2). The number of somatic
mutations in organoids (median 165, range 117–180) did not
significantly differ from that of the corresponding tumor biopsies
(median 146, range 127–207; p = 0.78, Mann-Whitney U test;
Table S3).
Of the total somatic and the subgroup of non-synonymous so-
matic mutations found in the HCC biopsies, a median of 88%
and 90%, respectively, was observed in the corresponding
HCC organoids at early passage of culturing (P3–P4) (Figures
5A, S3, and S4; Tables S3 and S4). Similar proportions (all so-
matic: 86%; non-synonymous somatic: 88%) were observed in
three representative cases where late-passage HCC organoids
(RP8) were profiled (Figures S3 and S7A; Tables S3 and S4).
Nearly all non-synonymous somatic mutations in bona fide can-
cer genes, including all of those in TP53 (p.Arg209fs in patient 2,
Table 1. HCC and CCC Patient Data Table
Patient Biopsy ID Sex Age (Years) Tumor Liver Disease(s) Cirrhosis BCLC Edmondson Growth Pattern AFP (IU/mL)
1 C655 male 55 HCC HCV; ALD no C III trabecular-pseudoglandular 269
2 C798 male 73 HCC NAFLD no C III solid-trabecular 20’377
5-A C948 male 57 HCC HCV; ALD yes C III trabecular 120054
5-B C949 III trabecular
9 C975 male 59 HCC HCV; ALD yes B III solid 250
12-I D045 male 69 HCC HCV no A III solid-trabecular 7’852
12-II D046 III solid-trabecular
13 D091 female 61 CCC none no – – – 4.4
16 D141 male 59 LELCC HBV yes – – – 2.1
20 D178 female 63 CCC none no – – – 3.1
25 D324 male 58 HCC HCV yes D III solid-trabecular 104’710
27 D359 male 86 HCC NAFLD no A III trabecular 5’917
29-A D386 male 80 HCC ALD; NAFLD no A IV solid 49.8
Clinical staging was done according to the Barcelona Clinic Liver Cancer (BCLC) staging system (Llovet et al., 1999). Serum alpha-fetoprotein (AFP)
concentrations were obtained from the clinical charts of the patients. Edmondson grade (Edmondson and Steiner, 1954) and the growth pattern were
determined in each biopsy on H&E-stained sections by two experienced hepato-pathologists (M.S.M. and L.M.T.). All CCC tumors were poorly differ-
entiated. AFP, alpha-fetoprotein; ALD, alcoholic liver disease; BCLC, Barcelona Clinic Liver Cancer; CCC, cholangiocellular carcinoma; HBV, hepatitis
B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LELCC, lymphoepithelioma-like cholangiocarcinoma; NAFLD, nonalcoholic fatty liver
disease.

























































































































































































































































































































ALD HBV HCV NAFLD A B C D Cirrhosis MVI Metastasis 0-10 10-20 20-200 200-400 400-1000 >1000 I II III IV
Growth 4/8 0/8 4/8 3/8 3/8 1/8 3/8 1/8 3/8 3/8 2/8 0/8 0/8 1/8 2/8 0/8 5/8 0/10 0/10 9/10 1/10
No growth 8/17 2/17 5/17 4/17 5/17 5/17 7/17 0/17 11/17 4/17 4/17 5/17 3/17 1/17 3/17 2/17 3/17 1/27 9/27 11/27 6/27
P value >0.99 >0.99 0.09 0.64 >0.99 0.62 >0.99 0.32 0.39 0.64 >0.99 0.14 0.53 >0.99 >0.99 >0.99 0.06 >0.99 0.08 0.01 0.65
Summary ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns * ns












(legend on next page)




hotspot p.Arg342* in patient 9, and p.Val157Phe in patient 12-II),
ARID1A (c.5125-2A > T in patients 5-A and 5-B), CTNNB1
(hotspot p.Ser45Ala and p.Arg528Cys in patients 5-A and 5-B),
TSC1 (p.Gln767* in patient 2), and LRP1B (p.Cys2903Arg in
patient 9), were found in the organoids at both early and late
passages (Figures 5B, S3, and S7B). Of all the non-synonymous
mutations in bona fide cancer genes, only two were lost in the
corresponding HCC organoid (BRD7 p.Phe340Ile in patient 9;
ARHGAP35 p.Glu1273Ala in patient 12-I). However, these muta-
tions were subclonal in the originating HCC biopsies (Figures
S3D and S4A), have not been previously reported in HCC, and
are predicted to be passenger mutations (Table S4). Overall,
we identified a median of 19 (range 8–29) and 14 (range 5–24)
novel somatic and non-synonymous somatic mutations in the
HCC organoids that were not present in the originating biopsies,
representing amedian of 15% and 12%of themutations present
Figure 2. Clinical, Histopathological, and Molecular Features of HCC Biopsies Used for Organoid Generation
(A) Color-coded table of patient characteristics of all biopsies (n = 38) used for organoid generation. Edmondson grade (Edmondson and Steiner, 1954) and the
growth pattern were determined in each biopsy on H&E-stained sections by two experienced hepato-pathologists (M.S.M. and L.M.T.). Clinical data were
extracted from the electronic patient information system of the hospital. Of note, only the Edmondson grade III was a significant determinant of successful
organoid generation (p = 0.01, Fisher’s exact test, two-sided). For the Edmondson grade, calculations were performed per biopsy, whereas all other parameters
were calculated per patient. ALD, alcoholic liver disease; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C
virus; MVI, macrovascular invasion; NAFLD, nonalcoholic fatty liver disease.
(B and C) Unsupervised hierarchical clustering analysis.
(B) Biopsy (organoid) cohort (this study) combined with all HCCs from TCGA cohort.
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Figure 3. Histopathological Characteristics of HCC and CCC Organoids and Their Primary Tumors
(A) Histological sections of HCC and CCC organoids and their original tumors stained with H&E. The originating tumors display primarily a solid-trabecular
architectural pattern with poor differentiation (Edmondson grades III and IV), features that are maintained in the corresponding HCC organoids. Arrowheads
indicate pseudoglandular structures in HCC organoids and intracytoplasmic lumen in CCC organoids.
(B) AFP expression detected by immunohistochemistry on organoids and original biopsies.
(C) Expression of biliary markers KRT7 and KRT19 detected by immunohistochemistry on organoids and original biopsies. Organoids were imaged at the
indicated passage numbers.
Scale bars: 100 mm.




in the HCC organoids, respectively. Most of these novel muta-
tions did not occur in bona fide cancer genes. Indeed, in four
of the seven tumor organoid lines, no additional non-synony-
mous mutations in cancer genes were identified. In patient
5-A, an ASXL1 mutation was found in both early- and late-pas-
sage HCC organoids, a PDGFRA mutation was found only in
the early passage, and an AXIN2 mutation only in the late pas-
sage, but not in the originating HCC biopsies (Figures 5B and

































Patient 1 1x106 no
Patient 2 1x106 yes
Patient 5-A 1x106 yes
Patient 5-B 1x106 yes
Patient 9 1x106 no
Patient 12-I 1x106 yes
Patient 12-II 1x106 yes
Patient 25 1x106 yes
Patient 27 not tested -
Patient 29-A not tested -
Patient 16 1x10E6 yes
Patient 20 1x10E6 yes


























































































Figure 4. Histological Analysis of Xenografts Derived from HCC and CCC Organoids
(A) Growth curves of the xenograft tumors.
(B) Histological sections of xenograft tumors derived from HCC and CCC organoids stained with H&E. The HCC marker AFP and the biliary marker KRT7 were
detected by immunohistochemistry. Scale bar: 100 mm.
(C) Trichrome and Alcian blue-PAS staining on biopsy, derivative organoids, and xenograft of patient 20. Collagen-rich areas representing the desmoplastic
stroma reaction are colored in blue in Trichrome-stained sections. Mucin production appears light blue in sections stained with Alcian blue-PAS (arrowheads).
Organoids were imaged at the indicated passage numbers. Scale bars: 100 mm.
(D) Statistics of the xenograft experiments.
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S7B). However, 23%–46% of the organoid-specific mutations
were present in both early- and late-passage organoids origi-
nating from patient 2, patient 5-A, and patient 5-B (Table S3),
strongly suggesting that a substantial proportion of the HCC or-
ganoid-specific mutations were likely present in the originating
tumors at low frequencies, rather than being genuinely novel.
A detailed analysis of the cancer cell fraction (CCF) of the
somatic mutations (i.e., the proportion of cancer cells harboring
a given genetic alteration) between the organoid cultures
and their matched originating tumor indicated that both
harbored subclonal mutations (Figures 5C and S3–S6). For
example, we observed similar extents of intratumor heterogene-
ity between the biopsies and organoids of patient 5 (Figures 5C
and S3–S6). This has been previously observed in colorectal
cancer organoids (van de Wetering et al., 2015) and is likely to
be a genuine advantage of organoid cultures compared with
cancer cell lines.
Copy number analysis showed that most amplifications
were preserved in HCC organoids, and the overall patterns
of copy number alterations were similar between the biopsies
and the derivative HCC organoids at early and late passage
(Figures S7C and S7D). For instance, the amplifications of
chr1q21.3 (encompassing MCL1, SETDB1, ARNT, and
MLLT11) in patient 5 (A and B), 8q24.13-24.23 (MYC and
NDRG1) in patient 2, and 11q13.2-13.4 (CCND1, FGF19,
FGF4, and FGF3) in patient 12-II were all found in their corre-
sponding organoids. However, the heterogeneity observed at
mutational level was also present at the copy number alter-
ation (CNA) level. In fact, an amplification on 18q12.2
restricted to the HCC biopsy of patient 9, but not seen in
the respective HCC organoids and two amplifications on
19q12 (CCNE1) and 19q13.2 (MAP3K10 and AKT2), was found
only in the derivative HCC organoids.
We next investigated whether the biological and chemical pro-
cesses that shape the mutational landscape were maintained in
the organoid cultures. The analysis of the mutational signatures
demonstrated that the mutational landscape of the HCC bi-
opsies and the organoids was largely driven by mutational pro-
cesses associated with signatures 1 (associated with aging), 3
(homologous recombination DNA repair deficiency), 6 (mismatch
repair deficiency), and 16 (previously found in liver cancer with
unknown etiology) (Alexandrov et al., 2013) (Figure S8). The
mutational signatures were remarkably consistent between the
organoids and the originating HCC biopsies. These results sug-
gest that themutational processes that drive tumor development
were maintained in the organoids. Of note, the same patterns of
mutational signatures were also maintained in late-passage or-
ganoids (Figure S8).
Taken together, these results demonstrate that the HCC
organoids derived from tumor biopsies largely maintain the ge-
netic alterations and mutational signatures observed in their
originating HCCs. Importantly, mutations and amplifications
affecting bona fide cancer genes found in the biopsies were pre-
served in the organoids. Furthermore, in line with previously pub-
lished reports (Lee et al., 2018; van de Wetering et al., 2015),
each HCC organoid line retained a remarkable intratumoral
mutational heterogeneity.
Generation of Organoids from Intrahepatic CCCs
In our consecutive series of patients with suspected primary liver
cancer who had a diagnostic needle biopsy (Table S1) therewere
four cases of intrahepatic CCCs and one case of a rare variant of
CCC, a lymphoepithelioma-like cholangiocarcinoma. All five
cases were poorly differentiated CCCs. In three cases we suc-
cessfully established CCC-derived tumor organoids. Morpho-
logically, CCC organoids resembled HCC organoids and formed
compact spheroids (Figures 1C and 3A), whereas the corre-
sponding non-tumor liver organoids formed single-cell layered
epithelial cysts as expected (Figures 1C and S1A). CCC organo-
ids displayed similar histological properties such as trabecular
and/or solid growth with cytoplasmic eosinophilia and highly
atypical cells like the poorly differentiated adenocarcinomas
from which they were derived (Figure 3A). Furthermore, some
cells within CCC organoids and their originating biopsies formed
intracytoplasmic lumens and produced Mucin, two character-
istic features of adenocarcinomas (Figures 3A and 4C). As ex-
pected, AFP expression was not detected in CCC tumor bi-
opsies and organoids (Figure 3B). All CCC organoid lines
expressed typical biliary markers such as KRT7 and KRT19
consistent with the expression pattern in the originating tumor
biopsies (Figure 3C).
The genetic analysis revealed hyper-mutator phenotypes in pa-
tient 16 (with the lymphoepithelioma-like cholangiocarcinoma)
and in patient 20 (Figure 5). Both tumors had >500 somatic muta-
tions. In patient 16, most of the mutations were maintained in the
organoids, whereas in patient 20, most were lost during the deri-
vation of organoids (Figure 5A). Interestingly, the vast majority of
somatic mutations in patient 16 were present in >80% of the tu-
mor cells, whereas in patient 20, most of them were found only
in subclonal cell populations (Figures S5 and S6; Table S4). It is
likely that most of the subclones in the originating tumor were
lost during the early steps of organoid culture. Patient 13 had 85
non-synonymous somatic mutations in the tumor. 36 were not
preserved in the organoids. Most of them were subclonal and
were not in bona fide cancer genes. The presumed cancer driver
mutations were preserved (Figure 5).
Figure 5. Repertoire of Genetic Alterations Found in the HCC and CCC Organoids and Their Originating Tumors
(A) Venn diagrams illustrate the number of somatic non-synonymous mutations present in each HCC biopsy and their derivative HCC organoids. The dashed line
denotes CCC-derived tumors and corresponding organoids.
(B) Repertoire of somatic non-synonymous mutations affecting cancer genes (Fujimoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014; Cancer Genome
Atlas Research Network, 2017). The effects of the mutations are color-coded according to the legend, with hotspots (Chang et al., 2016; Gao et al., 2017) colored
in red. Multiple non-synonymous mutations in the same gene are indicated by an asterisk. Loss of heterozygosity of the wild-type allele of a mutated gene is
represented by a diagonal bar, and mutations found to be clonal by ABSOLUTE (Carter et al., 2012) are indicated by a black box.
(C) Contour plots illustrate the distribution of the cancer cell fractions (CCFs) of somatic mutations in the tumors and their corresponding organoids, with the
increasing shades of red indicating higher number of somatic mutations at a given CCF.




We could successfully transplant the CCC organoids from pa-
tients 16 and 20 into immunodeficient mice. No xenografts could
be established from patient 13 despite repeated transplantation
attempts (Figure 4D). Surprisingly, histologic analysis of the
xenograft tissue revealed tumor areas with a desmoplastic
stroma reaction, a typical CCC feature that was also present in
the originating tumors, but not in the organoids due to the lack
of stromal cells (Figure 4C). This demonstrates that the capability
to induce a desmoplastic reaction and thus to reproduce the tu-
mormicroenvironment in vivo is intrinsically programmed in CCC
cells. Finally, Mucin-producing cells were also detected in the
xenograft tumors from CCC organoids (Figure 4C).
HCC and CCC Organoids Display Variable Sensitivity
to Sorafenib
In order to assess whether HCC-derived organoids would be a
suitable system for preclinical drug development, we treated
HCC organoid cultures with different concentrations of sorafenib
and monitored cell viability with CellTiter-Glo. The concentration
range was based on pharmacokinetic data from patients treated
with sorafenib (Nexavar) (Abou-Alfa et al., 2006). In our in vitro
assay, sorafenib reduced HCC organoid growth in a dose-
dependent manner (Figure 6A) with half-maximal inhibitory con-
centration (IC50) values that varied by 2.5-fold from 2.0 to 5.0 mM
(Figures 6B and 6C). Direct comparison of in vitro sorafenib ac-
tivity with the clinical response was not feasible because none
of the patients from whom we generated organoid cultures
were treated with sorafenib. The validation of the organoid
models as test systems for sorafenib response in vivowill require
the recruitment of many more patients and the generation of a
sizable number of additional HCC organoids derived from pa-
tients treated with sorafenib.
We also tested the efficacy of sorafenib on the three CCC
organoid lines. Notably, a CCC organoid derived from a rare
subtype of CCC (lymphoepithelioma-like CCC, patient 16) re-
sponded to sorafenib treatment in vitro with IC50 values compa-
rable with sorafenib-sensitive HCC organoids (Figures 6B and
6C). Sorafenib is not an established treatment for CCCs, but it
has recently been explored in a multicenter prospective study
that showed a modest effect on disease control rate (Luo
et al., 2017).
Taken together, our results demonstrate that organoids
derived from biopsies of primary liver cancers can be used to
test tumor-specific sensitivities to growth-inhibitory substances.
DISCUSSION
In vitro studies of HCC biology have so far been restricted to a
limited number of hepatoma and HCC cell lines. Most of them
have been established decades ago, and it is unclear how well
they represent the tumor biology of HCCs. HCC organoids over-
come many of the limitations of these cell lines. They can be
directly linked to a patient and to spatiotemporal information
such as a specific tumor nodule or a metastasis, or a specific











































































































Figure 6. Differential Drug Responses in Patient-Derived HCC and CCC Organoids under Sorafenib Treatment
HCC and CCC organoids were exposed to sorafenib at the indicated concentration for 6 days. DMSO-treated tumor organoids were used as control.
(A) Representative bright-field images of sorafenib-treated HCC organoids (patient 5-B). Scale bar: 200 mm.
(B) Sorafenib reduces cell viability of HCC and CCC organoids in a dose-dependent manner. The dashed line represents the IC50. Data are presented as the
percentage of control DMSO-treated tumor organoids and are the mean of at least two independent experiments performed in duplicate.
(C) Differential IC50 (in mM) of HCC and CCC organoids shown as mean ± SEM. Patient numbers correspond to Table 1.




time during the evolution of the cancer in a patient. Importantly,
we found that the organoids are polyclonal and thereby preserve
an important feature of the originating tumor that is linked to
cancer evolution, immune evasion, and resistance to oncostatic
and targeted therapies. Patient-derived tumor organoids have
recently been described for prostate (Gao et al., 2014), pancre-
atic (Boj et al., 2015), colorectal (van de Wetering et al., 2015),
breast (Sachs et al., 2018), and bladder cancer (Lee et al.,
2018). Broutier et al. (2017) reported the establishment of orga-
noid cultures derived from resections of primary liver cancers.
In our study, we report the establishment of organoids from
HCC needle biopsies, overcoming a major limitation of ap-
proaches that use surgically resected HCC specimens. Indeed,
surgical resection is a treatment option for the minority of HCC
patients with early tumor stages and/or a non-cirrhotic liver.
These patients usually do not receive systemic therapies. In
contrast, biopsies can also be obtained from patients with inter-
mediate and advanced tumor stages who frequently receive
systemic therapies. The use of biopsies therefore allows for
establishment of an organoid biobank that reflects the entire
spectrum of HCCs. Furthermore, such a biobank can be en-
riched to include clinical data such as response to treatments,
resistance development, and survival.
The use of tumor biopsies also allowed a comparison of tumor
and organoids. Of note, several biopsies from the same location
in a tumor could be obtained using an ultrasound-guided coaxial
biopsy technique. The resulting set of biopsies is mutually repre-
sentative and can be used for multidimensional analysis. We
found a striking similarity between originating tumors and orga-
noids in routine histopathology and immunostaining analysis.
Moreover, the individual tumor features were also maintained af-
ter transplantations into immunodeficient mice. We conclude
that these morphological features are inherently programmed
in the tumor cells and are not subject to the tumor environment
(Figure 3). Furthermore, the expression of well-established
HCC biomarkers, as well as the mutational landscape, is pre-
served in HCC organoids (Figure 5). When compared with the
previous study by Broutier et al. (2017) that used resected spec-
imens, our tissue collection procedure allowed for collection of
non-tumor liver biopsies at a site distant from the tumor nodule(s)
to generate non-tumor liver organoids for all patients and to
perform patient-specific normalization of our genomic and tran-
scriptomic data.
In our series of tumor biopsies we derived HCC organoids with
a success rate of !26% (per number of biopsies) and 33% (per
number of patients). This is lower compared with the reported
success rates for pancreatic cancer (75%–83%) (Boj et al.,
2015) and colorectal cancers (90%) (van de Wetering et al.,
2015), possibly because the cell of origin of HCCs, the hepato-
cytes, lack features of epithelial stem cells that favor their prop-
agation in the organoid culture system.
However, our success rate is in line with a recent study by
Pauli et al. (2017) reporting an average success rate of !38%
across different tumor types. In their report, the authors used
small-needle biopsies as tumor tissue source in some of their
cases and conclude that the major limitation to establish tumor
organoids was the insufficient amount of fresh tissue. Indeed,
given the limited amount of starting material (needle biopsies),
we could not set up a systematic screening of different culture
systems to improve the derivation efficiency. Broutier et al.
(2017) tried to optimize the culture conditions for the generation
of liver cancer organoids by removing some of the growth factors
contained in the original media recipe in order to reduce the
outgrowth of normal liver organoids. However, the changes
they performed did not result in organoid generation from all of
their tumor specimen. Based on informed guesses, we tried to
optimize culture conditions in a small number of cases where
we hadmore than one biopsy as a startingmaterial. For example,
we removed compounds with potential negative effects on HCC
proliferation such as Forskolin, N-acetyl-L-cysteine, nicotin-
amide, and HGF from the medium, and added FGF19, a factor
with potential growth-promoting effects for HCCs. However,
these limited efforts did not result in the establishment of addi-
tional HCC organoid lines. Nevertheless, we anticipate that addi-
tional efforts in refining the media recipes (Fujii et al., 2016), and
possibly also the use of tailored 3D matrices (Gjorevski et al.,
2016), to specifically accommodate the growth of HCC- and
CCC-derived organoids, respectively, will improve the success
rate. This would be a prerequisite for using HCC organoids as
patient-specific in vitro models of drug sensitivity with the aim
to inform treatment decisions on an individualized basis. Of
note, the time required to expand the organoid cultures for
drug testing is presently 4–12weeks. Urgent treatment decisions
will therefore not rely on in vitro drug testing of individual patient-
derived organoids, even if the success rate should be much
higher in the future. More realistically, systematic drug testing
in a large enough number of HCC organoids will allow to predict
patient responses to different treatments based on matching
molecular characteristics of tumor biopsies and organoids (Drost
and Clevers, 2018).
One other potential reason for the limited success rate could
be that HCC organoids can be generated only from a restricted
subset of HCCs. We therefore compared clinical, histopatholog-
ical, and molecular features of HCCs that could be propagated
as organoids with HCCs that could not. No significant correla-
tions were found with a comprehensive set of clinical data
(Figure 2A). Indeed, HCC organoids could be derived from pa-
tients with all major underlying liver diseases and different
clinical stages of HCC, demonstrating the potential of the orga-
noid technique for building up larger biobanks representing the
entire clinical spectrum of liver cancer. On the other side, there
was a significant correlation with one of the histopathological
features, the Edmondson grade of the tumors. HCC organoids
could only be generated from poorly differentiated tumors. It is
conceivable that the generation of HCC organoids requires a
cell proliferation rate threshold that is not reached in highly differ-
entiated, slow-growing Edmondson grade I and II tumors. This is
supported by our finding that the proliferation marker KI-67 and
cell-cycle pathway genes were upregulated in tumor biopsies
with successful organoid derivations compared with those
where organoids could not be generated (Figures S2A and
S2B; Table S5). These data are in line with those from Broutier
et al. (2017) showing that onlymoderately to poorly differentiated
HCCs with a KI-67 index >5% were able to generate organoids.
Of note, other histopathological features in our HCC cohort such
as the percentage of viable tumor cells in the biopsy, the amount




of stroma or immune cell infiltration, the growth pattern of the tu-
mor, or the degree of tumor necrosis were not correlated with
success or failure of organoid derivation (Table S1).
Finally, to investigate whether HCC organoids can only be
derived from a specificmolecular subtype of HCC, we compared
transcriptome data of all of our tumor biopsies with a reference
set of poorly differentiated HCCs from the TCGA database (Can-
cer Genome Atlas Research Network, 2017). We found no
enrichment of our samples in distinct subclasses of HCCs (Fig-
ure 2C). We conclude that the organoid technique described in
this manuscript allows the generation of a heterogeneous tumor
organoid biobank that is a representative sample of the entire
clinical, histopathological, and molecular spectrum of poorly
differentiated HCCs.
The analysis of the relative frequency of non-synonymous so-
maticmutations in the tumor biopsies and the HCCorganoids re-
vealed the expected preservation of highly prevalent putative
driver mutations. However, it also revealed that mutations pre-
sent in only a subset of tumor cells, i.e., subclone-specific muta-
tions, were also preserved, often with surprisingly similar relative
frequencies between tumor biopsies and HCC organoids (Fig-
ures 5C and S3–S6; Table S4). This is somewhat unexpected,
because it does not support a model where tumor organoids
are derived from a single cancer stem cell. There is compelling
evidence that intestinal organoids can be derived from single
LGR5-positive stem cells (Clevers, 2016). For liver-derived orga-
noids, this is less clear (Huch et al., 2015). It remains to be inves-
tigated whether the stem cell model is applicable for HCC tumor
organoids. In any case, the coexistence of different cancer cell
subclones with different sensitivities to targeted therapies is an
important factor linked to therapy failure (Fisher et al., 2013).
Therefore, we believe that organoid models will play a major
role in the development of novel drug candidates able to target
different genetic subclones within tumors to impede the selec-
tion of resistant cells present at low frequencies at therapy onset.
Furthermore, the knowledge of the patient-specific genetic
background will allow the unique opportunity to correlate
response to specific drugs with putative driver mutations, a pre-
requisite for future efforts of personalized management of tar-
geted therapies.
EXPERIMENTAL PROCEDURES
Human Tissues and Biopsy Procedure
Human tissueswere obtained from patients undergoing diagnostic liver biopsy
at the University Hospital Basel. Written informed consent was obtained from
all patients. The study was approved by the ethics committee of the north-
western part of Switzerland (Protocol Number EKNZ 2014-099). Ultrasound
(US)-guided needle biopsies were obtained from tumor lesion(s) with a coaxial
liver biopsy technique that allows taking several biopsy samples through a sin-
gle biopsy needle tract. After local anesthesia, the introducer needle was
advanced 2–3 cm into the liver parenchyma. In case of a focal lesion, the nee-
dle was positioned precisely at the tumor border. The trocar of the introducer
needle was removed, and up to five cylindrical biopsies of !1 mm diameter
and 10–30 mm in length were obtained with an automatic spring-loaded bi-
opsy needle (BioPince). The introducer needle was kept in place during the
entire procedure to ensure that all specimens came from the same area of
the tumor. One cylinder was fixed in formalin and paraffin-embedded for
diagnosis and staging. Additional cylinders were immediately snap-frozen in
liquid nitrogen for later use in DNA and RNA extraction or embedded in
O.C.T. (Tissue-Tek) and frozen using standard procedures. For organoid gen-
eration, biopsy pieces were placed in advanced DMEM/F-12 (GIBCO). For
control tissue, all patients who underwent US-guided HCC biopsy also got a
biopsy of the liver parenchyma at a site distant from the tumor. The needle tract
was filled with absorbable gelatin sponge before removal of the introducer
needle.
Organoid Culture
Tumor biopsy fragments designated for organoid generation typically
measured !1 mm 3 5–10 mm corresponding to a volume of !3.9–7.9 mm3.
They were transported to the laboratory on ice and further processed for orga-
noid generation within 20 min after collection. For tumor organoid generation,
biopsies underwent a limited digestion to small-cell clusters.We avoided com-
plete digestion into single cells because it has been reported that preservation
of cell-cell contacts enhances derivation efficiency (Kondo et al., 2011). Tumor
tissue was minced and shortly (maximum [max.] 2–4 min) digested with
2.5 mg/mL collagenase IV (Sigma), 0.1 mg/mL DNase (Sigma) at 37"C. The
yield of the procedure varied because of differences in the size of the tumor bi-
opsy available for the generation of organoids and the variable content of
viable tumor cells in the biopsies. Cell clusters were then seeded into reduced
growth factor BME2 (Basement Membrane Extract, Type 2; Amsbio). After
polymerization of BME2, expansion medium (Huch et al., 2015) was added
to the cells. The composition is advanced DMEM/F-12 (GIBCO) supplemented
with 1:50 B-27 (GIBCO), 1:100 N-2 (GIBCO), 10 mM nicotinamide (Sigma),
1.25 mM N-acetyl-L-cysteine (Sigma), 10 nM [Leu15]-gastrin (Sigma), 10 mM
forskolin (Tocris), 5 mM A83-01 (Tocris), 50 ng/mL EGF (PeproTech),
100 ng/mL FGF10 (PeproTech), 25 ng/ml HGF (PeproTech), 10% RSpo1-
conditioned medium, (homemade), and 30% Wnt3a-conditioned medium
(homemade). In the few cases for which enough biopsymaterial was available,
we tried an adapted version of the culture medium in comparison with the
normal one. The adapted medium lacked some of the original components re-
ported to have a negative effect on HCC cell proliferation (forskolin, N-acetyl-
L-cysteine, nicotinamide, HGF) and contained FGF19 because of the frequent
amplification of the FGF19 gene detected in HCCs and its positive effect on
proliferation of HCC cells. However, these attempts did not result in the
establishment of additional HCC organoid lines. Organoid cultures from non-
tumor liver biopsies were generated as previously described (Huch et al.,
2015). Tumor organoids were passaged after dissociation with 0.25%
Trypsin-EDTA (GIBCO). Non-tumor liver organoids were passaged by me-
chanical dissociation through a fire-polished Pasteur-pipette or incubation in
0.25% Trypsin-EDTA (GIBCO) for 2 min. Cryovials were prepared at regular in-
tervals by dissociating organoids and resuspending in Recovery Cell Culture
Freezing Medium (GIBCO) prior to freezing.
We could prepare frozen stocks of early (%P4) passages from all the samples
that yielded tumor organoids. All organoid lines could be kept in long-term
cultures with regular splitting for at least 1 year. All organoid cultures were regu-
larly tested for Mycoplasma contamination with the MycoAlert Mycoplasma
Detection Kit (Lonza) according to the manufacturer’s instructions.
Organoid Xenotransplantation
All experiments involving organoid transplantations into mice were performed
in strict accordance with Swiss law and were approved by the ethics commit-
tee of the northwestern part of Switzerland (Protocol Number EKNZ 2014-099)
and the Animal Care Committee of the Canton Basel-Stadt, Switzerland.
Tumor organoids, corresponding to 1 3 106 cells, were released from BME2
by incubating in Cell Recovery Solution (Corning), resuspended in !100 mL
50:50 (v/v) BME2:expansion medium, and injected subcutaneously into immu-
nodeficient non-obese diabetic (NOD) severe combined immunodeficiency
(SCID) gamma (NSG)mice (The Jackson Laboratory) at young age (6–8weeks).
Paired non-tumor liver organoids were used as negative control.
Histology and Immunohistochemistry
Liver biopsies from tumoral and non-tumor tissue, as well as tumor organoid
xenografts, were fixed in 4% phosphate-buffered formalin and embedded in
paraffin using standard procedures. Additional biopsies were also embedded
in O.C.T. (Tissue-Tek) and frozen using standard procedures. Tumor organo-
idswere released fromBME2 by incubating in Cell Recovery Solution (Corning)




following the manufacturer’s instructions. Organoids were then fixed in freshly
prepared 4% formalin solution in PBS for 30min at room temperature following
dehydration and paraffin embedding. Sections were subjected to H&E,
Masson’s trichrome, Alcian blue-periodic acid-Schiff (PAS), as well as immu-
nohistochemical staining, using standard procedures. Histopathological eval-
uation was assessed by two board-certified pathologists (M.S.M. and L.M.T.).
Tumors were classified based on architecture and cytological features, and
graded according to the Edmondson grading system (Edmondson and
Steiner, 1954).
For immunohistochemistry, the following primary antibodies were used for
automated staining on a Benchmark XT device (Ventana Medical Systems):
AFP (Ventana catalog number [Cat. No.] 760-2603), GS (Ventana Cat. No.
760-4898), GPC3 (Ventana Cat. No. 790-4564), HSP70 (Biocare Medical
CM407A), Keratin 7 (Ventana Cat. No. 790-4462), Keratin 19 (Ventana Cat.
No. 760-4281), and KI-67 (Ventana Cat. No. 760-4286).
Drug Treatment
Sorafenib tosylate (Cat. No. S-8502) was purchased from LC Laboratories,
dissolved in DMSO at 10 mM aliquots, and stored at!20"C. Tumor organoids
were plated at a density of 53 103 cells in 15 mL BME2 droplets in order to form
organoids. At day 6, sorafenib was added to the medium, and cell viability was
measured after 6 days using CellTiter-Glo 3D reagent (Promega). Lumines-
cence was measured on a Synergy H1 Multi-Mode Reader (BioTek Instru-
ments). Results were normalized to vehicle (=100% DMSO). Curve fitting
was performed using Prism (GraphPad) software and the nonlinear regression
equation. All experiments were performed at least two times in duplicate.
Results are shown as mean ± SEM.
DNA and RNA Extraction
Genomic DNA from tumor organoids was extracted using the DNeasy Blood &
Tissue kit (Qiagen) following the manufacturer’s instructions. Genomic DNA
and total RNA from biopsies were extracted using the ZR-Duet DNA and
RNA MiniPrep Plus kit (Zymo Research) following the manufacturer’s instruc-
tions. Prior to extraction, biopsies were crushed in liquid nitrogen to facilitate
lysis. Extracted DNA was quantified using the Qubit Fluorometer (Invitrogen).
Whole-Exome Sequencing
DNA extracted from eight HCC biopsy-derived organoid lines (patients 1, 2,
5-A, 5-B, 9, 12-I, 12-II, and 25), three CCC biopsy-derived organoid lines (pa-
tients 13, 16, and 20), the corresponding original biopsies, and the control
paired non-tumor biopsies were sequenced using whole-exome sequencing.
The eight HCC biopsies were derived from six patients and for three of the bi-
opsies, early- and late-passage organoids were profiled (Table S2). The tumor
biopsy sample corresponding to patient 1 had to be excluded from further an-
alyses because of low tumor cell content in the biopsy. Whole-exome capture
was performed using the SureSelectXT Clinical Research Exome (Agilent) plat-
form according to the manufacturer’s guidelines. Sequencing was performed
on an Illumina HiSeq 2500 at the Genomics Facility Basel according to the
manufacturer’s guidelines. Paired-end 101-bp reads were generated.
Whole-Exome Sequencing Analysis
Sequence reads were aligned to the reference human genome GRCh37 using
Burrows-Wheeler Aligner (BWA, v0.7.12) (Li and Durbin, 2009). Local realign-
ment, duplicate removal and base quality adjustment were performed using
the Genome Analysis Toolkit (GATK, v3.6) (McKenna et al., 2010) and Picard
(http://broadinstitute.github.io/picard/). Somatic single nucleotide variants
(SNVs) and small insertions and deletions (indels) were detected using MuTect
(v1.1.4) (Landau et al., 2013) and Strelka (v1.0.15) (Saunders et al., 2012),
respectively. We filtered out SNVs and indels outside of the target regions:
those with variant allelic fraction (VAF) of <1% and/or those supported by <3
reads. We excluded variants for which the tumor VAF was <5 times that of
the paired non-tumor VAF, as well as those found at >5% global minor allele
frequency of dbSNP (build 137). We further excluded variants identified in at
least two of a panel of 123 non-tumor samples, including the 4 non-tumor sam-
ples included in the current study, captured and sequenced using the same
protocols using the artifact detection mode of MuTect2 implemented in
GATK. All indels were manually inspected using the Integrative Genomics
Viewer (Thorvaldsdóttir et al., 2013). To account for the presence of somatic
mutations thatmay be present below the limit of sensitivity of somaticmutation
callers, we used GATK Unified Genotyper to interrogate the positions of all
unique mutations in all samples from a given patient to define the presence
of additional mutations.
Allele-specific CNAs were identified using FACETS (v0.5.5) (Shen and Se-
shan, 2016) as previously described (Piscuoglio et al., 2016), which performs
a joint segmentation of the total and allelic copy ratio and infers allele-specific
copy number states. Somatic mutations associated with the loss of the wild-
type allele (i.e., loss of heterozygosity [LOH]) were identified as those where
the lesser (minor) copy number state at the locus was 0. All mutations on
chromosome X in male patients were considered to be associated with
LOH. All gene amplifications and homozygous deletions were visually in-
spected using plots of raw log2 and allelic copy ratios. Copy number states
were collapsed to the gene level based on the median values to coding
gene resolution based on all coding genes retrieved from the Ensembl
(release GRCh37.p13).
The CCF of each mutation on the autosomes was inferred using the number
of reads supporting the reference and the alternate alleles, and the segmented
log2 ratio fromWES as input for ABSOLUTE (v1.0.6) (Carter et al., 2012). Solu-
tions fromABSOLUTEweremanually reviewed as recommended (Carter et al.,
2012; Landau et al., 2013). Amutation was classified as clonal if its clonal prob-
ability, as defined by ABSOLUTE, was >50%, or if the upper bound of the 95%
confidence interval of its CCF crosses 1.Mutations that did notmeet the above
criteria were considered subclonal.
Cancer genes were annotated according to the cancer gene lists described
by Kandoth et al. (2013) (127 significantly mutated genes), Lawrence et al.
(2014) (Cancer5000-S gene set), Fujimoto et al. (2016), or the TCGA (Cancer
Genome Atlas Research Network, 2017). Mutations affecting hotspot residues
(Chang et al., 2016; Gao et al., 2017) were annotated. Pathogenicity of
missense mutations was predicted using CHASM (liver cancer predictor, viral
or non-viral as appropriate) (Carter et al., 2009) and FATHMM (cancer predic-
tor) (Shihab et al., 2013).
Decomposition of the mutational signature was performed using
deconstructSigs (Rosenthal et al., 2016), based on the set of 30 mutational
signatures (‘‘signature.cosmic,’’ based on the signatures at https://cancer.
sanger.ac.uk/cosmic/signatures; Alexandrov et al., 2013; Nik-Zainal et al.,
2016).
RNA-Seq
RNA extracted from all HCC biopsies (n = 38; Table S1) and the paired non-tu-
mor biopsies were sequenced using RNA-seq. Tumor samples corresponding
to patients 1, 7-B (C959), 15-B, and 29-A had to be excluded from further an-
alyses because of low tumor cell content in the biopsy. 200 ng total RNA was
used for RNA-seq library prep with the TruSeq Stranded Total RNA Library
Prep Kit with Ribo-Zero Gold (Illumina) according to manufacturer’s specifica-
tions. SR126 sequencing was performed on an Illumina HiSeq 2500 using v4
SBS chemistry at the Genomics Facility Basel according to the manufacturer’s
guidelines. Primary data analysis was performed with the Illumina RTA version
1.18.66.3.
RNA Sequencing Analysis
Sequence reads were aligned to the human reference genome GRCh37
by STAR (Dobin et al., 2013) using the two-pass approach. Transcript quanti-
fication was performed using RSEM (Li and Dewey, 2011). For unsupervised
cluster analysis, we retrieved the TCGA Liver dataset RNA-seq data
(‘‘V2_MapSpliceRSEM’’) from the Genomics Data Commons Data Portal (Can-
cer Genome Atlas Research Network, 2017). We performed gene-level upper
quartile normalization of the combined dataset to the fixed threshold 1,000 as
described in the TCGA study (Cancer GenomeAtlas ResearchNetwork, 2017).
Genes whose expression was quantified to zero by RSEM (Li and Dewey,
2011) in >75%of the samples were removed. RSEM valueswere subsequently
log2-transformed, adding 0.5 to RSEM values prior to transformation. To iden-
tify genes with variable expression for clustering, genes with standard devia-
tion < 2 were excluded. Batch correction using the edgeR package (Niko-
layeva and Robinson, 2014) was performed to correct for systematic biases
between the datasets. Cluster analysis was performed using hierarchical




clustering using the Ward method and with a 1-Pearson correlation distance
(Cancer Genome Atlas Research Network, 2017).
For the TCGAHCC cohort (Cancer Genome Atlas Research Network, 2017),
images of diagnostic H&E slides were retrieved from the cbioportal (http://
www.cbioportal.org; accessed December 2017) (Gao et al., 2013) and re-
viewed by two expert hepato-pathologists (M.S.M. and L.M.T.) according to
the Edmondson grading system (Edmondson and Steiner, 1954) for compari-
son purposes. Differential expression analysis between biopsies that did or did
not yield organoids was performed using the edgeR package (Nikolayeva and
Robinson, 2014). Specifically, genes with <1 count per million in more than five
HCC biopsies were removed. Normalization was performed using the ‘‘TMM’’
(weighted trimmed mean) method, and differential expression was assessed
using the quasi-likelihood F-test.
Statistical Analysis
p values were calculated with Fisher’s exact test or Mann-Whitney test using
Prism (GraphPad) software, as specified in the Results section and in the figure
legends.
Data and Software Availability
Sequence data have been deposited at the European Genome-phenome
Archive (EGA), which is hosted by the EBI and the CRG, under accession num-
ber EGAS00001003115.
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Figure S1. Histological Analysis of Tumor and Non-tumor Derived Organoids from HCC and CCC 
Patients. Related to Figure 1, Figure 3 and Figure 4. (A) Representative Hematoxylin and Eosin 
images of paired non-tumor liver organoids derived from HCC and CCC patients. Scale bars: 100 µm. (B) 
Representative Hematoxylin and Eosin images of HCC organoids at early and late passage (range P4-
P28), showing no morphological differences after long-term culture. For Patient 2, HCC organoid culture 
time between early and late passage corresponds to 52 weeks, for Patient 5-A 29 weeks and Patient 5-B 
26 weeks. Scale bar: 100 µm. (C) Histological sections of three representative HCC biopsies, their 
derivative organoids and organoid-derived xenografts stained for Glypican 3 (GCP3), Glutamine 
Synthetase (GS) and Heat Shock Protein 70 (HSP70) by immunohistochemistry. Organoids were imaged 









Figure S2. KI-67 Analysis on HCC Tumor Biopsies Used for Organoid Generation. Related to 
Figure 2. (A) Representative tissue sections of ten randomly chosen HCC biopsies stained for the 
proliferation marker KI-67 by immunohistochemistry. Tumors that did not result in organoid growth have 
only few KI-67-positive nuclei. Scale bar: 100 µm. (B) Quantification of KI-67-positive nuclei for the ten 
HCC biopsies (p=0.0079, two-tailed t-test). Shown is the mean ± SEM of at least three images for each 


























































































































































































































































































































































































































































































































































































































































































































































































































































Figure S3. Repertoire of Somatic Mutations in Tumor Biopsies and Derivative Organoids of 
Patients 2, 5-A, 5-B and 9. Related to Figure 5. Heatmaps indicate the cancer cell fraction of somatic 
non-synonymous autosomal mutations as determined by ABSOLUTE (Carter et al., 2012) (blue, see color 
key) or their absence (grey) in each sequenced HCC tumor biopsy/ HCC organoids (A-D). Mutations 
affecting cancer genes (Fujimoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014) or hotspot 



















































































































































































































































































































































































































































































































































































Figure S4. Repertoire of Somatic Mutations in Tumor Biopsies and Derivative Organoids in 
Patients 12-I, 12-II, 25 and 13. Related to Figure 5. Heatmaps indicate the cancer cell fraction of 
somatic non-synonymous autosomal mutations as determined by ABSOLUTE (Carter et al., 2012) (blue, 
see color key) or their absence (grey) in each sequenced HCC tumor biopsy/ HCC organoids (A-D). 
Mutations affecting cancer genes (Fujimoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014) or 

































































































































































































































































































































































































































































































































































































































































































































Figure S5. Repertoire of Somatic Mutations in Tumor Biopsies and Derivative Organoids in Patient 
16. Related to Figure 5. Heatmaps indicate the cancer cell fraction of somatic non-synonymous 
autosomal mutations as determined by ABSOLUTE (Carter et al., 2012) (blue, see color key) or their 
absence (grey) in each sequenced HCC tumor biopsy/ HCC organoids. Mutations affecting cancer genes 
(Fujimoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014) or hotspot residues (Chang et al., 



























































































































































































































































































































































































































































































































































































































































































Figure S6. Repertoire of Somatic Mutations in Tumor Biopsies and Derivative Organoids in Patient 
20. Related to Figure 5. Heatmaps indicate the cancer cell fraction of somatic non-synonymous 
autosomal mutations as determined by ABSOLUTE (Carter et al., 2012) (blue, see color key) or their 
absence (grey) in each sequenced HCC tumor biopsy/ HCC organoids. Mutations affecting cancer genes 
(Fujimoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014) or hotspot residues (Chang et al., 

















Figure S7. Analysis of Long-term Genetic Stability in HCC and CCC Organoids. Related to Figure 5. 
(A) Venn diagrams illustrate the number of somatic non-synonymous mutations present in three 
representative HCC organoid lines at early and late passage. For whole exome sequencing analysis of the 
HCC organoids derived from Patient 2, culture time between early and late passage was 32 weeks, 
corresponding to 16 passages. For the HCC organoid lines 5-A and 5-B culture time was 8 weeks 
corresponding to 6 and 4 passages, respectively. (B) Repertoire of somatic non-synonymous mutations 
affecting cancer genes (Fujimoto et al., 2016; Kandoth et al., 2013; Lawrence et al., 2014) at early and 
late passage. The effects of the mutations are color-coded according to the legend, with hotspots (Chang 
et al., 2016; Gao et al., 2017) colored in red. The presence of multiple non-synonymous mutations in the 
same gene is represented by an asterisk. The presence of loss of heterozygosity of the wild-type allele of 
a mutated gene is represented by a diagonal bar, and mutations found to be clonal by ABSOLUTE (Carter 
et al., 2012) are indicated by a black box. (C) Heatmap of copy number alterations in HCC biopsies and 
derivative organoids (Patients 2, 5-A, 5-B, 9, 12-I, 12-II and 25) and CCC biopsies and derivative 
organoids (Patients 13, 16 and 20). Samples are presented in rows and chromosomal positions on the x-
axis (columns). Dark blue: amplification, light blue: copy number gain; white: neutral; light red: copy 
number loss; dark red: homozygous deletion. (D) Heatmap illustrating the copy number alterations 
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Figure S8. Mutational Signatures in Tumor Biopsies and Derivative Organoids. Related to Figure 5. 
(A) Barplots illustrate the mutational signatures of the HCC biopsies and the corresponding organoids at 
early and late passage (late passage only for Patients 2, 5-A and 5-B). In each panel, the colored barplot 
illustrates each mutational signature according to the 96 substitution classification (Alexandrov et al., 
2013) defined by the substitution classes (C>A, C>G, C>T, T>A, T>C and T>G bins) and the 5’ and 3’ 
sequence context, normalized using the observed trinucleotide frequency in the human exome to that in 
the human genome. The bars are ordered first by mutation class (C>A/G>T, C>G/G>C, C>T/G>A, 
T>A/A>T, T>C/A>G, T>G/A>C), then by the 5’ flanking base (A, C, G, T) and then by the 3’ flanking base 





7.1. Liver-derived organoid cultures 
In 2016, an estimate of 45 million people worldwide suffered from chronic liver dis-
ease owing to different underlying factors including viral hepatitis, alcohol abuse, 
non-alcoholic fatty liver disease and other risk factors leading to the development of 
cirrhosis182. Failure in the management of CLD can be attributed to the lack of suffi-
cient organs for liver transplantations. Cell therapies might offer an alternative to liver 
transplantation, however, current models based on iPSCs raise uncertainty regarding 
their genetic stability in culture since the reprogramming procedure of adult differen-
tiated cells into iPSCs can induce genetic and epigenetic alterations183. The recently-
developed liver organoid system based on the expansion of aSCs could provide a 
new alternative to iPSCs-based cell therapies127. Importantly, the reprogramming 
step is not required for organoids because the starting cell, the adult stem cell, has 
the intrinsic capability to proliferate and generate differentiated cells of its own line-
age, provided that the essential niche factors are present in the culture medium. This 
convenient advantage is reflected in the high genetic stability of organoids in culture 
and therefore, they could represent a valuable alternative to iPSCs for regenerative 
medicine purposes.  
 
The present thesis demonstrates the feasibility of generating organoid cultures from 
small needle biopsies of patients undergoing diagnostic liver biopsy procedure (Fig-
ure 10). Patients referred to our outpatient clinic present with the whole spectrum of 
liver disease and, accordingly, the organoid biobank generated in our lab encom-
passes most of these etiologies. Differently than for tissue material obtained from 
surgical resection, liver needle biopsies can be performed in almost every patient 
with liver disease, even in those with compromised liver function that are usually not 
amenable for surgery. In addition, it allows the establishment of large biobanks. Such 
biobanks can be used to identify inter-individual features that impact on therapy re-
sponse and therefore help to stratify patients in different treatment groups. In addi-
tion, liver biopsies can be obtained during the course of treatment to generate a lon-
gitudinal set of in vitro cultures that reflects the cellular and molecular changes in re-




Our biobank currently encompasses more than 100 organoid cultures derived from 
patients with different liver disease backgrounds, namely, HBV, HCV, AIH, ALD, cir-
rhosis, DILI, fibrosis, Morbus Wilson, NAFLD, PBC. A large proportion of our cultures 
was derived from the non-tumor tissue of liver cancer patients that, as previously out-
lined, suffer from the same underlying chronic liver diseases as those patients with-
out liver cancer.  
Organoids could be established in 100% of the cases, even from biopsy fragments 
as small as 5 mm in length by ~1 mm in diameter. After 3–4 weeks, the quantity of 
expanded organoids was sufficient to allow downstream histological and molecular 
analysis as well as cryopreservation for biobanking purposes. 
 
Liver organoids are composed of bipotent progenitors127 and their differentiation into 
the hepatocyte fate resulted in a strong upregulation of transcripts encoding major 
hepatocyte markers (Figure 11). Glycogen synthesis and Albumin secretion, two 
hallmarks of mature hepatocytes, were also detected upon differentiation. However, 
when compared to primary human hepatocytes and primary liver tissue (biopsy), the 
expression levels of the three assessed markers were significantly lower. HepG2 
cells — a widely used tumor-derived cell line with several hepatocyte features — also 
displayed higher levels of these markers, however, due to the fact that these are 
cancer cells, the difference in transcript levels may be explained by a general 
dysregulation of gene expression or their polyclonality as compared to non-tumoral 
cells. Nevertheless, the main reason may be related to the fact that the differentiation 
protocol is not optimal, and the cells do not reach the same maturation level as in the 
in vivo situation. Indeed, when comparing the expression levels of two major cholan-
giocyte markers, EpCAM and KRT19, we did not observe a reduction following dif-
ferentiation, despite the fact that the protocol is designed to inhibit cholangiocyte- 
and promote hepatocyte maturation. The fact that these markers are already present 
in undifferentiated organoids could be explained by the cellular origin within the liver. 
Indeed, the original report found that the organoid-initiating cell is residing in the 
cholangiocyte-harboring ductal compartment of the liver that forms the biliary tree127. 
The cells residing there are EpCAM- and KRT19-positive, two markers that are ab-
sent in mature hepatocytes. As previously reported, only EpCAM-positive cells were 
able to grow as organoids in vitro127. This excludes the possibility that mature 
hepatocytes could serve as the cell of origin in liver organoids. However, it does not 
exclude the fact that liver organoids may arise from adult stem- or progenitor cells 
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residing within the ducts in close proximity to mature cholangiocytes. Alternatively, 
organoids may arise from dedifferentiated hepatocytes or cholangiocytes. Indeed, 
the single cell-layered epithelium of liver organoids shares similarities with bile ducts 
in vivo (Figure 1). Hepatocytes in contrast, do not form cysts or ducts implying that 
liver organoids arise from cells that have the ability to do so.  
 
One of the main concepts of liver regeneration is based on the presence of bipotent 
progenitors in the Canal of Hering, a structure at the junction between cholangiocytes 
and hepatocytes (Figure 1). If organoids originated from such cells, it would explain 
their cystic or tubular growth. In some reports, the bipotent progenitors residing in the 
Canal of Hering are referred to as oval cells10. These cells are characterized by their 
ability to differentiate into hepatocytes as well as cholangiocytes, similarly to hepato-
blasts during liver development. This could explain the expression of both, cholangi-
ocyte- (EpCAM, KRT19, SOX9) and hepatocyte (HNF4a) markers in liver 
organoids127. Oval cells are thought to be dormant adult stem cells only appearing 
upon liver injury. The factors released during hepatocyte damage function as activa-
tors of oval cell proliferation and differentiation10. In vitro, this would be achieved 
through the numerous growth factors provided with the culture medium. Moreover, a 
recent study convincingly demonstrated the ability of ductal cells to proliferate and 
convert into hepatocytes to repopulate the liver upon massive hepatocyte loss24. The 
question whether all ductal cells or only the oval cell subpopulation is driving this re-
generative response remains to be answered. Nevertheless, the study confirms the 
intrinsic ability of ductal cells to transdifferentiate into hepatocytes under specific cir-
cumstances. Therefore, an improved differentiation protocol may also lead to such a 
conversion in vitro. To achieve this, we need to deepen our understanding of the sig-
nals regulating the maturation of newly-formed hepatocytes in vivo, independently 
from their origin. Indeed, transplantation of differentiated liver organoids into recipient 
mice, suggested that full hepatocyte maturation may only be reached after in vivo 
engraftment127.  
 
Despite the drawbacks of the current differentiation protocol, the goal to generate 
fully mature hepatocytes from undifferentiated organoids is probably not that far 
away. Indeed, examination of the ultrastructural features of liver organoids revealed 
structures exclusively found in mature hepatocytes, namely bile canaliculi (Figure 
12). Bile canaliculi are small tubes that collect the bile produced by hepatocytes (Fig-
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ure 1). The bile canalicular membrane represents the apical side of the hepatocyte 
and contains specific transporters that export bile acids into the canaliculi. This func-
tion is crucial for hepatocyte homeostasis, because bile acids are natural detergents 
and therefore toxic if they accumulate in the cell. Therefore, given that differentiated 
organoids produce bile acids127, the bile canaliculi-like structures revealed by TEM 
may actually be functional. In addition, the fact that these structures were also found 
in undifferentiated organoids (Figure 12), suggests that the cell of origin is indeed 
distinct from mature ductal cells/cholangiocytes that, in contrast to hepatocytes, don’t 
form bile canaliculi in vivo. Again, this speaks in favor of oval cells as the source of 
organoid-initiating cells because, as previously outlined, they share characteristics of 
both hepatocytes and cholangiocytes and this may include the formation of ear-
ly/immature canalicular-like structures. 
 
One recognized factor that influences cellular behavior in vitro is the matrix in which 
cells are suspended for three-dimensional growth. Matrigel® and BME2® are two 
widely-used extracellular matrix (ECM) hydrogels derived from Engelbreth-Holm-
Swarm mouse sarcoma, a tumor rich in laminin and, to a minor extent, collagen IV, 
heparin sulfate proteoglycans, and fibronectin. The use of laminin-rich matrices ena-
bles the growth of organoids irrespective of their tissue origin. This is due to one 
common feature of all epithelial organoid systems that have been developed so far: 
the cells from which they are derived are sitting on a basement membrane, whose 
main constituents are in fact laminin and collagen IV. For the liver, the only cells in 
contact with a basement membrane are ductal cells, whereas hepatocytes are pri-
marily embedded within collagen III, IV, V and fibronectin, while laminin is completely 
absent184. Therefore, the fact that Matrigel and BME2 are mainly composed of lam-
inin and lack sufficiently high concentrations of collagen III, IV and V, may explain 
why liver organoids fail to completely mature into hepatocytes under these conditions 
in vitro. Recent efforts to optimize the culture and differentiation of organoids include 
the generation of matrices directly from liver tissue instead of using murine tumors185, 
or the de novo synthesis of artificial hydrogels complemented with short peptides re-
quired for ECM signaling186. Importantly, these approaches also allow to define the 





In conclusion, the development of the liver organoid system allows for the first time to 
systematically culture and expand liver-derived progenitor cells from human tissue 
specimens. Contrary to PHHs, liver organoids can grow indefinitely and produce 
large cell numbers within short time frames. Provided that an improved differentiation 
protocol will allow the conversion of progenitors into fully mature hepatocytes, such 
cultures may represent a precious source for cell therapies and overcome the limited 
number of donors for liver transplantation. 
 
7.2. Liver cancer-derived organoid cultures 
Liver cancer, with HCC accounting for ~80% of the cases, is a global health problem 
that causes 830’000 deaths every year. The incidence continuously increased during 
the last years and is predicted to continue mostly due to an increase of liver patholo-
gies related to obesity. A small proportion of HCC is diagnosed at early stages, for 
which curative treatments exist, however, most of the tumors are detected at later 
stages, for which the therapeutic management of the disease is ineffective. 
A major drawback in HCC research has been the lack of appropriate models that re-
flect the biology and heterogeneity of HCCs observed in patients. This is mainly due 
to two reasons: first, the current human in vitro models in HCC research, cancer cell 
lines, were all derived decades ago and it is not clear how well they represent the 
primary tumors. Moreover, despite their broad utility, cell lines suffer from significant 
shortcomings such as the lack of a three-dimensional structure that preserves the 
cellular interactions of the primary tumor as well as the different cellular components. 
Second, in the specific case of HCCs, the material used to generate cell lines is pre-
dominantly derived from surgically resected specimens. But as previously outlined, 
surgical resection is not broadly applicable to HCC patients, especially at later dis-
ease stages, and the models generated with tissue obtained thereof fails to represent 
the whole spectrum of HCCs. Furthermore, current drug discovery programs aim at 
developing new therapies for patients with advanced HCC and therefore, the models 
used in basic- and pre-clinical research should ideally reflect the targeted patient 
spectrum to effectively translate into the clinic. 
 
The organoid system, initially developed for the culture of intestinal stem cells, offers 
new opportunities to develop personalized cancer models from a much larger spec-
trum of patients and individual tumors, than it was so far possible with conventional 
cancer cell lines. Organoids retain several features of the primary tumors, can be 
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successfully derived from different tumor nodules within the same patient and, im-
portantly, they can robustly model treatment response in patients148. It was therefore 
obvious to apply the organoid derivation protocol to HCC and combine it with the use 
of needle biopsy-derived tissue specimens, to cover all disease stages and over-
come the limitations of current models. 
 
We collected a series of tumor biopsies from patients with suspected HCC and pro-
cessed the tissue for organoid generation. Additional biopsies from the same tumor 
site were collected and immediately snap-frozen for later use in omics analyses, or 
formalin-fixed for histological evaluation.  
The examination of the histological properties of our HCC organoids revealed a re-
markable similarity with their originating tumors in terms of growth patterns and dif-
ferentiation grades. In addition, the expression of common HCC tumor markers was 
equally preserved, and their expression followed the same pattern that was observed 
in the primary tumors. Our biopsy cohort also included tumor tissue derived from 
CCCs that could also be propagated as organoids in vitro. Despite the different cell 
of origin, the culture medium used for all organoids, allowed the growth of CCC cells 
without altering their morphological features, indicating that the ability to reproduce 
the tissue architecture is an intrinsic property of the tumor cells. We further confirmed 
this with the generation of xenografts from transplanted tumor organoids. Indeed, the 
same histological features were maintained in the xenografts despite the different 
microenvironment that, in comparison to in vitro organoids, also contained other cell 
types and growth factors. The transplantation experiments also allowed the genera-
tion of xenografts from CCC organoids and the resulting tumors displayed various 
degrees of desmoplastic stroma, i.e. the accumulation of ECM around tumor cells 
typical for adenocarcinomas. 
 
The molecular landscape of the originating tumors was very well preserved in the 
corresponding organoids, complementing the high histological similarity. The number 
of non-synonymous somatic mutations between biopsy and organoids concorded to 
~90% across the different patients. Moreover, when specifically looking at mutations 
in cancer genes, nearly all identified oncogenes and tumor suppressors were pre-
served in the organoids. However, some mutations were lost during organoid deriva-
tion and new mutations, absent in the originating biopsy, were detected in the organ-
oids. The loss can be explained by the fact that some mutations were subclonal and 
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presumably not present in the whole biopsy since we only used a fragment of the en-
tire biopsy. Mutations exclusively found in the organoids can derive from in vitro cul-
turing and the increased mutation rate of tumor cells (tumor evolution). Importantly, 
only seven mutations throughout all the HCC cultures, either lost or newly acquired in 
organoids, affected cancer genes. These mutations were all subclonal and could 
therefore explain the discordance with the primary tumors. 
The analysis of somatic mutations in CCC biopsies and organoids revealed hyper-
mutator phenotype in two patients, with more than 500 somatic mutations per tumor. 
For one of the patients most of the mutations were preserved in the corresponding 
organoids, whereas for the other patient, 83% of the mutations detected in the biopsy 
were lost in the organoids. This again can be attributed to the fact that the mutations 
that were not preserved in the organoids were only present in subclonal cell popula-
tions within the originating tumor biopsy. However, in most of the cases, analysis of 
the cancer cell fraction (CCF) in the originating HCC and CCC biopsies, revealed the 
presence of subclonal mutations that were maintained at similar frequencies in the 
organoids. This underlines the advantage of organoids compared to typically clonal 
cancer cell lines.  
 
The different etiologies of HCC and CCC were all reflected in our organoid biobank, 
indicating that the underlying disease does not dictate the efficiency of generating 
organoid cultures. However, the overall efficiency to generate organoids from HCC 
biopsies was ~26% and ~33% per number of biopsies or patients, respectively. This 
seems low compared to other tumor organoid models such as colorectal can-
cer136,144, pancreatic cancer128, and breast cancer137, with efficiencies above 75%. 
The lower efficiency could be explained by the fact that, as previously outlined, the 
cell of origin of HCCs, the hepatocytes, do not form organoids with the actual organ-
oid culture system (identical to the one used for HCC organoids). Indeed, colorectal-, 
pancreatic- and breast cancers, all derive from epithelial (stem) cells that can be 
propagated as organoids in vitro125. Within the liver, only cholangiocyte-/ductal-like 
cells can form organoids and therefore, the culture conditions used to derive tumor 
organoids from liver cancers may be suboptimal for HCCs.  
Alternatively, the low success rate could imply that only a subclass of HCCs can be 
propagated in vitro. To investigate possible factors determining success or failure to 
generate organoids, we collected clinical- and histopathological data for all tumors 
used to generate organoids. There was no correlation with clinical parameters such 
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as the disease background, the presence or absence of cirrhosis, the severity of liver 
disease, the level of serum AFP, the metastatic status, and the tumor stage, again 
indicating the broad diversity of our tumor organoids. However, when looking at the 
histopathological features, one parameter in our analysis was clearly noticeable: the 
differentiation grade of the tumor. All tumors that successfully generated organoids in 
vitro, were derived from poorly differentiated (grades III and IV) HCCs according to 
the staging system by Edmondson and Steiner89. This finding may be explained by a 
progressive loss of the cells’ requirements for specific environmental cues with in-
creasing differentiation grade. Indeed, low-grade HCCs (grades I and II) retain nearly 
all features of normal hepatocytes and can be difficult to diagnose. One of these fea-
tures is the low proliferative activity of hepatocytes in vivo and in vitro under homeo-
static conditions. Accordingly, low-grade HCCs are predominantly slow-growing in 
vivo189 and may explain why they do not proliferate in vitro once they are processed 
for organoid generation. Indeed, when analyzing the expression of the proliferation 
marker KI-67, we only found <20% proliferating cells in those biopsies who did not 
generate organoids. In contrast, all biopsies that could be successfully propagated as 
tumor organoids harbored >50% proliferating cells. However, there is no sharp sepa-
ration between grade II and III tumors, as we also found high-grade HCCs with only 
few proliferating cells. It seems therefore, that a certain proliferative threshold repre-
sents the dominant feature dictating the success to generate organoids, inde-
pendently from their (micro-)environmental requirements. These findings however, 
does not imply that our tumor organoids are biased for a specific molecular subclass. 
Indeed, hierarchical clustering analysis of all biopsies used in our study together with 
a recently-published set of poorly differentiated HCCs from the TCGA cohort90, did 
not identify an enrichment for a defined subclass. We therefore conclude that our 
high-grade HCC organoids generated from tumor biopsies are a genuine representa-
tion of all classes of poorly differentiated HCCs. 
 
As outlined before, we anticipate that the organoid system will improve future drug 
development because of the higher physiological relevance compared to cancer cell 
lines and the ability to derive cultures from virtually all patient groups while preserv-
ing their respective tumor features. We tested the effect of sorafenib on our cohort of 
HCC organoids using the clinically-relevant dose range applied in patients159 and 
found different sensitivities across the different lines. It was not possible to conclude 
whether the response in organoids could be classified as sensitive or resistant to so-
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rafenib using dose-response curves only. Most of the patients from whom we derived 
organoids were treated with other modalities. Because of side effects, treatment on 
the two sole sorafenib-treated patients from our cohort had to be discontinued before 
treatment efficacy could be determined. The clinical relevance of drug testing in tu-
mor organoids has been recently confirmed in direct comparisons with patients suf-
fering from various gastrointestinal tumors148. For such direct comparisons we will 
need additional tumor organoids from patients undergoing sorafenib treatment. Im-
portantly, the generation of tumor organoids from patients resistant to sorafenib 
treatment could also allow to study the intrinsic resistance mechanisms in tumor 
cells.  
 
Increasing the efficiency to generate organoids from tumor biopsies will reduce the 
time needed to expand the biobank to a size that allows meaningful correlations with 
clinical outcomes in patients. It’s still not excluded that some of the HCCs might ben-
efit from an adapted version of the culture protocol. This could include a refined reci-
pe of the growth factor-enriched medium as well as novel matrices that may facilitate 
the growth of well differentiated HCCs with higher requirements to their microenvi-
ronment. Other improvements may come from the culture of tumor organoids under 
hypoxic conditions, an approach previously shown to expand the spectrum of CRCs 
that could be propagated in vitro144. 
 
Finally, the importance of the tumor microenvironment is well recognized69. Tumor 
organoids are purely composed of cancer cells and therefore, not completely repre-
sentative of the whole cancer ecosystem. Recently, culture systems that aimed to co-
culture tumor cells with endothelial cells190, fibroblasts145, or immune cells146 provided 
first insights into the interactions and/or dependencies of cancer cells and their cellu-
lar neighbors in the tumor microenvironment.    
 
7.3. Concluding remarks 
An important advantage of the organoid system is that long-term cultivation and bi-
obanking of living cells becomes for the first time possible in a substantial percentage 
of patients. The latest progress in organoid derivation from small biopsy tissue prom-
ises a big boost to personalized treatment approaches. However, using HCC organ-
oids for informed decision-making before treatment onset in the corresponding pa-
tient, may not be feasible. First, the time to derive and establish a new patient-
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derived HCC organoid line ranges from 4–12 weeks. Only then, cells will be suffi-
ciently expanded to allow their characterization together with a predictive drug testing 
in vitro. However, patients with advanced HCCs progress rapidly and treatment 
needs to be started immediately. Second, personalized treatment implies the genera-
tion of organoids for every patient, a premise that requires greater efficiencies in es-
tablishing organoids from HCCs.  
In our opinion, tumor organoids will rather demonstrate their utility to predict treat-
ment response based on the molecular features of the tumors in a non-individualized 
manner. Large pan-cancer molecular analyses revealed that driver gene mutations 
can affect 12 different signaling pathways and lead to the alteration of three core cel-
lular processes: cell fate, cell survival, and genome maintenance91. Therefore, it 
would be sufficient to generate a tumor organoid biobank encompassing all altered 
pathways and then link in vitro drug response to specific molecular alterations, e.g. 
mutations or copy number alterations, that are present in the respective tumor (or-
ganoids). Following this approach, we could reduce the number of models needed to 
cover the molecular spectrum to ~50–100 organoid lines. To serve as a true refer-
ence set, tumor organoids will require a comprehensive characterization by various 
omics approaches, also including proteomics/phosphoproteomics. Indeed, most sig-
naling pathways rely on phosphorylation cascades across multiple protein-protein 
interactions, obviously not captured by exome- or transcriptome-based sequencing 
methods. Importantly, small molecule inhibitors such as sorafenib act by preventing 
kinases to forward a signal along the pathway. We hypothesize that sorafenib re-
sistance may in part result from treatment-induced or pre-existing activation of by-
pass signaling pathways that are (only) detectable with phosphoproteomic analysis. 
These follow-up experiments are currently ongoing and will complement the existing 
molecular profile, as well as provide a dataset to investigate the effects of kinase 
modulators on tumor organoids with different backgrounds and molecular alterations.     
 
In conclusion, we developed a novel in vitro tool for the study of liver cancers and 
provide evidence for their physiological relevance and future clinical utility. The bi-
obank can be continuously expanded, clinical and molecular data annotated, and 
drug response profiles correlated with individual tumor features, offering a helpful re-
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Table S1. Complete List of Patient Biopsies Used for the Generation of Liver Cancer Organoid Cultures. Samples 
were obtained between July 2015 and September 2017 and are ordered chronologically according to the date of the 
biopsy. If more than one tumor nodule was biopsied in a given patient, the different nodules are designated with let-
ters (e.g. 5-A and 5-B). If more than one biopsy was taken from different locations of the same (large) nodule, the 
different locations are labeled with roman numbers (e.g. 12-I and 12-II). The five cholangiocellular carcinoma cases 
are shown in italic font. Sex, age, background liver disease, clinical staging according to the Barcelona Clinic Liver 
Cancer (BCLC) staging system and Alpha-Fetoprotein (AFP) serum concentrations were obtained from the clinical 
charts of the patients. The viable tumor cell content, Edmondson grade and the growth pattern were determined in 
each biopsy on Hematoxylin and Eosin stained sections by two experienced hepato-pathologists (M.S.M. and 
L.M.T.). All CCC tumors were poorly differentiated. ALD: Alcoholic Liver Disease; AFP: Alpha-Fetoprotein; BCLC: 
Barcelona Clinic Liver Cancer; CCC: Cholangiocellular Carcinoma; HBV: Hepatitis B Virus; HCC: Hepatocellular 
Carcinoma; HCV: Hepatitis C Virus; LELCC: Lymphoepithelioma-like Cholangiocarcinoma; NAFLD: Nonalcoholic 






Sex Age Tumor Liver 
Disease(s)




Necrosis Stroma Non-malignant 
Liver 




1 C655 Male 55 HCC HCV; ALD no C 10% 5% 80% 5% III trabecular-pseudoglandular 269  
2 C798 Male 73 HCC NAFLD no C 70% 5% 5% 20% III solid-trabecular 20'377  
3-A C937 Male 70 HCC HBV yes B 95% 5% II solid-trabecular 701  -
4-A C942 70% III solid-trabecular  -
4-B C944 30% III solid-pseudoglandular  -
5-A C948 80% 10% 10% III trabecular  
5-B C949 40% 30% 30% III trabecular  
6 C951 Female 71 HCC ALD yes C 80% 10% 10% III solid-trabecular 1'745  -
7-A C958 40% 10% 10% 40% III solid-trabecular  -
7-B C959 5% 95% n.e. n.e.  -
8 C964 Male 71 HCC ALD yes B 95% III solid-trabecular 2.6  -
7-B C965 Male 53 HCC HCV; ALD yes C 50% 10% 40% III solid-trabecular 228  -
9 C975 Male 59 HCC HCV; ALD yes B 50% 30% 20%% III solid 250  
3-B C977 Male 70 HCC HBV yes B 30% 20% 50% III solid 701  -
10-I D016 85% 15% III trabecular-pseudoglandular  -
10-II D017 75% 25% III trabecular-pseudoglandular  -
10-III D018 85% 15% II trabecular-pseudoglandular  -
11 D029 Female 73 HCC ALD yes B 50% 40% 10% II solid-trabecular 7.9  -
12-I D045 80% 10% 10% III solid-trabecular  
12-II D046 70% 10% 20% III solid-trabecular  
13 D091 Female 61 CCC none no n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 4.4  
14-I D096 40% 60% IV solid  -
14-II D097 30% 10% 60% IV solid  -
14-III D098 50% 20% 30% IV solid  -
15-A D135 80% 5% 15% IV solid-trabecular  -
15-B D136 5% 5% 10% 80% IV solid-trabecular  -
16 D141 Male 59 LELCC HBV yes n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 2.1  
17-A D152 90% 5% 5% II solid  -
17-B D153 95% 5% I/II solid  -
18 D156 Male 67 HCC HBV yes A 95% 5% II trabecular 205  -
19 D176 Male 79 HCC none no C 95% II pseudoglandular 0.9  -
20 D178 Female 63 CCC HCV yes n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. 3.1  
21 D268 Male 70 HCC NAFLD yes B 95% II trabecular 10.2  -
22-A D282 n.a. n.a. n.a. n.a. n.a. n.a. n.a.  -
22-B D283 n.a. n.a. n.a. n.a. n.a. n.a. n.a.  -
23-I D293 n.a. n.a. n.a. n.a. n.a. n.a. n.a.  -
23-II D296 n.a. n.a. n.a. n.a. n.a. n.a. n.a.  -
24-A D301 90% 5% 5% III solid-pseudoglandular  -
24-B D302 80% 20% III solid  -
25 D324 Male 58 HCC HCV yes D 70% 10% 20% III trabecular 104'710  
26 D332 Male 72 HCC ALD no A 90% 10% II solid-trabecular 3.1  -
27 D359 Male 86 HCC NAFLD no A 90% 10% III trabecular 5'917  
28 D373 Female 79 HCC HCV no C 65% II solid-trabecular 135  -
29-A D386 20% 10% 70% IV solid  
29-B D388 70% 10% 20% IV solid-trabecular  -
>100'000
Male 57 HCC HCV; ALD yes C 12'054
Male 76 HCC NAFLD yes C
228
Male 83 HCC none no A 231
Male 53 HCC HCV; ALD yes C
7'852
Male 75 HCC ALD no A 2
Male 69 HCC HCV no A
11.4
Male 73 HCC HCV yes B 678
Male 57 HCC HCV yes C
201.9
Female 74 CCC none no n.a. 11.8
Female 83 CCC NAFLD no n.a.
>400'000
Male 80 HCC ALD; NAFLD no A 49.8
Female 67 HCC ALD yes C
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Table S2. Whole Exome Sequencing Statistics. 
 
  

















Patient 2 HCC biopsy C798 94'400'859 84.833832 0.986912 0.929052 0.846582 0.762986 0.679087 0.597782 0.299673
Patient 5-A HCC biopsy C948 182'374'059 158.418593 0.99129 0.973319 0.93111 0.882093 0.831304 0.780505 0.553611
Patient 5-B HCC biopsy C949 175'590'720 151.835666 0.991171 0.972848 0.932723 0.889122 0.844978 0.799712 0.570083
Patient 9 HCC biopsy C975 106'802'239 96.985837 0.98905 0.946091 0.869019 0.788226 0.708543 0.633594 0.354944
Patient 12-I HCC biopsy D045 109'808'365 101.266678 0.990285 0.962181 0.902125 0.831947 0.758875 0.685875 0.384054
Patient 12-II HCC biopsy D046 106'176'163 93.784138 0.990509 0.96674 0.909361 0.839428 0.763436 0.685031 0.352563
Patient 13 CCC biopsy D091 52'417'380 49.568261 0.98486 0.908378 0.774253 0.630126 0.497682 0.387621 0.105262
Patient 16 CCC biopsy D141 51'804'174 48.658019 0.988706 0.934484 0.808445 0.660925 0.51506 0.389413 0.085029
Patient 20 CCC biopsy D178 48'277'502 44.973331 0.986826 0.917074 0.770792 0.60697 0.458088 0.33793 0.072328
Patient 25 HCC biopsy D324 169'053'773 145.133507 0.992001 0.982957 0.955138 0.916063 0.871091 0.822127 0.565329
Patient 2 Non-tumoral liver biopsy C797 55'597'906 51.514998 0.987624 0.916564 0.780781 0.636293 0.505447 0.397432 0.118063
Patient 5-A/B Non-tumoral liver biopsy C562 55'247'613 50.936808 0.990132 0.959643 0.855046 0.716609 0.57204 0.436664 0.081186
Patient 9 Non-tumoral liver biopsy C974 52'904'603 49.192584 0.985752 0.905382 0.765966 0.618861 0.486064 0.376917 0.104853
Patient 12-I/II Non-tumoral liver biopsy D043 47'954'416 44.604354 0.987038 0.912963 0.766297 0.604999 0.457908 0.339034 0.070557
Patient 13 Non-tumoral liver biopsy D089 48'362'073 45.750593 0.988441 0.938396 0.808547 0.649892 0.493208 0.360386 0.063489
Patient 16 Non-tumoral liver biopsy D140 58'733'948 54.028392 0.988459 0.929535 0.80807 0.673906 0.545263 0.433826 0.127464
Patient 20 Non-tumoral liver biopsy D177 50'955'773 49.419051 0.979436 0.892369 0.764814 0.626612 0.498259 0.390868 0.107444
Patient 25 Non-tumoral liver biopsy D323 100'073'292 88.711677 0.990714 0.964361 0.901141 0.82682 0.745931 0.663279 0.330326
Patient 2 early Organoid SN03 97'592'493 88.354733 0.989341 0.975786 0.932732 0.863128 0.7795 0.691544 0.322518
Patient 2 late Organoid SN04 91'169'165 82.477626 0.988877 0.971284 0.918346 0.838347 0.746465 0.652457 0.285949
Patient 5-A early Organoid SN05 99'157'797 88.881486 0.98934 0.97531 0.930665 0.860606 0.777803 0.690775 0.328442
Patient 5-A late Organoid SN06 101'447'853 93.594768 0.989411 0.976472 0.937101 0.873283 0.79587 0.713193 0.356365
Patient 5-B early Organoid SN07 98'038'120 89.963971 0.989228 0.974935 0.930919 0.861868 0.779373 0.693016 0.338199
Patient 5-B late Organoid SN08 91'421'651 85.565113 0.989111 0.973194 0.924945 0.850049 0.762593 0.672212 0.312226
Patient 9 Organoid SN09 92'503'866 85.293773 0.989486 0.973246 0.922417 0.844441 0.755309 0.665404 0.308846
Patient 12-I Organoid SN11 48'607'137 44.986138 0.988373 0.933043 0.781295 0.61079 0.459165 0.336837 0.066151
Patient 12-II Organoid SN10 85'979'664 77.71085 0.989002 0.967542 0.904676 0.813179 0.712399 0.613627 0.261313
Patient 13 Organoid SN12 46'906'182 43.317132 0.986808 0.927777 0.771911 0.599944 0.448793 0.326933 0.058203
Patient 16 Organoid SN13 39'472'727 37.402368 0.98626 0.904481 0.712167 0.518329 0.362321 0.248342 0.036972
Patient 20 Organoid SN14 64'941'346 57.49781 0.988992 0.959738 0.861499 0.73019 0.596509 0.473746 0.127552
Patient 25 Organoid SN15 199'686'354 167.892064 0.991861 0.987713 0.979065 0.962377 0.936599 0.902926 0.679912
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# mutations in 
tumor biopsy (% 
of total number 
of mutations)





# of which only 
in the early 
passage 
organoids (% 
of mutations in 
biopsy)
# of which only 
in the late 
passage 
organoids (% 
of mutations in 
biopsy)
# of which not 
in any organoid 
(% of mutations 
in biopsy)
# mutations not 
in tumor biopsy 
(% of total 
number of 
mutations)






# of novel 
mutations only 





# of novel 
mutations 





Patient 2 C798 153 127 (83%) 106 (83%) 3 (2%) 1 (1%) 17 (13%) 26 (17%) 6 (23%) 2 (8%) 18 (69%)
Patient 5-A C948 211 173 (82%) 146 (84%) 6 (3%) 3 (2%) 18 (10%) 38 (18%) 16 (42%) 9 (24%) 13 (34%)
Patient 5-B C949 196 168 (86%) 153 (91%) 1 (1%) 1 (1%) 13 (8%) 28 (14%) 13 (46%) 13 (46%) 2 (7%)
Patient 9 C975 225 207 (92%) NA 159 (77%) NA 48 (23%) 18 (8%) NA 18 (100%) NA
Patient 12-I D045 175 146 (83%) NA 136 (93%) NA 10 (7%) 29 (17%) NA 29 (100%) NA
Patient 12-II D046 162 143 (88%) NA 125 (87%) NA 18 (13%) 19 (12%) NA 19 (100%) NA
Patient 13 D091 130 115 (88%) NA 59 (51%) NA 56 (49%) 15 (12%) NA 15 (100%) NA
Patient 16 D141 830 760 (92%) NA 740 (97%) NA 20 (3%) 70 (8%) NA 70 (100%) NA
Patient 20 D178 938 920 (98%) NA 152 (17%) NA 768 (83%) 18 (2%) NA 18 (100%) NA
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of mutations)
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in the early 
passage 
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of mutations in 
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of mutations in 
biopsy)
# of which not 
in any organoid 
(% of mutations 
in biopsy)
# mutations not 
in tumor biopsy 
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Patient 2 C798 116 97 (84%) 80 (82%) 2 (2%) 1 (1%) 14 (14%) 19 (16%) 3 (16%) 2 (11%) 14 (74%)
Patient 5-A C948 161 128 (80%) 111 (87%) 4 (3%) 2 (2%) 11 (9%) 33 (20%) 12 (36%) 9 (27%) 12 (36%)
Patient 5-B C949 139 125 (90%) 115 (92%) 0 (0%) 0 (0%) 10 (8%) 14 (10%) 7 (50%) 7 (50%) 7 (50%)
Patient 9 C975 166 153 (92%) NA 119 (78%) NA 34 (22%) 13 (8%) NA 13 (100%) NA
Patient 12-I D045 124 100 (81%) NA 94 (94%) NA 6 (6%) 24 (19%) NA 24 (100%) NA
Patient 12-II D046 118 101 (86%) NA 91 (90%) NA 10 (10%) 17 (14%) NA 17 (100%) NA
Patient 13 D091 97 85 (88%) NA 49 (58%) NA 36 (42%) 12 (12%) NA 12 (100%) NA
Patient 16 D141 654 600 (92%) NA 587 (98%) NA 13 (2%) 54 (8%) NA 54 (100%) NA
Patient 20 D178 630 617 (98%) NA 103 (17%) NA 514 (83%) 13 (2%) NA 13 (100%) NA
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Patient 2 C798 3 3 (100%) 3 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (NA) 0 (NA) 0 (NA)
Patient 5-A C948 9 6 (67%) 6 (100%) 0 (0%) 0 (0%) 0 (0%) 3 (33%) 1 (33%) 1 (33%) 1 (33%)
Patient 5-B C949 5 5 (100%) 5 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (NA) 0 (NA) 0 (NA)
Patient 9 C975 4 4 (100%) NA 3 (75%) NA 1 (25%) 0 (0%) NA 0 (NA) NA
Patient 12-I D045 7 5 (71%) NA 4 (80%) NA 1 (20%) 2 (29%) NA 2 (100%) NA
Patient 12-II D046 4 4 (100%) NA 4 (100%) NA 0 (0%) 0 (0%) NA 0 (NA) NA
Patient 13 D091 7 6 (86%) NA 4 (67%) NA 2 (33%) 1 (14%) NA 1 (100%) NA
Patient 16 D141 17 17 (100%) NA 17 (100%) NA 0 (0%) 0 (0%) NA 0 (NA) NA
Patient 20 D178 17 17 (100%) NA 4 (24%) NA 13 (76%) 0 (0%) NA 0 (NA) NA
Patient 25 D324 4 3 (75%) NA 3 (100%) NA 0 (0%) 1 (25%) NA 1 (100%) NA
Includes all somatic muations
Includes only non-synonymous somatic mutations
Table S3: Somatic Mutation Counts in Tumor Biopsies and Derivative Organoids. Related to Figure 5
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Kandoth Lawrence Fujimoto Hotspot Facets LOH Call CHROM POS ALT CCF
Absolute 
Clonal
Patient 2, Biopsy C1orf159 p.Thr26Met missense_variant 0.322 0 90 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Biopsy ACTL8 p.Val6Ile missense_variant 0.0756303 0 119 88 . . . . . FALSE 1 18149519 A 0.28 Subclonal
Patient 2, Biopsy TMCO4 p.Ala211Ser missense_variant 0.467 0 30 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Biopsy HIVEP3 p.Met265fs frameshift_variant 0.40458 0 131 91 . . . . . FALSE 1 42049671 C 1 Subclonal
Patient 2, Biopsy LEPRE1 p.Asp253Val missense_variant 0.313 0 224 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Biopsy KIF2C p.Arg258Thr missense_variant 0.231 0 13 24 . . . . . FALSE 1 45221614 C 0.85 Clonal
Patient 2, Biopsy ELTD1 p.Ile35Ile synonymous_variant 0.571429 0 7 15 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Biopsy LRRC8C p.Phe667Phe synonymous_variant 0.217 0.019 60 53 . . . . . FALSE 1 90180130 C 0.8 Clonal
Patient 2, Biopsy GJA5 p.Lys233del disruptive_inframe_deletion 0.0868545 0 426 82 . . . . . FALSE 1 147230646 A 0.93 Clonal
Patient 2, Biopsy OTUD7B p.Lys550* stop_gained 0.06 0 433 97 . . . . . FALSE 1 149916640 A 0.64 Subclonal
Patient 2, Biopsy CA14 p.Ser215Trp missense_variant 0.016 0 250 138 . . . . . FALSE 1 150235522 G 0.17 Subclonal
Patient 2, Biopsy APOA2 p.Met34fs frameshift_variant 0.0576923 0 624 188 . . . . . FALSE 1 161193173 T 0.62 Subclonal
Patient 2, Biopsy GJC2 p.Leu353Pro missense_variant 0.192 0 26 22 . . . . . FALSE 1 228346517 C 0.9 Clonal
Patient 2, Biopsy OTX1 p.His260Gln missense_variant 0.024 0 250 117 . . . . . FALSE 2 63283166 G 0.14 Subclonal
Patient 2, Biopsy PROM2 p.Leu119Leu synonymous_variant 0.04 0 125 92 . . . . . FALSE 2 95941738 T 0.19 Subclonal
Patient 2, Biopsy CYP27C1 p.Pro243Pro synonymous_variant 0.104 0 106 64 . . . . . FALSE 2 127951434 G 0.49 Subclonal
Patient 2, Biopsy NEB p.Ile3069Thr missense_variant 0.057 0 493 222 . . . . . TRUE 2 152490376 G 0.21 Subclonal
Patient 2, Biopsy FASTKD2 p.Asn663Ser missense_variant 0.161 0 31 46 . . . . . FALSE 2 207655385 G 0.76 Clonal
Patient 2, Biopsy PIKFYVE p.Asn383Asn synonymous_variant 0.211 0 57 37 . . . . . FALSE 2 209165759 T 0.99 Clonal
Patient 2, Biopsy COL6A3 p.Ser220Ser synonymous_variant 0.19 0 205 126 . . . . . FALSE 2 238303279 T 0.89 Clonal
Patient 2, Biopsy SNED1 p.Ala316Val missense_variant 0.62 0 179 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Biopsy ATG4B p.Arg201Arg synonymous_variant 0.626 0 195 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Biopsy KIAA1143 p.Gln136Lys missense_variant 0.241 0 29 30 . . . . . FALSE 3 44794892 T 1 Clonal
Patient 2, Biopsy TMF1 p.Cys318Ser missense_variant 0.647 0 17 24 . . . . . FALSE 3 69096903 G 1 Clonal
Patient 2, Biopsy PPP4R2 p.Ser146Arg missense_variant 0.727 0 11 9 . . . . . FALSE 3 73112842 A 1 Clonal
Patient 2, Biopsy IFT57 p.Phe41Cys missense_variant 0.259 0 54 20 . . . . . FALSE 3 107941048 C 0.96 Clonal
Patient 2, Biopsy SPICE1 p.Leu419fs frameshift_variant 0.257143 0 35 61 . . . . . FALSE 3 113184532 G 0.95 Clonal
Patient 2, Biopsy ITGB5 p.Asp640His missense_variant&splice_region_variant 0.208 0 24 31 . . . . . FALSE 3 124487959 G 0.77 Clonal
Patient 2, Biopsy MSL2 p.Arg344Lys missense_variant 0.075 0 80 46 . . . . . FALSE 3 135870692 T 0.28 Subclonal
Patient 2, Biopsy PHC3 p.Trp937* stop_gained 0.012987 0 77 25 . . . . . FALSE 3 169820290 T 0.06 Subclonal
Patient 2, Biopsy EPHB3 p.Gln509Lys missense_variant 0.172 0 60 64 . . . . . FALSE 3 184295491 A 0.78 Clonal
Patient 2, Biopsy TMEM41A p.Phe44Phe synonymous_variant 0.333 0 18 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Biopsy ADH1A p.Glu253Glu synonymous_variant 0.0324074 0 216 102 . . . . . TRUE 4 100203572 T 0.12 Subclonal
Patient 2, Biopsy DNAJB14 p.Tyr38Cys missense_variant 0.097 0 62 29 . . . . . TRUE 4 100867616 C 0.36 Subclonal
Patient 2, Biopsy FAM149A p.Pro442Ser missense_variant 0.146 0 96 59 . . . . . TRUE 4 187077221 T 0.54 Subclonal
Patient 2, Biopsy BDP1 p.Ala932fs frameshift_variant 0.458333 0 48 56 . . . . . FALSE 5 70805704 T 1 Clonal
Patient 2, Biopsy SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.109375 0 64 72 . . . . . FALSE 5 131667533 T 0.4 Subclonal
Patient 2, Biopsy PPP1R18 p.Pro346His missense_variant 0.137 0 153 121 . . . . . TRUE 6 30652759 T 0.78 Clonal
Patient 2, Biopsy CFB p.Ile744Val missense_variant 0.842 0 184 115 . . . . . TRUE 6 31915584 G 1 Clonal
Patient 2, Biopsy ZFAND3 p.Gln168Arg missense_variant 0.159 0 44 16 . . . . . TRUE 6 38084489 G 0.91 Clonal
Patient 2, Biopsy DNAH8 p.Ser1436Arg missense_variant 0.0666667 0 15 18 . . . . . TRUE 6 38802396 G 0.38 Subclonal
Patient 2, Biopsy GLP1R p.Arg64Pro missense_variant 0.102 0.00489 728 409 . . . . . TRUE 6 39025263 C 0.58 Subclonal
Patient 2, Biopsy DST p.Lys6551Asn missense_variant 0.107 0 168 40 . . . . . TRUE 6 56366028 G 0.61 Subclonal
Patient 2, Biopsy ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.219 0 32 9 . . . . . TRUE 6 100964054 C 1 Clonal
Patient 2, Biopsy KIAA1919 p.Gln415Pro missense_variant 0.091 0 88 65 . . . . . TRUE 6 111588009 C 0.52 Subclonal
Patient 2, Biopsy AGPAT4 p.Glu149Gln missense_variant 0.016 0 250 250 . . . . . TRUE 6 161575246 G 0.09 Subclonal
Patient 2, Biopsy POU6F2 p.Gly132Val missense_variant 0.056 0 125 45 . . . . . TRUE 7 39247103 T 0.26 Subclonal
Patient 2, Biopsy COPS6 p.Phe168Leu missense_variant 0.554 0 56 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Biopsy CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 0.903 0 62 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Biopsy NUGGC p.Thr176Thr synonymous_variant 0.143 0 42 24 . . . . . FALSE 8 27925214 T 0.81 Clonal
Patient 2, Biopsy WRN p.Ala1179Ser missense_variant 0.24 0 25 28 TRUE . . . . FALSE 8 31004955 T 1 Clonal
Patient 2, Biopsy NSMAF p.Glu12* stop_gained 0.44 0 50 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Biopsy CSMD3 p.Asp293Asn missense_variant 0.278 0 18 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Biopsy CNTLN p.Lys862Thr missense_variant 0.896 0 48 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Biopsy TRMT10B p.Thr195Thr synonymous_variant 0.831 0 89 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Biopsy C9orf64 p.Ile114Met missense_variant 0.822 0 45 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Biopsy SLC28A3 p.Glu500* stop_gained 0.063 0 144 109 . . . . . TRUE 9 86900409 A 0.29 Subclonal
Patient 2, Biopsy TSC1 p.Gln767* stop_gained 0.841 0 270 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Biopsy INPP5E p.Ser582Ser synonymous_variant 0.038 0.006803 237 150 . . . . . TRUE 9 139324785 A 0.18 Subclonal
Patient 2, Biopsy PRKCQ p.Asn462Asn synonymous_variant 0.587 0 219 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Biopsy MASTL p.Arg793fs frameshift_variant 0.0602837 0 282 91 . . . . . FALSE 10 27469988 G 0.58 Subclonal
Patient 2, Biopsy HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 0.833 0 72 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Biopsy SFXN3 p.Val222Val synonymous_variant 0.786 0 42 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Biopsy EPS8L2 p.Asp172Tyr missense_variant 0.522 0 92 84 . . . . . FALSE 11 720735 T 1 Clonal
Patient 2, Biopsy HPX p.Ser288Gly missense_variant 0.441 0 59 60 . . . . . FALSE 11 6453221 C 1 Clonal
Patient 2, Biopsy DCHS1 p.Leu644Gln missense_variant 0.617 0 222 168 . . . . . FALSE 11 6655404 T 1 Clonal
Patient 2, Biopsy NELL1 p.Val349Leu missense_variant 0.333 0 30 23 . . . . . FALSE 11 20949989 C 1 Clonal
Patient 2, Biopsy KIAA1549L p.Gly1602Gly synonymous_variant 0.542 0 24 17 . . . . . FALSE 11 33667501 A 1 Clonal
Patient 2, Biopsy OR8K5 p.Pro283Ser missense_variant 0.075 0 40 22 . . . . . FALSE 11 55926947 A 0.28 Subclonal
Patient 2, Biopsy OR9Q1 p.Thr278Ala missense_variant 0.417 0 84 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Biopsy MS4A12 p.Pro255Pro synonymous_variant 0.408 0 98 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Biopsy LRP5 p.His965Asp missense_variant 0.049 0 678 407 . . . . . FALSE 11 68183861 G 0.23 Subclonal
Patient 2, Biopsy SYTL2 p.Glu1611Val missense_variant 0.378 0 37 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Biopsy FAT3 p.Glu2075Lys missense_variant 0.159 0 44 30 . . . . . FALSE 11 92532402 A 0.75 Clonal
Patient 2, Biopsy ARHGEF12 p.Leu630Phe missense_variant 0.45 0 211 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Biopsy TAS2R30 p.Val125Leu missense_variant 0.0357143 0 28 41 . . . . . TRUE 12 11286471 G 0.13 Subclonal
Patient 2, Biopsy HDAC7 p.Pro472Leu missense_variant 0.701 0.013 97 76 . . . . . FALSE 12 48188637 A 1 Clonal
Patient 2, Biopsy KMT2D p.Met1530Val missense_variant 0.658 0 231 145 TRUE TRUE TRUE . . FALSE 12 49439953 C 1 Clonal
Patient 2, Biopsy C12orf42 p.Gly270Arg missense_variant 0.185 0 92 30 . . . . . FALSE 12 103696161 T 1 Clonal
Patient 2, Biopsy SVOP p.Asp79Asn missense_variant 0.079 0 76 29 . . . . . FALSE 12 109366201 T 0.45 Subclonal
Patient 2, Biopsy ANKLE2 p.Gly46Gly synonymous_variant 0.13 0 23 13 . . . . . FALSE 12 133338247 T 0.74 Clonal
Patient 2, Biopsy CDX2 p.Ser208Asn missense_variant 0.147 0.013 143 75 TRUE . . . . TRUE 13 28539071 T 0.69 Subclonal
Patient 2, Biopsy PROSER1 p.Asn516Asn synonymous_variant 0.2 0 60 27 . . . . . TRUE 13 39587841 A 0.94 Clonal
Patient 2, Biopsy KPNA3 p.Leu323Leu synonymous_variant 0.405 0 74 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Biopsy NALCN p.Ile1593Val missense_variant 0.235 0 51 25 . . . . . TRUE 13 101712298 C 1 Clonal
Patient 2, Biopsy SALL2 p.Pro365Leu missense_variant 0.531 0 192 95 . . . . . FALSE 14 21992768 A 1 Clonal
Patient 2, Biopsy TRAV38-1 p.Ser13Phe missense_variant 0.148 0 54 13 . . . . . FALSE 14 22739891 T 0.84 Clonal
Patient 2, Biopsy AKAP6 p.Arg509* stop_gained 0.122 0 74 34 . . . . . FALSE 14 33015384 T 0.69 Subclonal
Patient 2, Biopsy SRSF5 p.Ser90Gly missense_variant 0.381 0 118 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Biopsy GOLGA5 p.Ala522Asp missense_variant 0.458 0.012 118 86 TRUE . . . . FALSE 14 93286126 A 1 Clonal
Patient 2, Biopsy DPH6 p.Leu45Gln missense_variant 0.875 0 32 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Biopsy SRRM2 p.Trp513* stop_gained 0.326 0 139 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Biopsy C16orf89 p.Leu128Leu synonymous_variant 0.298 0 84 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Biopsy ZNF843 p.Glu264Glu synonymous_variant 0.0422535 0 71 26 . . . . . FALSE 16 31447379 T 0.28 Subclonal
Patient 2, Biopsy CDH11 p.Glu391Asp missense_variant 0.011236 0 89 20 TRUE . . . . FALSE 16 65016031 A 0.08 Subclonal
Patient 2, Biopsy DPEP3 p.Arg3Trp missense_variant 0.256 0 39 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Biopsy ZNF469 p.Thr3815Met missense_variant 0.151 0 119 83 . . . . . FALSE 16 88505322 T 1 Clonal
Patient 2, Biopsy TP53 p.Arg209fs frameshift_variant 0.819767 0 172 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Biopsy KCNAB3 p.Leu224fs frameshift_variant 0.0201149 0 348 168 . . . . . TRUE 17 7827765 C 0.11 Subclonal
Patient 2, Biopsy RARA p.Asp449Asp synonymous_variant 0.225 0 41 40 TRUE . . . . FALSE 17 38512388 T 1 Clonal
Patient 2, Biopsy KRTAP4-11 p.Arg51Lys missense_variant 0.123288 0 73 38 . . . . . FALSE 17 39274416 T 0.7 Subclonal
Patient 2, Biopsy HOXB5 p.Arg224Leu missense_variant 0.17 0 153 74 . . . . . FALSE 17 46669710 A 0.97 Clonal
Patient 2, Biopsy AKAP1 p.Leu832Val missense_variant 0.138 0 65 32 . . . . . FALSE 17 55194282 G 0.79 Clonal
Patient 2, Biopsy USH1G p.Thr100Lys missense_variant 0.142 0 338 165 . . . . . FALSE 17 72916632 T 0.81 Subclonal
Patient 2, Biopsy DDC8 p.Gln416* stop_gained 0.105 0 172 100 . . . . . FALSE 17 76887340 A 0.6 Subclonal
Patient 2, Biopsy FASN p.Leu1826fs frameshift_variant 0.138889 0 288 142 . . . . . FALSE 17 80041170 G 0.79 Subclonal
Patient 2, Biopsy GALNT1 p.Arg426Cys missense_variant 0.25 0 12 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Biopsy FHOD3 p.Leu261Leu synonymous_variant 0.365 0 74 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Biopsy FHOD3 p.Arg1568His missense_variant 0.553 0 258 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Biopsy SMAD7 p.Pro215Leu missense_variant 0.633 0 60 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Biopsy DOT1L p.Ile1251Ile synonymous_variant 0.827 0.007519 151 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Biopsy ZNF414 p.Leu257Phe missense_variant 0.244 0 41 32 . . . . . TRUE 19 8576604 G 0.9 Clonal
Patient 2, Biopsy ADAMTS10 p.Val904Val synonymous_variant 0.516 0.011 124 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Biopsy MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.087 0 46 48 . . . . . TRUE 19 9015384 G 0.32 Subclonal
Patient 2, Biopsy ZNF561 p.Arg441Pro missense_variant 0.695 0 82 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Biopsy RAVER1 p.Ala477Ala synonymous_variant 0.833 0 12 14 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Biopsy CAPN12 p.His686Arg missense_variant 0.794 0 34 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Biopsy ERCC1 p.Gly133Gly synonymous_variant 0.877 0 204 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Biopsy RTN2 p.Ser211Ser synonymous_variant 0.073 0 206 153 . . . . . TRUE 19 45997605 C 0.27 Subclonal
Patient 2, Biopsy AC012313.1 p.Val202Met missense_variant 0.133 0 45 31 . . . . . TRUE 19 58908060 A 0.49 Subclonal
Patient 2, Biopsy PLCB4 p.Val86Phe missense_variant 0.578 0 45 30 . . . . . FALSE 20 9319571 T 1 Clonal
Patient 2, Biopsy MYH7B p.Ser797* stop_gained 0.381 0 194 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Biopsy BCL2L13 p.Ser190Leu missense_variant 0.154 0 65 38 . . . . . FALSE 22 18185121 T 0.57 Subclonal
Patient 2, Biopsy PPP1R3F p.Asn345Asn synonymous_variant 0.936 0 47 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Biopsy ARR3 p.Leu49Leu splice_region_variant&synonymous_variant 0.156 0 32 16 . . . . . TRUE X 69495933 A Did not evaluate
Patient 2, Biopsy FGF13 p.Glu54Lys missense_variant 0.881 0 59 15 . . . . . TRUE X 137939731 T Did not evaluate
Patient 2, Biopsy GABRE p.Lys302Met missense_variant 0.277 0 65 13 . . . . . TRUE X 151124212 A Did not evaluate
Patient 2, Organoids early p. C1orf159 p.Thr26Met missense_variant 0.583 0 48 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Organoids early p. ACTL8 p.Val6Ile missense_variant 0.104 0 78 70 . . . . . FALSE 1 18149519 A 0.41 Subclonal
Patient 2, Organoids early p. TMCO4 p.Ala211Ser missense_variant 0.719 0 32 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Organoids early p. HIVEP3 p.Met265fs frameshift_variant 0.40708 0 113 91 . . . . . FALSE 1 42049671 C 1 Clonal
Patient 2, Organoids early p. LEPRE1 p.Asp253Val missense_variant 0.451 0 175 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Organoids early p. KIF2C p.Arg258Thr missense_variant 0.154 0 26 24 . . . . . FALSE 1 45221614 C 0.62 Clonal
Patient 2, Organoids early p. HPDL p.Gly61Arg missense_variant 0.00826446 0 121 112 . . . . . FALSE 1 45793001 A 0.03 Subclonal
Patient 2, Organoids early p. ELTD1 p.Ile35Ile synonymous_variant 0.386 0 44 13 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Organoids early p. LRRC8C p.Phe667Phe synonymous_variant 0.361 0.019 158 53 . . . . . FALSE 1 90180130 C 1 Clonal
Patient 2, Organoids early p. GJA5 p.Lys233del disruptive_inframe_deletion 0.0896739 0 368 82 . . . . . FALSE 1 147230646 A 0.9 Clonal
Patient 2, Organoids early p. CA14 p.Ser215Trp missense_variant 0.065 0 277 112 . . . . . FALSE 1 150235522 G 0.65 Subclonal
Patient 2, Organoids early p. APOA2 p.Met34fs frameshift_variant 0.0546218 0 476 188 . . . . . FALSE 1 161193173 T 0.55 Subclonal
Patient 2, Organoids early p. GJC2 p.Leu353Pro missense_variant 0.111 0 36 22 . . . . . TRUE 1 228346517 C 0.56 Subclonal
Patient 2, Organoids early p. OTX1 p.His260Gln missense_variant 0.065 0 186 86 . . . . . FALSE 2 63283166 G 0.32 Subclonal
Patient 2, Organoids early p. PROM2 p.Leu119Leu synonymous_variant 0.208 0 96 68 . . . . . FALSE 2 95941738 T 1 Clonal
Patient 2, Organoids early p. CYP27C1 p.Pro243Pro synonymous_variant 0.086 0 70 64 . . . . . FALSE 2 127951434 G 0.43 Subclonal
Patient 2, Organoids early p. NEB p.Ile3069Thr missense_variant 0.313 0 387 222 . . . . . TRUE 2 152490376 G 0.94 Clonal
Patient 2, Organoids early p. FASTKD2 p.Asn663Ser missense_variant 0.399 0 138 46 . . . . . FALSE 2 207655385 G 1 Clonal
Patient 2, Organoids early p. PIKFYVE p.Asn383Asn synonymous_variant 0.262 0 130 37 . . . . . FALSE 2 209165759 T 1 Clonal
Patient 2, Organoids early p. COL6A3 p.Ser220Ser synonymous_variant 0.183 0 312 126 . . . . . FALSE 2 238303279 T 0.91 Clonal
Patient 2, Organoids early p. SNED1 p.Ala316Val missense_variant 0.658 0 152 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Organoids early p. ATG4B p.Arg201Arg synonymous_variant 0.704 0 159 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Organoids early p. KIAA1143 p.Gln136Lys missense_variant 0.245 0 53 30 . . . . . TRUE 3 44794892 T 0.98 Clonal
Patient 2, Organoids early p. TMF1 p.Cys318Ser missense_variant 0.625 0 48 24 . . . . . TRUE 3 69096903 G 1 Clonal
Patient 2, Organoids early p. PPP4R2 p.Ser146Arg missense_variant 0.1875 0 16 12 . . . . . TRUE 3 73112842 A 0.56 Subclonal
Patient 2, Organoids early p. SPICE1 p.Leu419fs frameshift_variant 0.328358 0 67 61 . . . . . TRUE 3 113184532 G 0.99 Clonal
Patient 2, Organoids early p. ITGB5 p.Asp640His missense_variant&splice_region_variant 0.462 0 13 31 . . . . . TRUE 3 124487959 G 1 Clonal
Patient 2, Organoids early p. MSL2 p.Arg344Lys missense_variant 0.28 0 93 46 . . . . . TRUE 3 135870692 T 0.84 Clonal
Patient 2, Organoids early p. PHC3 p.Trp937* stop_gained 0.099 0 141 19 . . . . . FALSE 3 169820290 T 0.6 Subclonal
Patient 2, Organoids early p. EPHB3 p.Gln509Lys missense_variant 0.113924 0 79 67 . . . . . FALSE 3 184295491 A 0.68 Clonal
Patient 2, Organoids early p. TMEM41A p.Phe44Phe synonymous_variant 0.171 0 41 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Organoids early p. ADH1A p.Glu253Glu synonymous_variant 0.0281124 0 249 102 . . . . . TRUE 4 100203572 T 0.08 Subclonal
Patient 2, Organoids early p. DNAJB14 p.Tyr38Cys missense_variant 0.4 0 70 29 . . . . . TRUE 4 100867616 C 1 Clonal
Patient 2, Organoids early p. BDP1 p.Ala932fs frameshift_variant 0.580645 0 93 56 . . . . . TRUE 5 70805704 T 1 Clonal
Patient 2, Organoids early p. SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.25974 0 77 72 . . . . . TRUE 5 131667533 T 0.78 Clonal
Patient 2, Organoids early p. CFB p.Ile744Val missense_variant 0.824 0 125 115 . . . . . TRUE 6 31915584 G 1 Clonal
Patient 2, Organoids early p. DNAH8 p.Ser1436Arg missense_variant 0.133 0 75 15 . . . . . TRUE 6 38802396 G 0.67 Subclonal
Patient 2, Organoids early p. DST p.Lys6551Asn missense_variant 0.125 0 263 40 . . . . . TRUE 6 56366028 G 0.63 Subclonal
Patient 2, Organoids early p. RIMS1 p.Lys718Asn missense_variant 0.13 0 100 16 . . . . . TRUE 6 72957743 T 0.65 Subclonal
Patient 2, Organoids early p. ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.163 0 43 9 . . . . . TRUE 6 100964054 C 0.81 Clonal
Patient 2, Organoids early p. KIAA1919 p.Gln415Pro missense_variant 0.185 0 130 65 . . . . . TRUE 6 111588009 C 0.92 Clonal
Patient 2, Organoids early p. AGPAT4 p.Glu149Gln missense_variant 0.098 0 214 189 . . . . . TRUE 6 161575246 G 0.49 Subclonal
Patient 2, Organoids early p. POU6F2 p.Gly132Val missense_variant 0.276 0 87 45 . . . . . TRUE 7 39247103 T 1 Clonal
Patient 2, Organoids early p. COPS6 p.Phe168Leu missense_variant 0.583 0 48 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Organoids early p. CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 1 0 41 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Organoids early p. MGAM p.Ser1292Ser synonymous_variant 0.0294118 0 34 49 . . . . . TRUE 7 141759328 T 0.12 Subclonal
Patient 2, Organoids early p. MGAM p.Ser2188Ser synonymous_variant 0.037 0 164 74 . . . . . TRUE 7 141785689 T 0.15 Subclonal
Patient 2, Organoids early p. NUGGC p.Thr176Thr synonymous_variant 0.343 0 35 24 . . . . . TRUE 8 27925214 T 1 Clonal
Patient 2, Organoids early p. WRN p.Ala1179Ser missense_variant 0.14 0 101 28 TRUE . . . . TRUE 8 31004955 T 0.55 Subclonal
Patient 2, Organoids early p. NSMAF p.Glu12* stop_gained 0.622 0 45 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Organoids early p. CSMD3 p.Asp293Asn missense_variant 0.214 0 182 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Organoids early p. ADCY8 p.His239Asn missense_variant 0.0070922 0 141 26 . . . . . FALSE 8 132051865 T 0.07 Subclonal
Patient 2, Organoids early p. CNTLN p.Lys862Thr missense_variant 1 0 44 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Organoids early p. TRMT10B p.Thr195Thr synonymous_variant 1 0 106 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Organoids early p. C9orf64 p.Ile114Met missense_variant 0.975 0 40 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Organoids early p. SLC28A3 p.Glu500* stop_gained 0.239 0 176 109 . . . . . TRUE 9 86900409 A 0.95 Clonal
Patient 2, Organoids early p. TSC1 p.Gln767* stop_gained 1 0 193 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Organoids early p. PRKCQ p.Asn462Asn synonymous_variant 0.673 0 269 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Organoids early p. MASTL p.Arg793fs frameshift_variant 0.077951 0 449 91 . . . . . FALSE 10 27469988 G 0.7 Subclonal
Patient 2, Organoids early p. HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 1 0 54 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Organoids early p. SFXN3 p.Val222Val synonymous_variant 1 0 31 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Organoids early p. EPS8L2 p.Asp172Tyr missense_variant 0.697 0 66 84 . . . . . TRUE 11 720735 T 1 Clonal
Patient 2, Organoids early p. HPX p.Ser288Gly missense_variant 0.682 0 44 60 . . . . . TRUE 11 6453221 C 1 Clonal
Patient 2, Organoids early p. DCHS1 p.Leu644Gln missense_variant 0.794 0 170 168 . . . . . TRUE 11 6655404 T 1 Clonal
Patient 2, Organoids early p. NELL1 p.Val349Leu missense_variant 0.25 0 44 23 . . . . . TRUE 11 20949989 C 1 Clonal
Patient 2, Organoids early p. KIAA1549L p.Gly1602Gly synonymous_variant 0.69 0 29 17 . . . . . TRUE 11 33667501 A 1 Clonal
Patient 2, Organoids early p. OR8K5 p.Pro283Ser missense_variant 0.219 0 96 18 . . . . . FALSE 11 55926947 A 1 Clonal
Patient 2, Organoids early p. OR9Q1 p.Thr278Ala missense_variant 0.412 0 102 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Organoids early p. MS4A12 p.Pro255Pro synonymous_variant 0.357 0 221 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Organoids early p. LRP5 p.His965Asp missense_variant 0.225 0 457 407 . . . . . FALSE 11 68183861 G 1 Clonal
Patient 2, Organoids early p. SYTL2 p.Glu1611Val missense_variant 0.418 0 79 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Organoids early p. ARHGEF12 p.Leu630Phe missense_variant 0.457 0 210 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Organoids early p. TAS2R30 p.Val125Leu missense_variant 0.157 0 102 35 . . . . . TRUE 12 11286471 G 0.63 Subclonal
Patient 2, Organoids early p. HDAC7 p.Pro472Leu missense_variant 0.792 0.013 72 76 . . . . . TRUE 12 48188637 A 1 Clonal
Patient 2, Organoids early p. KMT2D p.Met1530Val missense_variant 0.776 0 157 145 TRUE TRUE TRUE . . TRUE 12 49439953 C 1 Clonal
Patient 2, Organoids early p. C12orf42 p.Gly270Arg missense_variant 0.198 0 96 30 . . . . . TRUE 12 103696161 T 0.99 Clonal
Patient 2, Organoids early p. SVOP p.Asp79Asn missense_variant 0.164 0 63 29 . . . . . TRUE 12 109366201 T 0.79 Clonal
Patient 2, Organoids early p. ANKLE2 p.Gly46Gly synonymous_variant 0.385 0 13 13 . . . . . TRUE 12 133338247 T 1 Clonal
Patient 2, Organoids early p. KPNA3 p.Leu323Leu synonymous_variant 0.388 0 103 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Organoids early p. SALL2 p.Pro365Leu missense_variant 0.625 0 96 95 . . . . . TRUE 14 21992768 A 1 Clonal
Patient 2, Organoids early p. TRAV36DV7 p.Gly103Arg missense_variant 0.078 0 51 23 . . . . . TRUE 14 22695116 A 0.31 Subclonal
Patient 2, Organoids early p. SRSF5 p.Ser90Gly missense_variant 0.517 0 145 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Organoids early p. GOLGA5 p.Ala522Asp missense_variant 0.439 0.012 198 86 TRUE . . . . FALSE 14 93286126 A 1 Clonal
Patient 2, Organoids early p. DPH6 p.Leu45Gln missense_variant 1 0 53 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Organoids early p. SRRM2 p.Trp513* stop_gained 0.442 0 86 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Organoids early p. C16orf89 p.Leu128Leu synonymous_variant 0.541 0 74 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Organoids early p. ZNF843 p.Glu264Glu synonymous_variant 0.146 0 41 21 . . . . . FALSE 16 31447379 T 0.73 Clonal
Patient 2, Organoids early p. CDH11 p.Glu391Asp missense_variant 0.111 0 54 17 TRUE . . . . FALSE 16 65016031 A 0.56 Subclonal
Patient 2, Organoids early p. DPEP3 p.Arg3Trp missense_variant 0.321 0 28 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Organoids early p. ZNF469 p.Thr3815Met missense_variant 0.205 0 88 83 . . . . . FALSE 16 88505322 T 1 Clonal
Patient 2, Organoids early p. TP53 p.Arg209fs frameshift_variant 0.92381 0 105 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Organoids early p. RARA p.Asp449Asp synonymous_variant 0.142857 0 70 48 TRUE . . . . TRUE 17 38512388 T 0.71 Clonal
Patient 2, Organoids early p. KRTAP4-11 p.Arg51Lys missense_variant 0.0952381 0 105 38 . . . . . TRUE 17 39274416 T 0.48 Subclonal
Patient 2, Organoids early p. HOXB5 p.Arg224Leu missense_variant 0.189 0 95 74 . . . . . TRUE 17 46669710 A 0.95 Clonal
Patient 2, Organoids early p. AKAP1 p.Leu832Val missense_variant 0.205 0 44 32 . . . . . TRUE 17 55194282 G 1 Clonal
Patient 2, Organoids early p. USH1G p.Thr100Lys missense_variant 0.182 0 198 165 . . . . . TRUE 17 72916632 T 0.91 Clonal
Patient 2, Organoids early p. DDC8 p.Gln416* stop_gained 0.254 0 142 100 . . . . . TRUE 17 76887340 A 1 Clonal
Patient 2, Organoids early p. FASN p.Leu1826fs frameshift_variant 0.190476 0 168 142 . . . . . TRUE 17 80041170 G 0.95 Clonal
Patient 2, Organoids early p. GALNT1 p.Arg426Cys missense_variant 0.429 0 21 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Organoids early p. FHOD3 p.Leu261Leu synonymous_variant 0.383 0 115 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Organoids early p. FHOD3 p.Arg1568His missense_variant 0.503 0 183 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Organoids early p. SMAD7 p.Pro215Leu missense_variant 0.47 0 66 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Organoids early p. DOT1L p.Ile1251Ile synonymous_variant 1 0.007519 125 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Organoids early p. ZNF414 p.Leu257Phe missense_variant 0.226 0 31 32 . . . . . TRUE 19 8576604 G 0.68 Clonal
Patient 2, Organoids early p. ADAMTS10 p.Val904Val synonymous_variant 0.582 0.011 79 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Organoids early p. MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.255 0 47 48 . . . . . TRUE 19 9015384 G 0.77 Clonal
Patient 2, Organoids early p. ZNF561 p.Arg441Pro missense_variant 1 0 125 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Organoids early p. RAVER1 p.Ala477Ala synonymous_variant 1 0 8 16 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Organoids early p. CAPN12 p.His686Arg missense_variant 1 0 23 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Organoids early p. ERCC1 p.Gly133Gly synonymous_variant 1 0 101 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Organoids early p. RTN2 p.Ser211Ser synonymous_variant 0.362 0 105 153 . . . . . TRUE 19 45997605 C 1 Clonal
Patient 2, Organoids early p. GPR4 p.Pro359Pro synonymous_variant 0.00980392 0 102 128 . . . . . TRUE 19 46094048 T 0.03 Subclonal
Patient 2, Organoids early p. PLCB4 p.Val86Phe missense_variant 0.714 0 84 30 . . . . . TRUE 20 9319571 T 1 Clonal
Patient 2, Organoids early p. MYH7B p.Ser797* stop_gained 0.356 0 90 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Organoids early p. CNKSR2 p.Glu480Gly missense_variant 0.052 0 77 18 . . . . . TRUE X 21581401 G Did not evaluate
Patient 2, Organoids early p. PPP1R3F p.Asn345Asn synonymous_variant 1 0 28 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Organoids early p. FGF13 p.Glu54Lys missense_variant 1 0 45 15 . . . . . TRUE X 137939731 T Did not evaluate
Patient 2, Organoids late p. C1orf159 p.Thr26Met missense_variant 0.391 0 46 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Organoids late p. ACTL8 p.Val6Ile missense_variant 0.094 0 64 70 . . . . . FALSE 1 18149519 A 0.29 Subclonal
Patient 2, Organoids late p. TMCO4 p.Ala211Ser missense_variant 0.583 0 36 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Organoids late p. HIVEP3 p.Met265fs frameshift_variant 0.357143 0 98 91 . . . . . FALSE 1 42049671 C 1 Clonal
Patient 2, Organoids late p. LEPRE1 p.Asp253Val missense_variant 0.549 0 175 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Organoids late p. KIF2C p.Arg258Thr missense_variant 0.2 0 20 24 . . . . . FALSE 1 45221614 C 0.62 Subclonal
Patient 2, Organoids late p. HPDL p.Gly61Arg missense_variant 0.16 0 94 84 . . . . . FALSE 1 45793001 A 0.49 Subclonal
Patient 2, Organoids late p. ELTD1 p.Ile35Ile synonymous_variant 0.514 0 37 13 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Organoids late p. LRRC8C p.Phe667Phe synonymous_variant 0.405 0.019 116 53 . . . . . FALSE 1 90180130 C 1 Clonal
Patient 2, Organoids late p. GJA5 p.Lys233del disruptive_inframe_deletion 0.0888889 0 315 82 . . . . . FALSE 1 147230646 A 0.81 Clonal
Patient 2, Organoids late p. CA14 p.Ser215Trp missense_variant 0.115 0 252 112 . . . . . FALSE 1 150235522 G 1 Clonal
Patient 2, Organoids late p. APOA2 p.Met34fs frameshift_variant 0.0527638 0 398 188 . . . . . FALSE 1 161193173 T 0.48 Subclonal
Patient 2, Organoids late p. GJC2 p.Leu353Pro missense_variant 0.227 0 22 22 . . . . . TRUE 1 228346517 C 0.93 Clonal
Patient 2, Organoids late p. OTX1 p.His260Gln missense_variant 0.177 0 198 86 . . . . . FALSE 2 63283166 G 0.9 Clonal
Patient 2, Organoids late p. PROM2 p.Leu119Leu synonymous_variant 0.195 0 77 68 . . . . . FALSE 2 95941738 T 0.99 Clonal
Patient 2, Organoids late p. CYP27C1 p.Pro243Pro synonymous_variant 0.186 0 70 64 . . . . . FALSE 2 127951434 G 0.94 Clonal
Patient 2, Organoids late p. NEB p.Ile3069Thr missense_variant 0.324 0 438 222 . . . . . TRUE 2 152490376 G 1 Clonal
Patient 2, Organoids late p. NBEAL1 p.Trp1775Cys missense_variant 0.09 0 89 21 . . . . . FALSE 2 204013821 T 0.46 Subclonal
Patient 2, Organoids late p. FASTKD2 p.Asn663Ser missense_variant 0.336 0 143 46 . . . . . FALSE 2 207655385 G 1 Clonal
Patient 2, Organoids late p. PIKFYVE p.Asn383Asn synonymous_variant 0.311 0 132 37 . . . . . FALSE 2 209165759 T 1 Clonal
Patient 2, Organoids late p. NCL p.Asp200_Asp201del disruptive_inframe_deletion 0.166667 0 150 40 . . . . . FALSE 2 232326258 C 0.85 Clonal
Patient 2, Organoids late p. COL6A3 p.Ser220Ser synonymous_variant 0.201 0 334 126 . . . . . FALSE 2 238303279 T 1 Clonal
Patient 2, Organoids late p. SNED1 p.Ala316Val missense_variant 0.607 0 183 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Organoids late p. ATG4B p.Arg201Arg synonymous_variant 0.732 0 149 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Organoids late p. C3orf20 p.Ile46Leu missense_variant 0.049 0 122 60 . . . . . FALSE 3 14724356 C 0.2 Subclonal
Patient 2, Organoids late p. SGOL1 p.Asp380Asp synonymous_variant 0.073 0 137 57 . . . . . FALSE 3 20215883 A 0.3 Subclonal
Patient 2, Organoids late p. KIAA1143 p.Gln136Lys missense_variant 0.215 0 65 30 . . . . . FALSE 3 44794892 T 0.88 Clonal
Patient 2, Organoids late p. TMF1 p.Cys318Ser missense_variant 0.543 0 35 24 . . . . . FALSE 3 69096903 G 1 Clonal
Patient 2, Organoids late p. PPP4R2 p.Ser146Arg missense_variant 0.182 0 22 9 . . . . . FALSE 3 73112842 A 0.56 Subclonal
Patient 2, Organoids late p. SPICE1 p.Leu419fs frameshift_variant 0.292035 0 113 61 . . . . . FALSE 3 113184532 G 0.9 Clonal
Patient 2, Organoids late p. ITGB5 p.Asp640His missense_variant&splice_region_variant 0.591 0 22 31 . . . . . FALSE 3 124487959 G 1 Clonal
Patient 2, Organoids late p. MSL2 p.Arg344Lys missense_variant 0.351 0 111 46 . . . . . FALSE 3 135870692 T 1 Clonal
Patient 2, Organoids late p. PHC3 p.Trp937* stop_gained 0.162 0 143 19 . . . . . FALSE 3 169820290 T 0.82 Clonal
Patient 2, Organoids late p. EPHB3 p.Gln509Lys missense_variant 0.159 0 63 64 . . . . . FALSE 3 184295491 A 0.81 Clonal
Patient 2, Organoids late p. TMEM41A p.Phe44Phe synonymous_variant 0.409 0 22 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Organoids late p. ADH1A p.Glu253Glu synonymous_variant 0.037 0 134 84 . . . . . TRUE 4 100203572 T 0.08 Subclonal
Patient 2, Organoids late p. DNAJB14 p.Tyr38Cys missense_variant 0.578 0 45 29 . . . . . TRUE 4 100867616 C 1 Clonal
Patient 2, Organoids late p. ADAMTS16 p.Val68Val synonymous_variant 0.056 0 107 63 . . . . . TRUE 5 5146271 G 0.23 Subclonal
Patient 2, Organoids late p. BDP1 p.Ala932fs frameshift_variant 0.701031 0 97 56 . . . . . TRUE 5 70805704 T 1 Clonal
Patient 2, Organoids late p. SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.258621 0 58 72 . . . . . TRUE 5 131667533 T 0.8 Clonal
Patient 2, Organoids late p. CFB p.Ile744Val missense_variant 0.791 0 110 115 . . . . . FALSE 6 31915584 G 1 Clonal
Patient 2, Organoids late p. DNAH8 p.Ser1436Arg missense_variant 0.103 0 58 15 . . . . . FALSE 6 38802396 G 0.53 Subclonal
Patient 2, Organoids late p. RIMS1 p.Lys718Asn missense_variant 0.149 0 87 16 . . . . . FALSE 6 72957743 T 0.76 Clonal
Patient 2, Organoids late p. ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.188 0 48 9 . . . . . FALSE 6 100964054 C 0.95 Clonal
Patient 2, Organoids late p. KIAA1919 p.Gln415Pro missense_variant 0.186 0 118 65 . . . . . FALSE 6 111588009 C 0.95 Clonal
Patient 2, Organoids late p. AGPAT4 p.Glu149Gln missense_variant 0.213 0 221 189 . . . . . FALSE 6 161575246 G 1 Clonal
Patient 2, Organoids late p. SDIM1 p.Arg56Gly missense_variant 0.045 0 89 64 . . . . . FALSE 6 166307988 C 0.23 Subclonal
Patient 2, Organoids late p. POU6F2 p.Gly132Val missense_variant 0.26 0 97 45 . . . . . TRUE 7 39247103 T 1 Clonal
Patient 2, Organoids late p. COPS6 p.Phe168Leu missense_variant 0.488 0 43 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Organoids late p. CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 1 0 40 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Organoids late p. MGAM p.Ser1292Ser synonymous_variant 0.175 0 40 38 . . . . . TRUE 7 141759328 T 0.71 Clonal
Patient 2, Organoids late p. MGAM p.Ser2188Ser synonymous_variant 0.083 0 168 74 . . . . . TRUE 7 141785689 T 0.34 Subclonal
Patient 2, Organoids late p. NOS3 p.Ala181Thr missense_variant 0.333 0.026 30 38 . . . . . TRUE 7 150693972 A 1 Clonal
Patient 2, Organoids late p. NUGGC p.Thr176Thr synonymous_variant 0.154 0 39 24 . . . . . FALSE 8 27925214 T 0.63 Subclonal
Patient 2, Organoids late p. WRN p.Ala1179Ser missense_variant 0.304 0 92 28 TRUE . . . . FALSE 8 31004955 T 1 Clonal
Patient 2, Organoids late p. NSMAF p.Glu12* stop_gained 0.395 0 39 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Organoids late p. CA8 p.Pro63Pro synonymous_variant 0.056 0 269 79 . . . . . FALSE 8 61192351 A 0.34 Subclonal
Patient 2, Organoids late p. CSMD3 p.Asp293Asn missense_variant 0.232 0 194 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Organoids late p. ADCY8 p.His239Asn missense_variant 0.093 0 172 22 . . . . . FALSE 8 132051865 T 1 Clonal
Patient 2, Organoids late p. CNTLN p.Lys862Thr missense_variant 1 0 53 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Organoids late p. TRMT10B p.Thr195Thr synonymous_variant 1 0 116 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Organoids late p. C9orf64 p.Ile114Met missense_variant 0.978 0 46 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Organoids late p. TSC1 p.Gln767* stop_gained 0.99 0 202 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Organoids late p. PRKCQ p.Asn462Asn synonymous_variant 0.734 0 244 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Organoids late p. MASTL p.Arg793fs frameshift_variant 0.0522193 0 383 91 . . . . . FALSE 10 27469988 G 0.42 Subclonal
Patient 2, Organoids late p. HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 1 0 55 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Organoids late p. SFXN3 p.Val222Val synonymous_variant 0.967 0 30 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Organoids late p. EPS8L2 p.Asp172Tyr missense_variant 0.742 0 62 84 . . . . . FALSE 11 720735 T 1 Clonal
Patient 2, Organoids late p. HPX p.Ser288Gly missense_variant 0.814 0 43 60 . . . . . FALSE 11 6453221 C 1 Clonal
Patient 2, Organoids late p. DCHS1 p.Leu644Gln missense_variant 0.656 0 160 168 . . . . . FALSE 11 6655404 T 1 Clonal
Patient 2, Organoids late p. NELL1 p.Val349Leu missense_variant 0.2 0 50 23 . . . . . FALSE 11 20949989 C 0.82 Clonal
Patient 2, Organoids late p. KIAA1549L p.Gly1602Gly synonymous_variant 0.522 0 23 17 . . . . . FALSE 11 33667501 A 1 Clonal
Patient 2, Organoids late p. OR8K5 p.Pro283Ser missense_variant 0.185185 0 108 22 . . . . . FALSE 11 55926947 A 0.76 Clonal
Patient 2, Organoids late p. OR9Q1 p.Thr278Ala missense_variant 0.43 0 79 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Organoids late p. MS4A12 p.Pro255Pro synonymous_variant 0.445 0 209 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Organoids late p. LRP5 p.His965Asp missense_variant 0.208 0 448 407 . . . . . FALSE 11 68183861 G 0.85 Clonal
Patient 2, Organoids late p. SYTL2 p.Glu1611Val missense_variant 0.484 0 63 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Organoids late p. ARHGEF12 p.Leu630Phe missense_variant 0.584 0 166 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Organoids late p. TAS2R30 p.Val125Leu missense_variant 0.272 0 103 35 . . . . . TRUE 12 11286471 G 0.84 Clonal
Patient 2, Organoids late p. HDAC7 p.Pro472Leu missense_variant 0.792 0.013 77 76 . . . . . TRUE 12 48188637 A 1 Clonal
Patient 2, Organoids late p. KMT2D p.Met1530Val missense_variant 0.769 0 134 145 TRUE TRUE TRUE . . TRUE 12 49439953 C 1 Clonal
Patient 2, Organoids late p. C12orf42 p.Gly270Arg missense_variant 0.205 0 78 30 . . . . . TRUE 12 103696161 T 0.84 Clonal
Patient 2, Organoids late p. SVOP p.Asp79Asn missense_variant 0.237 0 59 29 . . . . . TRUE 12 109366201 T 0.97 Clonal
Patient 2, Organoids late p. ANKLE2 p.Gly46Gly synonymous_variant 0.166667 0 18 17 . . . . . TRUE 12 133338247 T 0.68 Clonal
Patient 2, Organoids late p. KPNA3 p.Leu323Leu synonymous_variant 0.5 0 94 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Organoids late p. MYCBP2 p.Met3453Val missense_variant 0.087 0 126 29 . . . . . TRUE 13 77667310 C 0.36 Subclonal
Patient 2, Organoids late p. MBNL2 p.Lys178Asn missense_variant 0.143 0 21 11 . . . . . TRUE 13 97995464 T 0.58 Subclonal
Patient 2, Organoids late p. SALL2 p.Pro365Leu missense_variant 0.767 0 91 95 . . . . . FALSE 14 21992768 A 1 Clonal
Patient 2, Organoids late p. AKAP6 p.Arg509* stop_gained 0.00806452 0 124 41 . . . . . FALSE 14 33015384 T 0.03 Subclonal
Patient 2, Organoids late p. SRSF5 p.Ser90Gly missense_variant 0.6 0 115 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Organoids late p. GOLGA5 p.Ala522Asp missense_variant 0.288 0.012 156 86 TRUE . . . . FALSE 14 93286126 A 0.89 Clonal
Patient 2, Organoids late p. DPH6 p.Leu45Gln missense_variant 1 0 67 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Organoids late p. PLA2G4E p.Cys505Phe missense_variant 0.2 0 25 21 . . . . . TRUE 15 42282390 A 0.82 Clonal
Patient 2, Organoids late p. SRRM2 p.Trp513* stop_gained 0.529 0 87 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Organoids late p. SLX4 p.Pro198Gln missense_variant 0.085 0.004926 176 203 . . . . . FALSE 16 3656642 T 0.35 Subclonal
Patient 2, Organoids late p. C16orf71 p.Glu92Gln missense_variant 0.281 0 57 49 . . . . . FALSE 16 4787945 C 1 Clonal
Patient 2, Organoids late p. C16orf89 p.Leu128Leu synonymous_variant 0.412 0 51 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Organoids late p. CDH11 p.Glu391Asp missense_variant 0.191 0 68 17 TRUE . . . . FALSE 16 65016031 A 0.97 Clonal
Patient 2, Organoids late p. DPEP3 p.Arg3Trp missense_variant 0.55 0 20 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Organoids late p. ZNF469 p.Thr3815Met missense_variant 0.132 0 76 83 . . . . . FALSE 16 88505322 T 0.67 Subclonal
Patient 2, Organoids late p. TP53 p.Arg209fs frameshift_variant 0.931373 0 102 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Organoids late p. MFAP4 p.Pro33Leu missense_variant 0.181 0 116 74 . . . . . TRUE 17 19290135 A 0.74 Subclonal
Patient 2, Organoids late p. RARA p.Asp449Asp synonymous_variant 0.25 0 32 40 TRUE . . . . TRUE 17 38512388 T 1 Clonal
Patient 2, Organoids late p. KRTAP4-11 p.Arg51Lys missense_variant 0.063 0 80 31 . . . . . TRUE 17 39274416 T 0.32 Subclonal
Patient 2, Organoids late p. HOXB5 p.Arg224Leu missense_variant 0.173 0 81 74 . . . . . TRUE 17 46669710 A 0.88 Clonal
Patient 2, Organoids late p. AKAP1 p.Leu832Val missense_variant 0.255 0 51 32 . . . . . TRUE 17 55194282 G 1 Clonal
Patient 2, Organoids late p. USH1G p.Thr100Lys missense_variant 0.147 0 231 165 . . . . . TRUE 17 72916632 T 0.75 Subclonal
Patient 2, Organoids late p. DDC8 p.Gln416* stop_gained 0.123 0 138 100 . . . . . TRUE 17 76887340 A 0.63 Subclonal
Patient 2, Organoids late p. FASN p.Leu1826fs frameshift_variant 0.19898 0 196 142 . . . . . TRUE 17 80041170 G 1 Clonal
Patient 2, Organoids late p. GALNT1 p.Arg426Cys missense_variant 0.6 0 15 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Organoids late p. FHOD3 p.Leu261Leu synonymous_variant 0.61 0 82 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Organoids late p. FHOD3 p.Arg1568His missense_variant 0.601 0 143 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Organoids late p. SMAD7 p.Pro215Leu missense_variant 0.536 0 28 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Organoids late p. DOT1L p.Ile1251Ile synonymous_variant 1 0.007519 95 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Organoids late p. ZNF414 p.Leu257Phe missense_variant 0.4 0 25 32 . . . . . TRUE 19 8576604 G 1 Clonal
Patient 2, Organoids late p. ADAMTS10 p.Val904Val synonymous_variant 0.667 0.011 69 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Organoids late p. MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.38 0 50 48 . . . . . TRUE 19 9015384 G 1 Clonal
Patient 2, Organoids late p. ZNF561 p.Arg441Pro missense_variant 0.985 0 133 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Organoids late p. RAVER1 p.Ala477Ala synonymous_variant 1 0 9 16 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Organoids late p. CAPN12 p.His686Arg missense_variant 1 0 25 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Organoids late p. MARK4 p.Gly258Gly synonymous_variant 0.064 0 48 75 . . . . . TRUE 19 45774954 A 0.19 Subclonal
Patient 2, Organoids late p. ERCC1 p.Gly133Gly synonymous_variant 1 0 118 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Organoids late p. RTN2 p.Ser211Ser synonymous_variant 0.373 0 118 153 . . . . . TRUE 19 45997605 C 1 Clonal
Patient 2, Organoids late p. GPR4 p.Pro359Pro synonymous_variant 0.38 0 92 106 . . . . . TRUE 19 46094048 T 1 Clonal
Patient 2, Organoids late p. PLCB4 p.Val86Phe missense_variant 0.75 0 76 30 . . . . . FALSE 20 9319571 T 1 Clonal
Patient 2, Organoids late p. MYH7B p.Ser797* stop_gained 0.417 0 103 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Organoids late p. SMTN p.Gln325Lys missense_variant 0.164 0 128 183 . . . . . FALSE 22 31486982 A 0.51 Subclonal
Patient 2, Organoids late p. SCML2 p.Thr408Ser missense_variant 0.058 0 69 12 . . . . . TRUE X 18276215 A Did not evaluate
Patient 2, Organoids late p. PPP1R3F p.Asn345Asn synonymous_variant 1 0 29 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Organoids late p. HEPH p.Ala382Ser missense_variant 0.087 0 104 30 . . . . . TRUE X 65409699 T Did not evaluate
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Clonal
Patient 2, Biopsy C1orf159 p.Thr26Met missense_variant 0.322 0 90 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Biopsy ACTL8 p.Val6Ile missense_variant 0.0756303 0 119 88 . . . . . FALSE 1 18149519 A 0.28 Subclonal
Patient 2, Biopsy TMCO4 p.Ala211Ser missense_variant 0.467 0 30 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Biopsy HIVEP3 p.Met265fs frameshift_variant 0.40458 0 131 91 . . . . . FALSE 1 42049671 C 1 Subclonal
Patient 2, Biopsy LEPRE1 p.Asp253Val missense_variant 0.313 0 224 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Biopsy KIF2C p.Arg258Thr missense_variant 0.231 0 13 24 . . . . . FALSE 1 45221614 C 0.85 Clonal
Patient 2, Biopsy ELTD1 p.Ile35Ile synonymous_variant 0.571429 0 7 15 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Biopsy LRRC8C p.Phe667Phe synonymous_variant 0.217 0.019 60 53 . . . . . FALSE 1 90180130 C 0.8 Clonal
Patient 2, Biopsy GJA5 p.Lys233del disruptive_inframe_deletion 0.0868545 0 426 82 . . . . . FALSE 1 147230646 A 0.93 Clonal
Patient 2, Biopsy OTUD7B p.Lys550* stop_gained 0.06 0 433 97 . . . . . FALSE 1 149916640 A 0.64 Subclonal
Patient 2, Biopsy CA14 p.Ser215Trp missense_variant 0.016 0 250 138 . . . . . FALSE 1 150235522 G 0.17 Subclonal
Patient 2, Biopsy APOA2 p.Met34fs frameshift_variant 0.0576923 0 624 188 . . . . . FALSE 1 161193173 T 0.62 Subclonal
Patient 2, Biopsy GJC2 p.Leu353Pro missense_variant 0.192 0 26 22 . . . . . FALSE 1 228346517 C 0.9 Clonal
Patient 2, Biopsy OTX1 p.His260Gln missense_variant 0.024 0 250 117 . . . . . FALSE 2 63283166 G 0.14 Subclonal
Patient 2, Biopsy PROM2 p.Leu119Leu synonymous_variant 0.04 0 125 92 . . . . . FALSE 2 95941738 T 0.19 Subclonal
Patient 2, Biopsy CYP27C1 p.Pro243Pro synonymous_variant 0.104 0 106 64 . . . . . FALSE 2 127951434 G 0.49 Subclonal
Patient 2, Biopsy NEB p.Ile3069Thr missense_variant 0.057 0 493 222 . . . . . TRUE 2 152490376 G 0.21 Subclonal
Patient 2, Biopsy FASTKD2 p.Asn663Ser missense_variant 0.161 0 31 46 . . . . . FALSE 2 207655385 G 0.76 Clonal
Patient 2, Biopsy PIKFYVE p.Asn383Asn synonymous_variant 0.211 0 57 37 . . . . . FALSE 2 209165759 T 0.99 Clonal
Patient 2, Biopsy COL6A3 p.Ser220Ser synonymous_variant 0.19 0 205 126 . . . . . FALSE 2 238303279 T 0.89 Clonal
Patient 2, Biopsy SNED1 p.Ala316Val missense_variant 0.62 0 179 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Biopsy ATG4B p.Arg201Arg synonymous_variant 0.626 0 195 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Biopsy KIAA1143 p.Gln136Lys missense_variant 0.241 0 29 30 . . . . . FALSE 3 44794892 T 1 Clonal
Patient 2, Biopsy TMF1 p.Cys318Ser missense_variant 0.647 0 17 24 . . . . . FALSE 3 69096903 G 1 Clonal
Patient 2, Biopsy PPP4R2 p.Ser146Arg missense_variant 0.727 0 11 9 . . . . . FALSE 3 73112842 A 1 Clonal
Patient 2, Biopsy IFT57 p.Phe41Cys missense_variant 0.259 0 54 20 . . . . . FALSE 3 107941048 C 0.96 Clonal
Patient 2, Biopsy SPICE1 p.Leu419fs frameshift_variant 0.257143 0 35 61 . . . . . FALSE 3 113184532 G 0.95 Clonal
Patient 2, Biopsy ITGB5 p.Asp640His missense_variant&splice_region_variant 0.208 0 24 31 . . . . . FALSE 3 124487959 G 0.77 Clonal
Patient 2, Biopsy MSL2 p.Arg344Lys missense_variant 0.075 0 80 46 . . . . . FALSE 3 135870692 T 0.28 Subclonal
Patient 2, Biopsy PHC3 p.Trp937* stop_gained 0.012987 0 77 25 . . . . . FALSE 3 169820290 T 0.06 Subclonal
Patient 2, Biopsy EPHB3 p.Gln509Lys missense_variant 0.172 0 60 64 . . . . . FALSE 3 184295491 A 0.78 Clonal
Patient 2, Biopsy TMEM41A p.Phe44Phe synonymous_variant 0.333 0 18 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Biopsy ADH1A p.Glu253Glu synonymous_variant 0.0324074 0 216 102 . . . . . TRUE 4 100203572 T 0.12 Subclonal
Patient 2, Biopsy DNAJB14 p.Tyr38Cys missense_variant 0.097 0 62 29 . . . . . TRUE 4 100867616 C 0.36 Subclonal
Patient 2, Biopsy FAM149A p.Pro442Ser missense_variant 0.146 0 96 59 . . . . . TRUE 4 187077221 T 0.54 Subclonal
Patient 2, Biopsy BDP1 p.Ala932fs frameshift_variant 0.458333 0 48 56 . . . . . FALSE 5 70805704 T 1 Clonal
Patient 2, Biopsy SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.109375 0 64 72 . . . . . FALSE 5 131667533 T 0.4 Subclonal
Patient 2, Biopsy PPP1R18 p.Pro346His missense_variant 0.137 0 153 121 . . . . . TRUE 6 30652759 T 0.78 Clonal
Patient 2, Biopsy CFB p.Ile744Val missense_variant 0.842 0 184 115 . . . . . TRUE 6 31915584 G 1 Clonal
Patient 2, Biopsy ZFAND3 p.Gln168Arg missense_variant 0.159 0 44 16 . . . . . TRUE 6 38084489 G 0.91 Clonal
Patient 2, Biopsy DNAH8 p.Ser1436Arg missense_variant 0.0666667 0 15 18 . . . . . TRUE 6 38802396 G 0.38 Subclonal
Patient 2, Biopsy GLP1R p.Arg64Pro missense_variant 0.102 0.00489 728 409 . . . . . TRUE 6 39025263 C 0.58 Subclonal
Patient 2, Biopsy DST p.Lys6551Asn missense_variant 0.107 0 168 40 . . . . . TRUE 6 56366028 G 0.61 Subclonal
Patient 2, Biopsy ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.219 0 32 9 . . . . . TRUE 6 100964054 C 1 Clonal
Patient 2, Biopsy KIAA1919 p.Gln415Pro missense_variant 0.091 0 88 65 . . . . . TRUE 6 111588009 C 0.52 Subclonal
Patient 2, Biopsy AGPAT4 p.Glu149Gln missense_variant 0.016 0 250 250 . . . . . TRUE 6 161575246 G 0.09 Subclonal
Patient 2, Biopsy POU6F2 p.Gly132Val missense_variant 0.056 0 125 45 . . . . . TRUE 7 39247103 T 0.26 Subclonal
Patient 2, Biopsy COPS6 p.Phe168Leu missense_variant 0.554 0 56 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Biopsy CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 0.903 0 62 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Biopsy NUGGC p.Thr176Thr synonymous_variant 0.143 0 42 24 . . . . . FALSE 8 27925214 T 0.81 Clonal
Patient 2, Biopsy WRN p.Ala1179Ser missense_variant 0.24 0 25 28 TRUE . . . . FALSE 8 31004955 T 1 Clonal
Patient 2, Biopsy NSMAF p.Glu12* stop_gained 0.44 0 50 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Biopsy CSMD3 p.Asp293Asn missense_variant 0.278 0 18 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Biopsy CNTLN p.Lys862Thr missense_variant 0.896 0 48 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Biopsy TRMT10B p.Thr195Thr synonymous_variant 0.831 0 89 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Biopsy C9orf64 p.Ile114Met missense_variant 0.822 0 45 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Biopsy SLC28A3 p.Glu500* stop_gained 0.063 0 144 109 . . . . . TRUE 9 86900409 A 0.29 Subclonal
Patient 2, Biopsy TSC1 p.Gln767* stop_gained 0.841 0 270 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Biopsy INPP5E p.Ser582Ser synonymous_variant 0.038 0.006803 237 150 . . . . . TRUE 9 139324785 A 0.18 Subclonal
Patient 2, Biopsy PRKCQ p.Asn462Asn synonymous_variant 0.587 0 219 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Biopsy MASTL p.Arg793fs frameshift_variant 0.0602837 0 282 91 . . . . . FALSE 10 27469988 G 0.58 Subclonal
Patient 2, Biopsy HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 0.833 0 72 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Biopsy SFXN3 p.Val222Val synonymous_variant 0.786 0 42 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Biopsy EPS8L2 p.Asp172Tyr missense_variant 0.522 0 92 84 . . . . . FALSE 11 720735 T 1 Clonal
Patient 2, Biopsy HPX p.Ser288Gly missense_variant 0.441 0 59 60 . . . . . FALSE 11 6453221 C 1 Clonal
Patient 2, Biopsy DCHS1 p.Leu644Gln missense_variant 0.617 0 222 168 . . . . . FALSE 11 6655404 T 1 Clonal
Patient 2, Biopsy NELL1 p.Val349Leu missense_variant 0.333 0 30 23 . . . . . FALSE 11 20949989 C 1 Clonal
Patient 2, Biopsy KIAA1549L p.Gly1602Gly synonymous_variant 0.542 0 24 17 . . . . . FALSE 11 33667501 A 1 Clonal
Patient 2, Biopsy OR8K5 p.Pro283Ser missense_variant 0.075 0 40 22 . . . . . FALSE 11 55926947 A 0.28 Subclonal
Patient 2, Biopsy OR9Q1 p.Thr278Ala missense_variant 0.417 0 84 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Biopsy MS4A12 p.Pro255Pro synonymous_variant 0.408 0 98 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Biopsy LRP5 p.His965Asp missense_variant 0.049 0 678 407 . . . . . FALSE 11 68183861 G 0.23 Subclonal
Patient 2, Biopsy SYTL2 p.Glu1611Val missense_variant 0.378 0 37 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Biopsy FAT3 p.Glu2075Lys missense_variant 0.159 0 44 30 . . . . . FALSE 11 92532402 A 0.75 Clonal
Patient 2, Biopsy ARHGEF12 p.Leu630Phe missense_variant 0.45 0 211 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Biopsy TAS2R30 p.Val125Leu missense_variant 0.0357143 0 28 41 . . . . . TRUE 12 11286471 G 0.13 Subclonal
Patient 2, Biopsy HDAC7 p.Pro472Leu missense_variant 0.701 0.013 97 76 . . . . . FALSE 12 48188637 A 1 Clonal
Patient 2, Biopsy KMT2D p.Met1530Val missense_variant 0.658 0 231 145 TRUE TRUE TRUE . . FALSE 12 49439953 C 1 Clonal
Patient 2, Biopsy C12orf42 p.Gly270Arg missense_variant 0.185 0 92 30 . . . . . FALSE 12 103696161 T 1 Clonal
Patient 2, Biopsy SVOP p.Asp79Asn missense_variant 0.079 0 76 29 . . . . . FALSE 12 109366201 T 0.45 Subclonal
Patient 2, Biopsy ANKLE2 p.Gly46Gly synonymous_variant 0.13 0 23 13 . . . . . FALSE 12 133338247 T 0.74 Clonal
Patient 2, Biopsy CDX2 p.Ser208Asn missense_variant 0.147 0.013 143 75 TRUE . . . . TRUE 13 28539071 T 0.69 Subclonal
Patient 2, Biopsy PROSER1 p.Asn516Asn synonymous_variant 0.2 0 60 27 . . . . . TRUE 13 39587841 A 0.94 Clonal
Patient 2, Biopsy KPNA3 p.Leu323Leu synonymous_variant 0.405 0 74 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Biopsy NALCN p.Ile1593Val missense_variant 0.235 0 51 25 . . . . . TRUE 13 101712298 C 1 Clonal
Patient 2, Biopsy SALL2 p.Pro365Leu missense_variant 0.531 0 192 95 . . . . . FALSE 14 21992768 A 1 Clonal
Patient 2, Biopsy TRAV38-1 p.Ser13Phe missense_variant 0.148 0 54 13 . . . . . FALSE 14 22739891 T 0.84 Clonal
Patient 2, Biopsy AKAP6 p.Arg509* stop_gained 0.122 0 74 34 . . . . . FALSE 14 33015384 T 0.69 Subclonal
Patient 2, Biopsy SRSF5 p.Ser90Gly missense_variant 0.381 0 118 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Biopsy GOLGA5 p.Ala522Asp missense_variant 0.458 0.012 118 86 TRUE . . . . FALSE 14 93286126 A 1 Clonal
Patient 2, Biopsy DPH6 p.Leu45Gln missense_variant 0.875 0 32 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Biopsy SRRM2 p.Trp513* stop_gained 0.326 0 139 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Biopsy C16orf89 p.Leu128Leu synonymous_variant 0.298 0 84 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Biopsy ZNF843 p.Glu264Glu synonymous_variant 0.0422535 0 71 26 . . . . . FALSE 16 31447379 T 0.28 Subclonal
Patient 2, Biopsy CDH11 p.Glu391Asp missense_variant 0.011236 0 89 20 TRUE . . . . FALSE 16 65016031 A 0.08 Subclonal
Patient 2, Biopsy DPEP3 p.Arg3Trp missense_variant 0.256 0 39 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Biopsy ZNF469 p.Thr3815Met missense_variant 0.151 0 119 83 . . . . . FALSE 16 88505322 T 1 Clonal
Patient 2, Biopsy TP53 p.Arg209fs frameshift_variant 0.819767 0 172 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Biopsy KCNAB3 p.Leu224fs frameshift_variant 0.0201149 0 348 168 . . . . . TRUE 17 7827765 C 0.11 Subclonal
Patient 2, Biopsy RARA p.Asp449Asp synonymous_variant 0.225 0 41 40 TRUE . . . . FALSE 17 38512388 T 1 Clonal
Patient 2, Biopsy KRTAP4-11 p.Arg51Lys missense_variant 0.123288 0 73 38 . . . . . FALSE 17 39274416 T 0.7 Subclonal
Patient 2, Biopsy HOXB5 p.Arg224Leu missense_variant 0.17 0 153 74 . . . . . FALSE 17 46669710 A 0.97 Clonal
Patient 2, Biopsy AKAP1 p.Leu832Val missense_variant 0.138 0 65 32 . . . . . FALSE 17 55194282 G 0.79 Clonal
Patient 2, Biopsy USH1G p.Thr100Lys missense_variant 0.142 0 338 165 . . . . . FALSE 17 72916632 T 0.81 Subclonal
Patient 2, Biopsy DDC8 p.Gln416* stop_gained 0.105 0 172 100 . . . . . FALSE 17 76887340 A 0.6 Subclonal
Patient 2, Biopsy FASN p.Leu1826fs frameshift_variant 0.138889 0 288 142 . . . . . FALSE 17 80041170 G 0.79 Subclonal
Patient 2, Biopsy GALNT1 p.Arg426Cys missense_variant 0.25 0 12 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Biopsy FHOD3 p.Leu261Leu synonymous_variant 0.365 0 74 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Biopsy FHOD3 p.Arg1568His missense_variant 0.553 0 258 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Biopsy SMAD7 p.Pro215Leu missense_variant 0.633 0 60 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Biopsy DOT1L p.Ile1251Ile synonymous_variant 0.827 0.007519 151 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Biopsy ZNF414 p.Leu257Phe missense_variant 0.244 0 41 32 . . . . . TRUE 19 8576604 G 0.9 Clonal
Patient 2, Biopsy ADAMTS10 p.Val904Val synonymous_variant 0.516 0.011 124 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Biopsy MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.087 0 46 48 . . . . . TRUE 19 9015384 G 0.32 Subclonal
Patient 2, Biopsy ZNF561 p.Arg441Pro missense_variant 0.695 0 82 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Biopsy RAVER1 p.Ala477Ala synonymous_variant 0.833 0 12 14 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Biopsy CAPN12 p.His686Arg missense_variant 0.794 0 34 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Biopsy ERCC1 p.Gly133Gly synonymous_variant 0.877 0 204 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Biopsy RTN2 p.Ser211Ser synonymous_variant 0.073 0 206 153 . . . . . TRUE 19 45997605 C 0.27 Subclonal
Patient 2, Biopsy AC012313.1 p.Val202Met missense_variant 0.133 0 45 31 . . . . . TRUE 19 58908060 A 0.49 Subclonal
Patient 2, Biopsy PLCB4 p.Val86Phe missense_variant 0.578 0 45 30 . . . . . FALSE 20 9319571 T 1 Clonal
Patient 2, Biopsy MYH7B p.Ser797* stop_gained 0.381 0 194 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Biopsy BCL2L13 p.Ser190Leu missense_variant 0.154 0 65 38 . . . . . FALSE 22 18185121 T 0.57 Subclonal
Patient 2, Biopsy PPP1R3F p.Asn345Asn synonymous_variant 0.936 0 47 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Biopsy ARR3 p.Leu49Leu splice_region_variant&synonymous_variant 0.156 0 32 16 . . . . . TRUE X 69495933 A Did not evaluate
Patient 2, Biopsy FGF13 p.Glu54Lys missense_variant 0.881 0 59 15 . . . . . TRUE X 137939731 T Did not evaluate
Patient 2, Biopsy GABRE p.Lys302Met missense_variant 0.277 0 65 13 . . . . . TRUE X 151124212 A Did not evaluate
Patient 2, Organoids early p. C1orf159 p.Thr26Met missense_variant 0.583 0 48 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Organoids early p. ACTL8 p.Val6Ile missense_variant 0.104 0 78 70 . . . . . FALSE 1 18149519 A 0.41 Subclonal
Patient 2, Organoids early p. TMCO4 p.Ala211Ser missense_variant 0.719 0 32 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Organoids early p. HIVEP3 p.Met265fs frameshift_variant 0.40708 0 113 91 . . . . . FALSE 1 42049671 C 1 Clonal
Patient 2, Organoids early p. LEPRE1 p.Asp253Val missense_variant 0.451 0 175 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Organoids early p. KIF2C p.Arg258Thr missense_variant 0.154 0 26 24 . . . . . FALSE 1 45221614 C 0.62 Clonal
Patient 2, Organoids early p. HPDL p.Gly61Arg missense_variant 0.00826446 0 121 112 . . . . . FALSE 1 45793001 A 0.03 Subclonal
Patient 2, Organoids early p. ELTD1 p.Ile35Ile synonymous_variant 0.386 0 44 13 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Organoids early p. LRRC8C p.Phe667Phe synonymous_variant 0.361 0.019 158 53 . . . . . FALSE 1 90180130 C 1 Clonal
Patient 2, Organoids early p. GJA5 p.Lys233del disruptive_inframe_deletion 0.0896739 0 368 82 . . . . . FALSE 1 147230646 A 0.9 Clonal
Patient 2, Organoids early p. CA14 p.Ser215Trp missense_variant 0.065 0 277 112 . . . . . FALSE 1 150235522 G 0.65 Subclonal
Patient 2, Organoids early p. APOA2 p.Met34fs frameshift_variant 0.0546218 0 476 188 . . . . . FALSE 1 161193173 T 0.55 Subclonal
Patient 2, Organoids early p. GJC2 p.Leu353Pro missense_variant 0.111 0 36 22 . . . . . TRUE 1 228346517 C 0.56 Subclonal
Patient 2, Organoids early p. OTX1 p.His260Gln missense_variant 0.065 0 186 86 . . . . . FALSE 2 63283166 G 0.32 Subclonal
Patient 2, Organoids early p. PROM2 p.Leu119Leu synonymous_variant 0.208 0 96 68 . . . . . FALSE 2 95941738 T 1 Clonal
Patient 2, Organoids early p. CYP27C1 p.Pro243Pro synonymous_variant 0.086 0 70 64 . . . . . FALSE 2 127951434 G 0.43 Subclonal
Patient 2, Organoids early p. NEB p.Ile3069Thr missense_variant 0.313 0 387 222 . . . . . TRUE 2 152490376 G 0.94 Clonal
Patient 2, Organoids early p. FASTKD2 p.Asn663Ser missense_variant 0.399 0 138 46 . . . . . FALSE 2 207655385 G 1 Clonal
Patient 2, Organoids early p. PIKFYVE p.Asn383Asn synonymous_variant 0.262 0 130 37 . . . . . FALSE 2 209165759 T 1 Clonal
Patient 2, Organoids early p. COL6A3 p.Ser220Ser synonymous_variant 0.183 0 312 126 . . . . . FALSE 2 238303279 T 0.91 Clonal
Patient 2, Organoids early p. SNED1 p.Ala316Val missense_variant 0.658 0 152 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Organoids early p. ATG4B p.Arg201Arg synonymous_variant 0.704 0 159 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Organoids early p. KIAA1143 p.Gln136Lys missense_variant 0.245 0 53 30 . . . . . TRUE 3 44794892 T 0.98 Clonal
Patient 2, Organoids early p. TMF1 p.Cys318Ser missense_variant 0.625 0 48 24 . . . . . TRUE 3 69096903 G 1 Clonal
Patient 2, Organoids early p. PPP4R2 p.Ser146Arg missense_variant 0.1875 0 16 12 . . . . . TRUE 3 73112842 A 0.56 Subclonal
Patient 2, Organoids early p. SPICE1 p.Leu419fs frameshift_variant 0.328358 0 67 61 . . . . . TRUE 3 113184532 G 0.99 Clonal
Patient 2, Organoids early p. ITGB5 p.Asp640His missense_variant&splice_region_variant 0.462 0 13 31 . . . . . TRUE 3 124487959 G 1 Clonal
Patient 2, Organoids early p. MSL2 p.Arg344Lys missense_variant 0.28 0 93 46 . . . . . TRUE 3 135870692 T 0.84 Clonal
Patient 2, Organoids early p. PHC3 p.Trp937* stop_gained 0.099 0 141 19 . . . . . FALSE 3 169820290 T 0.6 Subclonal
Patient 2, Organoids early p. EPHB3 p.Gln509Lys missense_variant 0.113924 0 79 67 . . . . . FALSE 3 184295491 A 0.68 Clonal
Patient 2, Organoids early p. TMEM41A p.Phe44Phe synonymous_variant 0.171 0 41 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Organoids early p. ADH1A p.Glu253Glu synonymous_variant 0.0281124 0 249 102 . . . . . TRUE 4 100203572 T 0.08 Subclonal
Patient 2, Organoids early p. DNAJB14 p.Tyr38Cys missense_variant 0.4 0 70 29 . . . . . TRUE 4 100867616 C 1 Clonal
Patient 2, Organoids early p. BDP1 p.Ala932fs frameshift_variant 0.580645 0 93 56 . . . . . TRUE 5 70805704 T 1 Clonal
Patient 2, Organoids early p. SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.25974 0 77 72 . . . . . TRUE 5 131667533 T 0.78 Clonal
Patient 2, Organoids early p. CFB p.Ile744Val missense_variant 0.824 0 125 115 . . . . . TRUE 6 31915584 G 1 Clonal
Patient 2, Organoids early p. DNAH8 p.Ser1436Arg missense_variant 0.133 0 75 15 . . . . . TRUE 6 38802396 G 0.67 Subclonal
Patient 2, Organoids early p. DST p.Lys6551Asn missense_variant 0.125 0 263 40 . . . . . TRUE 6 56366028 G 0.63 Subclonal
Patient 2, Organoids early p. RIMS1 p.Lys718Asn missense_variant 0.13 0 100 16 . . . . . TRUE 6 72957743 T 0.65 Subclonal
Patient 2, Organoids early p. ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.163 0 43 9 . . . . . TRUE 6 100964054 C 0.81 Clonal
Patient 2, Organoids early p. KIAA1919 p.Gln415Pro missense_variant 0.185 0 130 65 . . . . . TRUE 6 111588009 C 0.92 Clonal
Patient 2, Organoids early p. AGPAT4 p.Glu149Gln missense_variant 0.098 0 214 189 . . . . . TRUE 6 161575246 G 0.49 Subclonal
Patient 2, Organoids early p. POU6F2 p.Gly132Val missense_variant 0.276 0 87 45 . . . . . TRUE 7 39247103 T 1 Clonal
Patient 2, Organoids early p. COPS6 p.Phe168Leu missense_variant 0.583 0 48 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Organoids early p. CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 1 0 41 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Organoids early p. MGAM p.Ser1292Ser synonymous_variant 0.0294118 0 34 49 . . . . . TRUE 7 141759328 T 0.12 Subclonal
Patient 2, Organoids early p. MGAM p.Ser2188Ser synonymous_variant 0.037 0 164 74 . . . . . TRUE 7 141785689 T 0.15 Subclonal
Patient 2, Organoids early p. NUGGC p.Thr176Thr synonymous_variant 0.343 0 35 24 . . . . . TRUE 8 27925214 T 1 Clonal
Patient 2, Organoids early p. WRN p.Ala1179Ser missense_variant 0.14 0 101 28 TRUE . . . . TRUE 8 31004955 T 0.55 Subclonal
Patient 2, Organoids early p. NSMAF p.Glu12* stop_gained 0.622 0 45 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Organoids early p. CSMD3 p.Asp293Asn missense_variant 0.214 0 182 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Organoids early p. ADCY8 p.His239Asn missense_variant 0.0070922 0 141 26 . . . . . FALSE 8 132051865 T 0.07 Subclonal
Patient 2, Organoids early p. CNTLN p.Lys862Thr missense_variant 1 0 44 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Organoids early p. TRMT10B p.Thr195Thr synonymous_variant 1 0 106 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Organoids early p. C9orf64 p.Ile114Met missense_variant 0.975 0 40 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Organoids early p. SLC28A3 p.Glu500* stop_gained 0.239 0 176 109 . . . . . TRUE 9 86900409 A 0.95 Clonal
Patient 2, Organoids early p. TSC1 p.Gln767* stop_gained 1 0 193 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Organoids early p. PRKCQ p.Asn462Asn synonymous_variant 0.673 0 269 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Organoids early p. MASTL p.Arg793fs frameshift_variant 0.077951 0 449 91 . . . . . FALSE 10 27469988 G 0.7 Subclonal
Patient 2, Organoids early p. HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 1 0 54 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Organoids early p. SFXN3 p.Val222Val synonymous_variant 1 0 31 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Organoids early p. EPS8L2 p.Asp172Tyr missense_variant 0.697 0 66 84 . . . . . TRUE 11 720735 T 1 Clonal
Patient 2, Organoids early p. HPX p.Ser288Gly missense_variant 0.682 0 44 60 . . . . . TRUE 11 6453221 C 1 Clonal
Patient 2, Organoids early p. DCHS1 p.Leu644Gln missense_variant 0.794 0 170 168 . . . . . TRUE 11 6655404 T 1 Clonal
Patient 2, Organoids early p. NELL1 p.Val349Leu missense_variant 0.25 0 44 23 . . . . . TRUE 11 20949989 C 1 Clonal
Patient 2, Organoids early p. KIAA1549L p.Gly1602Gly synonymous_variant 0.69 0 29 17 . . . . . TRUE 11 33667501 A 1 Clonal
Patient 2, Organoids early p. OR8K5 p.Pro283Ser missense_variant 0.219 0 96 18 . . . . . FALSE 11 55926947 A 1 Clonal
Patient 2, Organoids early p. OR9Q1 p.Thr278Ala missense_variant 0.412 0 102 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Organoids early p. MS4A12 p.Pro255Pro synonymous_variant 0.357 0 221 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Organoids early p. LRP5 p.His965Asp missense_variant 0.225 0 457 407 . . . . . FALSE 11 68183861 G 1 Clonal
Patient 2, Organoids early p. SYTL2 p.Glu1611Val missense_variant 0.418 0 79 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Organoids early p. ARHGEF12 p.Leu630Phe missense_variant 0.457 0 210 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Organoids early p. TAS2R30 p.Val125Leu missense_variant 0.157 0 102 35 . . . . . TRUE 12 11286471 G 0.63 Subclonal
Patient 2, Organoids early p. HDAC7 p.Pro472Leu missense_variant 0.792 0.013 72 76 . . . . . TRUE 12 48188637 A 1 Clonal
Patient 2, Organoids early p. KMT2D p.Met1530Val missense_variant 0.776 0 157 145 TRUE TRUE TRUE . . TRUE 12 49439953 C 1 Clonal
Patient 2, Organoids early p. C12orf42 p.Gly270Arg missense_variant 0.198 0 96 30 . . . . . TRUE 12 103696161 T 0.99 Clonal
Patient 2, Organoids early p. SVOP p.Asp79Asn missense_variant 0.164 0 63 29 . . . . . TRUE 12 109366201 T 0.79 Clonal
Patient 2, Organoids early p. ANKLE2 p.Gly46Gly synonymous_variant 0.385 0 13 13 . . . . . TRUE 12 133338247 T 1 Clonal
Patient 2, Organoids early p. KPNA3 p.Leu323Leu synonymous_variant 0.388 0 103 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Organoids early p. SALL2 p.Pro365Leu missense_variant 0.625 0 96 95 . . . . . TRUE 14 21992768 A 1 Clonal
Patient 2, Organoids early p. TRAV36DV7 p.Gly103Arg missense_variant 0.078 0 51 23 . . . . . TRUE 14 22695116 A 0.31 Subclonal
Patient 2, Organoids early p. SRSF5 p.Ser90Gly missense_variant 0.517 0 145 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Organoids early p. GOLGA5 p.Ala522Asp missense_variant 0.439 0.012 198 86 TRUE . . . . FALSE 14 93286126 A 1 Clonal
Patient 2, Organoids early p. DPH6 p.Leu45Gln missense_variant 1 0 53 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Organoids early p. SRRM2 p.Trp513* stop_gained 0.442 0 86 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Organoids early p. C16orf89 p.Leu128Leu synonymous_variant 0.541 0 74 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Organoids early p. ZNF843 p.Glu264Glu synonymous_variant 0.146 0 41 21 . . . . . FALSE 16 31447379 T 0.73 Clonal
Patient 2, Organoids early p. CDH11 p.Glu391Asp missense_variant 0.111 0 54 17 TRUE . . . . FALSE 16 65016031 A 0.56 Subclonal
Patient 2, Organoids early p. DPEP3 p.Arg3Trp missense_variant 0.321 0 28 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Organoids early p. ZNF469 p.Thr3815Met missense_variant 0.205 0 88 83 . . . . . FALSE 16 88505322 T 1 Clonal
Patient 2, Organoids early p. TP53 p.Arg209fs frameshift_variant 0.92381 0 105 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Organoids early p. RARA p.Asp449Asp synonymous_variant 0.142857 0 70 48 TRUE . . . . TRUE 17 38512388 T 0.71 Clonal
Patient 2, Organoids early p. KRTAP4-11 p.Arg51Lys missense_variant 0.0952381 0 105 38 . . . . . TRUE 17 39274416 T 0.48 Subclonal
Patient 2, Organoids early p. HOXB5 p.Arg224Leu missense_variant 0.189 0 95 74 . . . . . TRUE 17 46669710 A 0.95 Clonal
Patient 2, Organoids early p. AKAP1 p.Leu832Val missense_variant 0.205 0 44 32 . . . . . TRUE 17 55194282 G 1 Clonal
Patient 2, Organoids early p. USH1G p.Thr100Lys missense_variant 0.182 0 198 165 . . . . . TRUE 17 72916632 T 0.91 Clonal
Patient 2, Organoids early p. DDC8 p.Gln416* stop_gained 0.254 0 142 100 . . . . . TRUE 17 76887340 A 1 Clonal
Patient 2, Organoids early p. FASN p.Leu1826fs frameshift_variant 0.190476 0 168 142 . . . . . TRUE 17 80041170 G 0.95 Clonal
Patient 2, Organoids early p. GALNT1 p.Arg426Cys missense_variant 0.429 0 21 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Organoids early p. FHOD3 p.Leu261Leu synonymous_variant 0.383 0 115 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Organoids early p. FHOD3 p.Arg1568His missense_variant 0.503 0 183 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Organoids early p. SMAD7 p.Pro215Leu missense_variant 0.47 0 66 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Organoids early p. DOT1L p.Ile1251Ile synonymous_variant 1 0.007519 125 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Organoids early p. ZNF414 p.Leu257Phe missense_variant 0.226 0 31 32 . . . . . TRUE 19 8576604 G 0.68 Clonal
Patient 2, Organoids early p. ADAMTS10 p.Val904Val synonymous_variant 0.582 0.011 79 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Organoids early p. MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.255 0 47 48 . . . . . TRUE 19 9015384 G 0.77 Clonal
Patient 2, Organoids early p. ZNF561 p.Arg441Pro missense_variant 1 0 125 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Organoids early p. RAVER1 p.Ala477Ala synonymous_variant 1 0 8 16 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Organoids early p. CAPN12 p.His686Arg missense_variant 1 0 23 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Organoids early p. ERCC1 p.Gly133Gly synonymous_variant 1 0 101 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Organoids early p. RTN2 p.Ser211Ser synonymous_variant 0.362 0 105 153 . . . . . TRUE 19 45997605 C 1 Clonal
Patient 2, Organoids early p. GPR4 p.Pro359Pro synonymous_variant 0.00980392 0 102 128 . . . . . TRUE 19 46094048 T 0.03 Subclonal
Patient 2, Organoids early p. PLCB4 p.Val86Phe missense_variant 0.714 0 84 30 . . . . . TRUE 20 9319571 T 1 Clonal
Patient 2, Organoids early p. MYH7B p.Ser797* stop_gained 0.356 0 90 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Organoids early p. CNKSR2 p.Glu480Gly missense_variant 0.052 0 77 18 . . . . . TRUE X 21581401 G Did not evaluate
Patient 2, Organoids early p. PPP1R3F p.Asn345Asn synonymous_variant 1 0 28 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Organoids early p. FGF13 p.Glu54Lys missense_variant 1 0 45 15 . . . . . TRUE X 137939731 T Did not evaluate
Patient 2, Organoids late p. C1orf159 p.Thr26Met missense_variant 0.391 0 46 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Organoids late p. ACTL8 p.Val6Ile missense_variant 0.094 0 64 70 . . . . . FALSE 1 18149519 A 0.29 Subclonal
Patient 2, Organoids late p. TMCO4 p.Ala211Ser missense_variant 0.583 0 36 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Organoids late p. HIVEP3 p.Met265fs frameshift_variant 0.357143 0 98 91 . . . . . FALSE 1 42049671 C 1 Clonal
Patient 2, Organoids late p. LEPRE1 p.Asp253Val missense_variant 0.549 0 175 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Organoids late p. KIF2C p.Arg258Thr missense_variant 0.2 0 20 24 . . . . . FALSE 1 45221614 C 0.62 Subclonal
Patient 2, Organoids late p. HPDL p.Gly61Arg missense_variant 0.16 0 94 84 . . . . . FALSE 1 45793001 A 0.49 Subclonal
Patient 2, Organoids late p. ELTD1 p.Ile35Ile synonymous_variant 0.514 0 37 13 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Organoids late p. LRRC8C p.Phe667Phe synonymous_variant 0.405 0.019 116 53 . . . . . FALSE 1 90180130 C 1 Clonal
Patient 2, Organoids late p. GJA5 p.Lys233del disruptive_inframe_deletion 0.0888889 0 315 82 . . . . . FALSE 1 147230646 A 0.81 Clonal
Patient 2, Organoids late p. CA14 p.Ser215Trp missense_variant 0.115 0 252 112 . . . . . FALSE 1 150235522 G 1 Clonal
Patient 2, Organoids late p. APOA2 p.Met34fs frameshift_variant 0.0527638 0 398 188 . . . . . FALSE 1 161193173 T 0.48 Subclonal
Patient 2, Organoids late p. GJC2 p.Leu353Pro missense_variant 0.227 0 22 22 . . . . . TRUE 1 228346517 C 0.93 Clonal
Patient 2, Organoids late p. OTX1 p.His260Gln missense_variant 0.177 0 198 86 . . . . . FALSE 2 63283166 G 0.9 Clonal
Patient 2, Organoids late p. PROM2 p.Leu119Leu synonymous_variant 0.195 0 77 68 . . . . . FALSE 2 95941738 T 0.99 Clonal
Patient 2, Organoids late p. CYP27C1 p.Pro243Pro synonymous_variant 0.186 0 70 64 . . . . . FALSE 2 127951434 G 0.94 Clonal
Patient 2, Organoids late p. NEB p.Ile3069Thr missense_variant 0.324 0 438 222 . . . . . TRUE 2 152490376 G 1 Clonal
Patient 2, Organoids late p. NBEAL1 p.Trp1775Cys missense_variant 0.09 0 89 21 . . . . . FALSE 2 204013821 T 0.46 Subclonal
Patient 2, Organoids late p. FASTKD2 p.Asn663Ser missense_variant 0.336 0 143 46 . . . . . FALSE 2 207655385 G 1 Clonal
Patient 2, Organoids late p. PIKFYVE p.Asn383Asn synonymous_variant 0.311 0 132 37 . . . . . FALSE 2 209165759 T 1 Clonal
Patient 2, Organoids late p. NCL p.Asp200_Asp201del disruptive_inframe_deletion 0.166667 0 150 40 . . . . . FALSE 2 232326258 C 0.85 Clonal
Patient 2, Organoids late p. COL6A3 p.Ser220Ser synonymous_variant 0.201 0 334 126 . . . . . FALSE 2 238303279 T 1 Clonal
Patient 2, Organoids late p. SNED1 p.Ala316Val missense_variant 0.607 0 183 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Organoids late p. ATG4B p.Arg201Arg synonymous_variant 0.732 0 149 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Organoids late p. C3orf20 p.Ile46Leu missense_variant 0.049 0 122 60 . . . . . FALSE 3 14724356 C 0.2 Subclonal
Patient 2, Organoids late p. SGOL1 p.Asp380Asp synonymous_variant 0.073 0 137 57 . . . . . FALSE 3 20215883 A 0.3 Subclonal
Patient 2, Organoids late p. KIAA1143 p.Gln136Lys missense_variant 0.215 0 65 30 . . . . . FALSE 3 44794892 T 0.88 Clonal
Patient 2, Organoids late p. TMF1 p.Cys318Ser missense_variant 0.543 0 35 24 . . . . . FALSE 3 69096903 G 1 Clonal
Patient 2, Organoids late p. PPP4R2 p.Ser146Arg missense_variant 0.182 0 22 9 . . . . . FALSE 3 73112842 A 0.56 Subclonal
Patient 2, Organoids late p. SPICE1 p.Leu419fs frameshift_variant 0.292035 0 113 61 . . . . . FALSE 3 113184532 G 0.9 Clonal
Patient 2, Organoids late p. ITGB5 p.Asp640His missense_variant&splice_region_variant 0.591 0 22 31 . . . . . FALSE 3 124487959 G 1 Clonal
Patient 2, Organoids late p. MSL2 p.Arg344Lys missense_variant 0.351 0 111 46 . . . . . FALSE 3 135870692 T 1 Clonal
Patient 2, Organoids late p. PHC3 p.Trp937* stop_gained 0.162 0 143 19 . . . . . FALSE 3 169820290 T 0.82 Clonal
Patient 2, Organoids late p. EPHB3 p.Gln509Lys missense_variant 0.159 0 63 64 . . . . . FALSE 3 184295491 A 0.81 Clonal
Patient 2, Organoids late p. TMEM41A p.Phe44Phe synonymous_variant 0.409 0 22 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Organoids late p. ADH1A p.Glu253Glu synonymous_variant 0.037 0 134 84 . . . . . TRUE 4 100203572 T 0.08 Subclonal
Patient 2, Organoids late p. DNAJB14 p.Tyr38Cys missense_variant 0.578 0 45 29 . . . . . TRUE 4 100867616 C 1 Clonal
Patient 2, Organoids late p. ADAMTS16 p.Val68Val synonymous_variant 0.056 0 107 63 . . . . . TRUE 5 5146271 G 0.23 Subclonal
Patient 2, Organoids late p. BDP1 p.Ala932fs frameshift_variant 0.701031 0 97 56 . . . . . TRUE 5 70805704 T 1 Clonal
Patient 2, Organoids late p. SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.258621 0 58 72 . . . . . TRUE 5 131667533 T 0.8 Clonal
Patient 2, Organoids late p. CFB p.Ile744Val missense_variant 0.791 0 110 115 . . . . . FALSE 6 31915584 G 1 Clonal
Patient 2, Organoids late p. DNAH8 p.Ser1436Arg missense_variant 0.103 0 58 15 . . . . . FALSE 6 38802396 G 0.53 Subclonal
Patient 2, Organoids late p. RIMS1 p.Lys718Asn missense_variant 0.149 0 87 16 . . . . . FALSE 6 72957743 T 0.76 Clonal
Patient 2, Organoids late p. ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.188 0 48 9 . . . . . FALSE 6 100964054 C 0.95 Clonal
Patient 2, Organoids late p. KIAA1919 p.Gln415Pro missense_variant 0.186 0 118 65 . . . . . FALSE 6 111588009 C 0.95 Clonal
Patient 2, Organoids late p. AGPAT4 p.Glu149Gln missense_variant 0.213 0 221 189 . . . . . FALSE 6 161575246 G 1 Clonal
Patient 2, Organoids late p. SDIM1 p.Arg56Gly missense_variant 0.045 0 89 64 . . . . . FALSE 6 166307988 C 0.23 Subclonal
Patient 2, Organoids late p. POU6F2 p.Gly132Val missense_variant 0.26 0 97 45 . . . . . TRUE 7 39247103 T 1 Clonal
Patient 2, Organoids late p. COPS6 p.Phe168Leu missense_variant 0.488 0 43 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Organoids late p. CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 1 0 40 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Organoids late p. MGAM p.Ser1292Ser synonymous_variant 0.175 0 40 38 . . . . . TRUE 7 141759328 T 0.71 Clonal
Patient 2, Organoids late p. MGAM p.Ser2188Ser synonymous_variant 0.083 0 168 74 . . . . . TRUE 7 141785689 T 0.34 Subclonal
Patient 2, Organoids late p. NOS3 p.Ala181Thr missense_variant 0.333 0.026 30 38 . . . . . TRUE 7 150693972 A 1 Clonal
Patient 2, Organoids late p. NUGGC p.Thr176Thr synonymous_variant 0.154 0 39 24 . . . . . FALSE 8 27925214 T 0.63 Subclonal
Patient 2, Organoids late p. WRN p.Ala1179Ser missense_variant 0.304 0 92 28 TRUE . . . . FALSE 8 31004955 T 1 Clonal
Patient 2, Organoids late p. NSMAF p.Glu12* stop_gained 0.395 0 39 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Organoids late p. CA8 p.Pro63Pro synonymous_variant 0.056 0 269 79 . . . . . FALSE 8 61192351 A 0.34 Subclonal
Patient 2, Organoids late p. CSMD3 p.Asp293Asn missense_variant 0.232 0 194 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Organoids late p. ADCY8 p.His239Asn missense_variant 0.093 0 172 22 . . . . . FALSE 8 132051865 T 1 Clonal
Patient 2, Organoids late p. CNTLN p.Lys862Thr missense_variant 1 0 53 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Organoids late p. TRMT10B p.Thr195Thr synonymous_variant 1 0 116 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Organoids late p. C9orf64 p.Ile114Met missense_variant 0.978 0 46 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Organoids late p. TSC1 p.Gln767* stop_gained 0.99 0 202 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Organoids late p. PRKCQ p.Asn462Asn synonymous_variant 0.734 0 244 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Organoids late p. MASTL p.Arg793fs frameshift_variant 0.0522193 0 383 91 . . . . . FALSE 10 27469988 G 0.42 Subclonal
Patient 2, Organoids late p. HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 1 0 55 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Organoids late p. SFXN3 p.Val222Val synonymous_variant 0.967 0 30 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Organoids late p. EPS8L2 p.Asp172Tyr missense_variant 0.742 0 62 84 . . . . . FALSE 11 720735 T 1 Clonal
Patient 2, Organoids late p. HPX p.Ser288Gly missense_variant 0.814 0 43 60 . . . . . FALSE 11 6453221 C 1 Clonal
Patient 2, Organoids late p. DCHS1 p.Leu644Gln missense_variant 0.656 0 160 168 . . . . . FALSE 11 6655404 T 1 Clonal
Patient 2, Organoids late p. NELL1 p.Val349Leu missense_variant 0.2 0 50 23 . . . . . FALSE 11 20949989 C 0.82 Clonal
Patient 2, Organoids late p. KIAA1549L p.Gly1602Gly synonymous_variant 0.522 0 23 17 . . . . . FALSE 11 33667501 A 1 Clonal
Patient 2, Organoids late p. OR8K5 p.Pro283Ser missense_variant 0.185185 0 108 22 . . . . . FALSE 11 55926947 A 0.76 Clonal
Patient 2, Organoids late p. OR9Q1 p.Thr278Ala missense_variant 0.43 0 79 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Organoids late p. MS4A12 p.Pro255Pro synonymous_variant 0.445 0 209 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Organoids late p. LRP5 p.His965Asp missense_variant 0.208 0 448 407 . . . . . FALSE 11 68183861 G 0.85 Clonal
Patient 2, Organoids late p. SYTL2 p.Glu1611Val missense_variant 0.484 0 63 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Organoids late p. ARHGEF12 p.Leu630Phe missense_variant 0.584 0 166 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Organoids late p. TAS2R30 p.Val125Leu missense_variant 0.272 0 103 35 . . . . . TRUE 12 11286471 G 0.84 Clonal
Patient 2, Organoids late p. HDAC7 p.Pro472Leu missense_variant 0.792 0.013 77 76 . . . . . TRUE 12 48188637 A 1 Clonal
Patient 2, Organoids late p. KMT2D p.Met1530Val missense_variant 0.769 0 134 145 TRUE TRUE TRUE . . TRUE 12 49439953 C 1 Clonal
Patient 2, Organoids late p. C12orf42 p.Gly270Arg missense_variant 0.205 0 78 30 . . . . . TRUE 12 103696161 T 0.84 Clonal
Patient 2, Organoids late p. SVOP p.Asp79Asn missense_variant 0.237 0 59 29 . . . . . TRUE 12 109366201 T 0.97 Clonal
Patient 2, Organoids late p. ANKLE2 p.Gly46Gly synonymous_variant 0.166667 0 18 17 . . . . . TRUE 12 133338247 T 0.68 Clonal
Patient 2, Organoids late p. KPNA3 p.Leu323Leu synonymous_variant 0.5 0 94 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Organoids late p. MYCBP2 p.Met3453Val missense_variant 0.087 0 126 29 . . . . . TRUE 13 77667310 C 0.36 Subclonal
Patient 2, Organoids late p. MBNL2 p.Lys178Asn missense_variant 0.143 0 21 11 . . . . . TRUE 13 97995464 T 0.58 Subclonal
Patient 2, Organoids late p. SALL2 p.Pro365Leu missense_variant 0.767 0 91 95 . . . . . FALSE 14 21992768 A 1 Clonal
Patient 2, Organoids late p. AKAP6 p.Arg509* stop_gained 0.00806452 0 124 41 . . . . . FALSE 14 33015384 T 0.03 Subclonal
Patient 2, Organoids late p. SRSF5 p.Ser90Gly missense_variant 0.6 0 115 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Organoids late p. GOLGA5 p.Ala522Asp missense_variant 0.288 0.012 156 86 TRUE . . . . FALSE 14 93286126 A 0.89 Clonal
Patient 2, Organoids late p. DPH6 p.Leu45Gln missense_variant 1 0 67 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Organoids late p. PLA2G4E p.Cys505Phe missense_variant 0.2 0 25 21 . . . . . TRUE 15 42282390 A 0.82 Clonal
Patient 2, Organoids late p. SRRM2 p.Trp513* stop_gained 0.529 0 87 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Organoids late p. SLX4 p.Pro198Gln missense_variant 0.085 0.004926 176 203 . . . . . FALSE 16 3656642 T 0.35 Subclonal
Patient 2, Organoids late p. C16orf71 p.Glu92Gln missense_variant 0.281 0 57 49 . . . . . FALSE 16 4787945 C 1 Clonal
Patient 2, Organoids late p. C16orf89 p.Leu128Leu synonymous_variant 0.412 0 51 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Organoids late p. CDH11 p.Glu391Asp missense_variant 0.191 0 68 17 TRUE . . . . FALSE 16 65016031 A 0.97 Clonal
Patient 2, Organoids late p. DPEP3 p.Arg3Trp missense_variant 0.55 0 20 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Organoids late p. ZNF469 p.Thr3815Met missense_variant 0.132 0 76 83 . . . . . FALSE 16 88505322 T 0.67 Subclonal
Patient 2, Organoids late p. TP53 p.Arg209fs frameshift_variant 0.931373 0 102 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Organoids late p. MFAP4 p.Pro33Leu missense_variant 0.181 0 116 74 . . . . . TRUE 17 19290135 A 0.74 Subclonal
Patient 2, Organoids late p. RARA p.Asp449Asp synonymous_variant 0.25 0 32 40 TRUE . . . . TRUE 17 38512388 T 1 Clonal
Patient 2, Organoids late p. KRTAP4-11 p.Arg51Lys missense_variant 0.063 0 80 31 . . . . . TRUE 17 39274416 T 0.32 Subclonal
Patient 2, Organoids late p. HOXB5 p.Arg224Leu missense_variant 0.173 0 81 74 . . . . . TRUE 17 46669710 A 0.88 Clonal
Patient 2, Organoids late p. AKAP1 p.Leu832Val missense_variant 0.255 0 51 32 . . . . . TRUE 17 55194282 G 1 Clonal
Patient 2, Organoids late p. USH1G p.Thr100Lys missense_variant 0.147 0 231 165 . . . . . TRUE 17 72916632 T 0.75 Subclonal
Patient 2, Organoids late p. DDC8 p.Gln416* stop_gained 0.123 0 138 100 . . . . . TRUE 17 76887340 A 0.63 Subclonal
Patient 2, Organoids late p. FASN p.Leu1826fs frameshift_variant 0.19898 0 196 142 . . . . . TRUE 17 80041170 G 1 Clonal
Patient 2, Organoids late p. GALNT1 p.Arg426Cys missense_variant 0.6 0 15 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Organoids late p. FHOD3 p.Leu261Leu synonymous_variant 0.61 0 82 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Organoids late p. FHOD3 p.Arg1568His missense_variant 0.601 0 143 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Organoids late p. SMAD7 p.Pro215Leu missense_variant 0.536 0 28 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Organoids late p. DOT1L p.Ile1251Ile synonymous_variant 1 0.007519 95 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Organoids late p. ZNF414 p.Leu257Phe missense_variant 0.4 0 25 32 . . . . . TRUE 19 8576604 G 1 Clonal
Patient 2, Organoids late p. ADAMTS10 p.Val904Val synonymous_variant 0.667 0.011 69 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Organoids late p. MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.38 0 50 48 . . . . . TRUE 19 9015384 G 1 Clonal
Patient 2, Organoids late p. ZNF561 p.Arg441Pro missense_variant 0.985 0 133 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Organoids late p. RAVER1 p.Ala477Ala synonymous_variant 1 0 9 16 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Organoids late p. CAPN12 p.His686Arg missense_variant 1 0 25 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Organoids late p. MARK4 p.Gly258Gly synonymous_variant 0.064 0 48 75 . . . . . TRUE 19 45774954 A 0.19 Subclonal
Patient 2, Organoids late p. ERCC1 p.Gly133Gly synonymous_variant 1 0 118 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Organoids late p. RTN2 p.Ser211Ser synonymous_variant 0.373 0 118 153 . . . . . TRUE 19 45997605 C 1 Clonal
Patient 2, Organoids late p. GPR4 p.Pro359Pro synonymous_variant 0.38 0 92 106 . . . . . TRUE 19 46094048 T 1 Clonal
Patient 2, Organoids late p. PLCB4 p.Val86Phe missense_variant 0.75 0 76 30 . . . . . FALSE 20 9319571 T 1 Clonal
Patient 2, Organoids late p. MYH7B p.Ser797* stop_gained 0.417 0 103 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Organoids late p. SMTN p.Gln325Lys missense_variant 0.164 0 128 183 . . . . . FALSE 22 31486982 A 0.51 Subclonal
Patient 2, Organoids late p. SCML2 p.Thr408Ser missense_variant 0.058 0 69 12 . . . . . TRUE X 18276215 A Did not evaluate
Patient 2, Organoids late p. PPP1R3F p.Asn345Asn synonymous_variant 1 0 29 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Organoids late p. HEPH p.Ala382Ser missense_variant 0.087 0 104 30 . . . . . TRUE X 65409699 T Did not evaluate




Table S4. Lists of Somatic Single Nucleotide Variants, Insertions and Deletions Identified by Whole Exome Sequenc-
ing in the Samples Included in the Study. Note: only data for patient 2 is shown here. The whole data list accessible 
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Kandoth Lawrence Fujimoto Hotspot Facets LOH Call CHROM POS ALT CCF
Absolute 
Clonal
Patient 2, Biopsy C1orf159 p.Thr26Met missense_variant 0.322 0 90 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Biopsy ACTL8 p.Val6Ile missense_variant 0.0756303 0 119 88 . . . . . FALSE 1 18149519 A 0.28 Subclonal
Patient 2, Biopsy TMCO4 p.Ala211Ser missense_variant 0.467 0 30 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Biopsy HIVEP3 p.Met265fs frameshift_variant 0.40458 0 131 91 . . . . . FALSE 1 42049671 C 1 Subclonal
Patient 2, Biopsy LEPRE1 p.Asp253Val missense_variant 0.313 0 224 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Biopsy KIF2C p.Arg258Thr missense_variant 0.231 0 13 24 . . . . . FALSE 1 45221614 C 0.85 Clonal
Patient 2, Biopsy ELTD1 p.Ile35Ile synonymous_variant 0.571429 0 7 15 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Biopsy LRRC8C p.Phe667Phe synonymous_variant 0.217 0.019 60 53 . . . . . FALSE 1 90180130 C 0.8 Clonal
Patient 2, Biopsy GJA5 p.Lys233del disruptive_inframe_deletion 0.0868545 0 426 82 . . . . . FALSE 1 147230646 A 0.93 Clonal
Patient 2, Biopsy OTUD7B p.Lys550* stop_gained 0.06 0 433 97 . . . . . FALSE 1 149916640 A 0.64 Subclonal
Patient 2, Biopsy CA14 p.Ser215Trp missense_variant 0.016 0 250 138 . . . . . FALSE 1 150235522 G 0.17 Subclonal
Patient 2, Biopsy APOA2 p.Met34fs frameshift_variant 0.0576923 0 624 188 . . . . . FALSE 1 161193173 T 0.62 Subclonal
Patient 2, Biopsy GJC2 p.Leu353Pro missense_variant 0.192 0 26 22 . . . . . FALSE 1 228346517 C 0.9 Clonal
Patient 2, Biopsy OTX1 p.His260Gln missense_variant 0.024 0 250 117 . . . . . FALSE 2 63283166 G 0.14 Subclonal
Patient 2, Biopsy PROM2 p.Leu119Leu synonymous_variant 0.04 0 125 92 . . . . . FALSE 2 95941738 T 0.19 Subclonal
Patient 2, Biopsy CYP27C1 p.Pro243Pro synonymous_variant 0.104 0 106 64 . . . . . FALSE 2 127951434 G 0.49 Subclonal
Patient 2, Biopsy NEB p.Ile3069Thr missense_variant 0.057 0 493 222 . . . . . TRUE 2 152490376 G 0.21 Subclonal
Patient 2, Biopsy FASTKD2 p.Asn663Ser missense_variant 0.161 0 31 46 . . . . . FALSE 2 207655385 G 0.76 Clonal
Patient 2, Biopsy PIKFYVE p.Asn383Asn synonymous_variant 0.211 0 57 37 . . . . . FALSE 2 209165759 T 0.99 Clonal
Patient 2, Biopsy COL6A3 p.Ser220Ser synonymous_variant 0.19 0 205 126 . . . . . FALSE 2 238303279 T 0.89 Clonal
Patient 2, Biopsy SNED1 p.Ala316Val missense_variant 0.62 0 179 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Biopsy ATG4B p.Arg201Arg synonymous_variant 0.626 0 195 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Biopsy KIAA1143 p.Gln136Lys missense_variant 0.241 0 29 30 . . . . . FALSE 3 44794892 T 1 Clonal
Patient 2, Biopsy TMF1 p.Cys318Ser missense_variant 0.647 0 17 24 . . . . . FALSE 3 69096903 G 1 Clonal
Patient 2, Biopsy PPP4R2 p.Ser146Arg missense_variant 0.727 0 11 9 . . . . . FALSE 3 73112842 A 1 Clonal
Patient 2, Biopsy IFT57 p.Phe41Cys missense_variant 0.259 0 54 20 . . . . . FALSE 3 107941048 C 0.96 Clonal
Patient 2, Biopsy SPICE1 p.Leu419fs frameshift_variant 0.257143 0 35 61 . . . . . FALSE 3 113184532 G 0.95 Clonal
Patient 2, Biopsy ITGB5 p.Asp640His missense_variant&splice_region_variant 0.208 0 24 31 . . . . . FALSE 3 124487959 G 0.77 Clonal
Patient 2, Biopsy MSL2 p.Arg344Lys missense_variant 0.075 0 80 46 . . . . . FALSE 3 135870692 T 0.28 Subclonal
Patient 2, Biopsy PHC3 p.Trp937* stop_gained 0.012987 0 77 25 . . . . . FALSE 3 169820290 T 0.06 Subclonal
Patient 2, Biopsy EPHB3 p.Gln509Lys missense_variant 0.172 0 60 64 . . . . . FALSE 3 184295491 A 0.78 Clonal
Patient 2, Biopsy TMEM41A p.Phe44Phe synonymous_variant 0.333 0 18 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Biopsy ADH1A p.Glu253Glu synonymous_variant 0.0324074 0 216 102 . . . . . TRUE 4 100203572 T 0.12 Subclonal
Patient 2, Biopsy DNAJB14 p.Tyr38Cys missense_variant 0.097 0 62 29 . . . . . TRUE 4 100867616 C 0.36 Subclonal
Patient 2, Biopsy FAM149A p.Pro442Ser missense_variant 0.146 0 96 59 . . . . . TRUE 4 187077221 T 0.54 Subclonal
Patient 2, Biopsy BDP1 p.Ala932fs frameshift_variant 0.458333 0 48 56 . . . . . FALSE 5 70805704 T 1 Clonal
Patient 2, Biopsy SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.109375 0 64 72 . . . . . FALSE 5 131667533 T 0.4 Subclonal
Patient 2, Biopsy PPP1R18 p.Pro346His missense_variant 0.137 0 153 121 . . . . . TRUE 6 30652759 T 0.78 Clonal
Patient 2, Biopsy CFB p.Ile744Val missense_variant 0.842 0 184 115 . . . . . TRUE 6 31915584 G 1 Clonal
Patient 2, Biopsy ZFAND3 p.Gln168Arg missense_variant 0.159 0 44 16 . . . . . TRUE 6 38084489 G 0.91 Clonal
Patient 2, Biopsy DNAH8 p.Ser1436Arg missense_variant 0.0666667 0 15 18 . . . . . TRUE 6 38802396 G 0.38 Subclonal
Patient 2, Biopsy GLP1R p.Arg64Pro missense_variant 0.102 0.00489 728 409 . . . . . TRUE 6 39025263 C 0.58 Subclonal
Patient 2, Biopsy DST p.Lys6551Asn missense_variant 0.107 0 168 40 . . . . . TRUE 6 56366028 G 0.61 Subclonal
Patient 2, Biopsy ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.219 0 32 9 . . . . . TRUE 6 100964054 C 1 Clonal
Patient 2, Biopsy KIAA1919 p.Gln415Pro missense_variant 0.091 0 88 65 . . . . . TRUE 6 111588009 C 0.52 Subclonal
Patient 2, Biopsy AGPAT4 p.Glu149Gln missense_variant 0.016 0 250 250 . . . . . TRUE 6 161575246 G 0.09 Subclonal
Patient 2, Biopsy POU6F2 p.Gly132Val missense_variant 0.056 0 125 45 . . . . . TRUE 7 39247103 T 0.26 Subclonal
Patient 2, Biopsy COPS6 p.Phe168Leu missense_variant 0.554 0 56 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Biopsy CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 0.903 0 62 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Biopsy NUGGC p.Thr176Thr synonymous_variant 0.143 0 42 24 . . . . . FALSE 8 27925214 T 0.81 Clonal
Patient 2, Biopsy WRN p.Ala1179Ser missense_variant 0.24 0 25 28 TRUE . . . . FALSE 8 31004955 T 1 Clonal
Patient 2, Biopsy NSMAF p.Glu12* stop_gained 0.44 0 50 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Biopsy CSMD3 p.Asp293Asn missense_variant 0.278 0 18 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Biopsy CNTLN p.Lys862Thr missense_variant 0.896 0 48 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Biopsy TRMT10B p.Thr195Thr synonymous_variant 0.831 0 89 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Biopsy C9orf64 p.Ile114Met missense_variant 0.822 0 45 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Biopsy SLC28A3 p.Glu500* stop_gained 0.063 0 144 109 . . . . . TRUE 9 86900409 A 0.29 Subclonal
Patient 2, Biopsy TSC1 p.Gln767* stop_gained 0.841 0 270 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Biopsy INPP5E p.Ser582Ser synonymous_variant 0.038 0.006803 237 150 . . . . . TRUE 9 139324785 A 0.18 Subclonal
Patient 2, Biopsy PRKCQ p.Asn462Asn synonymous_variant 0.587 0 219 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Biopsy MASTL p.Arg793fs frameshift_variant 0.0602837 0 282 91 . . . . . FALSE 10 27469988 G 0.58 Subclonal
Patient 2, Biopsy HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 0.833 0 72 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Biopsy SFXN3 p.Val222Val synonymous_variant 0.786 0 42 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Biopsy EPS8L2 p.Asp172Tyr missense_variant 0.522 0 92 84 . . . . . FALSE 11 720735 T 1 Clonal
Patient 2, Biopsy HPX p.Ser288Gly missense_variant 0.441 0 59 60 . . . . . FALSE 11 6453221 C 1 Clonal
Patient 2, Biopsy DCHS1 p.Leu644Gln missense_variant 0.617 0 222 168 . . . . . FALSE 11 6655404 T 1 Clonal
Patient 2, Biopsy NELL1 p.Val349Leu missense_variant 0.333 0 30 23 . . . . . FALSE 11 20949989 C 1 Clonal
Patient 2, Biopsy KIAA1549L p.Gly1602Gly synonymous_variant 0.542 0 24 17 . . . . . FALSE 11 33667501 A 1 Clonal
Patient 2, Biopsy OR8K5 p.Pro283Ser missense_variant 0.075 0 40 22 . . . . . FALSE 11 55926947 A 0.28 Subclonal
Patient 2, Biopsy OR9Q1 p.Thr278Ala missense_variant 0.417 0 84 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Biopsy MS4A12 p.Pro255Pro synonymous_variant 0.408 0 98 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Biopsy LRP5 p.His965Asp missense_variant 0.049 0 678 407 . . . . . FALSE 11 68183861 G 0.23 Subclonal
Patient 2, Biopsy SYTL2 p.Glu1611Val missense_variant 0.378 0 37 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Biopsy FAT3 p.Glu2075Lys missense_variant 0.159 0 44 30 . . . . . FALSE 11 92532402 A 0.75 Clonal
Patient 2, Biopsy ARHGEF12 p.Leu630Phe missense_variant 0.45 0 211 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Biopsy TAS2R30 p.Val125Leu missense_variant 0.0357143 0 28 41 . . . . . TRUE 12 11286471 G 0.13 Subclonal
Patient 2, Biopsy HDAC7 p.Pro472Leu missense_variant 0.701 0.013 97 76 . . . . . FALSE 12 48188637 A 1 Clonal
Patient 2, Biopsy KMT2D p.Met1530Val missense_variant 0.658 0 231 145 TRUE TRUE TRUE . . FALSE 12 49439953 C 1 Clonal
Patient 2, Biopsy C12orf42 p.Gly270Arg missense_variant 0.185 0 92 30 . . . . . FALSE 12 103696161 T 1 Clonal
Patient 2, Biopsy SVOP p.Asp79Asn missense_variant 0.079 0 76 29 . . . . . FALSE 12 109366201 T 0.45 Subclonal
Patient 2, Biopsy ANKLE2 p.Gly46Gly synonymous_variant 0.13 0 23 13 . . . . . FALSE 12 133338247 T 0.74 Clonal
Patient 2, Biopsy CDX2 p.Ser208Asn missense_variant 0.147 0.013 143 75 TRUE . . . . TRUE 13 28539071 T 0.69 Subclonal
Patient 2, Biopsy PROSER1 p.Asn516Asn synonymous_variant 0.2 0 60 27 . . . . . TRUE 13 39587841 A 0.94 Clonal
Patient 2, Biopsy KPNA3 p.Leu323Leu synonymous_variant 0.405 0 74 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Biopsy NALCN p.Ile1593Val missense_variant 0.235 0 51 25 . . . . . TRUE 13 101712298 C 1 Clonal
Patient 2, Biopsy SALL2 p.Pro365Leu missense_variant 0.531 0 192 95 . . . . . FALSE 14 21992768 A 1 Clonal
Patient 2, Biopsy TRAV38-1 p.Ser13Phe missense_variant 0.148 0 54 13 . . . . . FALSE 14 22739891 T 0.84 Clonal
Patient 2, Biopsy AKAP6 p.Arg509* stop_gained 0.122 0 74 34 . . . . . FALSE 14 33015384 T 0.69 Subclonal
Patient 2, Biopsy SRSF5 p.Ser90Gly missense_variant 0.381 0 118 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Biopsy GOLGA5 p.Ala522Asp missense_variant 0.458 0.012 118 86 TRUE . . . . FALSE 14 93286126 A 1 Clonal
Patient 2, Biopsy DPH6 p.Leu45Gln missense_variant 0.875 0 32 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Biopsy SRRM2 p.Trp513* stop_gained 0.326 0 139 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Biopsy C16orf89 p.Leu128Leu synonymous_variant 0.298 0 84 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Biopsy ZNF843 p.Glu264Glu synonymous_variant 0.0422535 0 71 26 . . . . . FALSE 16 31447379 T 0.28 Subclonal
Patient 2, Biopsy CDH11 p.Glu391Asp missense_variant 0.011236 0 89 20 TRUE . . . . FALSE 16 65016031 A 0.08 Subclonal
Patient 2, Biopsy DPEP3 p.Arg3Trp missense_variant 0.256 0 39 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Biopsy ZNF469 p.Thr3815Met missense_variant 0.151 0 119 83 . . . . . FALSE 16 88505322 T 1 Clonal
Patient 2, Biopsy TP53 p.Arg209fs frameshift_variant 0.819767 0 172 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Biopsy KCNAB3 p.Leu224fs frameshift_variant 0.0201149 0 348 168 . . . . . TRUE 17 7827765 C 0.11 Subclonal
Patient 2, Biopsy RARA p.Asp449Asp synonymous_variant 0.225 0 41 40 TRUE . . . . FALSE 17 38512388 T 1 Clonal
Patient 2, Biopsy KRTAP4-11 p.Arg51Lys missense_variant 0.123288 0 73 38 . . . . . FALSE 17 39274416 T 0.7 Subclonal
Patient 2, Biopsy HOXB5 p.Arg224Leu missense_variant 0.17 0 153 74 . . . . . FALSE 17 46669710 A 0.97 Clonal
Patient 2, Biopsy AKAP1 p.Leu832Val missense_variant 0.138 0 65 32 . . . . . FALSE 17 55194282 G 0.79 Clonal
Patient 2, Biopsy USH1G p.Thr100Lys missense_variant 0.142 0 338 165 . . . . . FALSE 17 72916632 T 0.81 Subclonal
Patient 2, Biopsy DDC8 p.Gln416* stop_gained 0.105 0 172 100 . . . . . FALSE 17 76887340 A 0.6 Subclonal
Patient 2, Biopsy FASN p.Leu1826fs frameshift_variant 0.138889 0 288 142 . . . . . FALSE 17 80041170 G 0.79 Subclonal
Patient 2, Biopsy GALNT1 p.Arg426Cys missense_variant 0.25 0 12 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Biopsy FHOD3 p.Leu261Leu synonymous_variant 0.365 0 74 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Biopsy FHOD3 p.Arg1568His missense_variant 0.553 0 258 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Biopsy SMAD7 p.Pro215Leu missense_variant 0.633 0 60 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Biopsy DOT1L p.Ile1251Ile synonymous_variant 0.827 0.007519 151 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Biopsy ZNF414 p.Leu257Phe missense_variant 0.244 0 41 32 . . . . . TRUE 19 8576604 G 0.9 Clonal
Patient 2, Biopsy ADAMTS10 p.Val904Val synonymous_variant 0.516 0.011 124 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Biopsy MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.087 0 46 48 . . . . . TRUE 19 9015384 G 0.32 Subclonal
Patient 2, Biopsy ZNF561 p.Arg441Pro missense_variant 0.695 0 82 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Biopsy RAVER1 p.Ala477Ala synonymous_variant 0.833 0 12 14 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Biopsy CAPN12 p.His686Arg missense_variant 0.794 0 34 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Biopsy ERCC1 p.Gly133Gly synonymous_variant 0.877 0 204 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Biopsy RTN2 p.Ser211Ser synonymous_variant 0.073 0 206 153 . . . . . TRUE 19 45997605 C 0.27 Subclonal
Patient 2, Biopsy AC012313.1 p.Val202Met missense_variant 0.133 0 45 31 . . . . . TRUE 19 58908060 A 0.49 Subclonal
Patient 2, Biopsy PLCB4 p.Val86Phe missense_variant 0.578 0 45 30 . . . . . FALSE 20 9319571 T 1 Clonal
Patient 2, Biopsy MYH7B p.Ser797* stop_gained 0.381 0 194 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Biopsy BCL2L13 p.Ser190Leu missense_variant 0.154 0 65 38 . . . . . FALSE 22 18185121 T 0.57 Subclonal
Patient 2, Biopsy PPP1R3F p.Asn345Asn synonymous_variant 0.936 0 47 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Biopsy ARR3 p.Leu49Leu splice_region_variant&synonymous_variant 0.156 0 32 16 . . . . . TRUE X 69495933 A Did not evaluate
Patient 2, Biopsy FGF13 p.Glu54Lys missense_variant 0.881 0 59 15 . . . . . TRUE X 137939731 T Did not evaluate
Patient 2, Biopsy GABRE p.Lys302Met missense_variant 0.277 0 65 13 . . . . . TRUE X 151124212 A Did not evaluate
Patient 2, Organoids early p. C1orf159 p.Thr26Met missense_variant 0.583 0 48 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Organoids early p. ACTL8 p.Val6Ile missense_variant 0.104 0 78 70 . . . . . FALSE 1 18149519 A 0.41 Subclonal
Patient 2, Organoids early p. TMCO4 p.Ala211Ser missense_variant 0.719 0 32 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Organoids early p. HIVEP3 p.Met265fs frameshift_variant 0.40708 0 113 91 . . . . . FALSE 1 42049671 C 1 Clonal
Patient 2, Organoids early p. LEPRE1 p.Asp253Val missense_variant 0.451 0 175 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Organoids early p. KIF2C p.Arg258Thr missense_variant 0.154 0 26 24 . . . . . FALSE 1 45221614 C 0.62 Clonal
Patient 2, Organoids early p. HPDL p.Gly61Arg missense_variant 0.00826446 0 121 112 . . . . . FALSE 1 45793001 A 0.03 Subclonal
Patient 2, Organoids early p. ELTD1 p.Ile35Ile synonymous_variant 0.386 0 44 13 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Organoids early p. LRRC8C p.Phe667Phe synonymous_variant 0.361 0.019 158 53 . . . . . FALSE 1 90180130 C 1 Clonal
Patient 2, Organoids early p. GJA5 p.Lys233del disruptive_inframe_deletion 0.0896739 0 368 82 . . . . . FALSE 1 147230646 A 0.9 Clonal
Patient 2, Organoids early p. CA14 p.Ser215Trp missense_variant 0.065 0 277 112 . . . . . FALSE 1 150235522 G 0.65 Subclonal
Patient 2, Organoids early p. APOA2 p.Met34fs frameshift_variant 0.0546218 0 476 188 . . . . . FALSE 1 161193173 T 0.55 Subclonal
Patient 2, Organoids early p. GJC2 p.Leu353Pro missense_variant 0.111 0 36 22 . . . . . TRUE 1 228346517 C 0.56 Subclonal
Patient 2, Organoids early p. OTX1 p.His260Gln missense_variant 0.065 0 186 86 . . . . . FALSE 2 63283166 G 0.32 Subclonal
Patient 2, Organoids early p. PROM2 p.Leu119Leu synonymous_variant 0.208 0 96 68 . . . . . FALSE 2 95941738 T 1 Clonal
Patient 2, Organoids early p. CYP27C1 p.Pro243Pro synonymous_variant 0.086 0 70 64 . . . . . FALSE 2 127951434 G 0.43 Subclonal
Patient 2, Organoids early p. NEB p.Ile3069Thr missense_variant 0.313 0 387 222 . . . . . TRUE 2 152490376 G 0.94 Clonal
Patient 2, Organoids early p. FASTKD2 p.Asn663Ser missense_variant 0.399 0 138 46 . . . . . FALSE 2 207655385 G 1 Clonal
Patient 2, Organoids early p. PIKFYVE p.Asn383Asn synonymous_variant 0.262 0 130 37 . . . . . FALSE 2 209165759 T 1 Clonal
Patient 2, Organoids early p. COL6A3 p.Ser220Ser synonymous_variant 0.183 0 312 126 . . . . . FALSE 2 238303279 T 0.91 Clonal
Patient 2, Organoids early p. SNED1 p.Ala316Val missense_variant 0.658 0 152 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Organoids early p. ATG4B p.Arg201Arg synonymous_variant 0.704 0 159 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Organoids early p. KIAA1143 p.Gln136Lys missense_variant 0.245 0 53 30 . . . . . TRUE 3 44794892 T 0.98 Clonal
Patient 2, Organoids early p. TMF1 p.Cys318Ser missense_variant 0.625 0 48 24 . . . . . TRUE 3 69096903 G 1 Clonal
Patient 2, Organoids early p. PPP4R2 p.Ser146Arg missense_variant 0.1875 0 16 12 . . . . . TRUE 3 73112842 A 0.56 Subclonal
Patient 2, Organoids early p. SPICE1 p.Leu419fs frameshift_variant 0.328358 0 67 61 . . . . . TRUE 3 113184532 G 0.99 Clonal
Patient 2, Organoids early p. ITGB5 p.Asp640His missense_variant&splice_region_variant 0.462 0 13 31 . . . . . TRUE 3 124487959 G 1 Clonal
Patient 2, Organoids early p. MSL2 p.Arg344Lys missense_variant 0.28 0 93 46 . . . . . TRUE 3 135870692 T 0.84 Clonal
Patient 2, Organoids early p. PHC3 p.Trp937* stop_gained 0.099 0 141 19 . . . . . FALSE 3 169820290 T 0.6 Subclonal
Patient 2, Organoids early p. EPHB3 p.Gln509Lys missense_variant 0.113924 0 79 67 . . . . . FALSE 3 184295491 A 0.68 Clonal
Patient 2, Organoids early p. TMEM41A p.Phe44Phe synonymous_variant 0.171 0 41 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Organoids early p. ADH1A p.Glu253Glu synonymous_variant 0.0281124 0 249 102 . . . . . TRUE 4 100203572 T 0.08 Subclonal
Patient 2, Organoids early p. DNAJB14 p.Tyr38Cys missense_variant 0.4 0 70 29 . . . . . TRUE 4 100867616 C 1 Clonal
Patient 2, Organoids early p. BDP1 p.Ala932fs frameshift_variant 0.580645 0 93 56 . . . . . TRUE 5 70805704 T 1 Clonal
Patient 2, Organoids early p. SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.25974 0 77 72 . . . . . TRUE 5 131667533 T 0.78 Clonal
Patient 2, Organoids early p. CFB p.Ile744Val missense_variant 0.824 0 125 115 . . . . . TRUE 6 31915584 G 1 Clonal
Patient 2, Organoids early p. DNAH8 p.Ser1436Arg missense_variant 0.133 0 75 15 . . . . . TRUE 6 38802396 G 0.67 Subclonal
Patient 2, Organoids early p. DST p.Lys6551Asn missense_variant 0.125 0 263 40 . . . . . TRUE 6 56366028 G 0.63 Subclonal
Patient 2, Organoids early p. RIMS1 p.Lys718Asn missense_variant 0.13 0 100 16 . . . . . TRUE 6 72957743 T 0.65 Subclonal
Patient 2, Organoids early p. ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.163 0 43 9 . . . . . TRUE 6 100964054 C 0.81 Clonal
Patient 2, Organoids early p. KIAA1919 p.Gln415Pro missense_variant 0.185 0 130 65 . . . . . TRUE 6 111588009 C 0.92 Clonal
Patient 2, Organoids early p. AGPAT4 p.Glu149Gln missense_variant 0.098 0 214 189 . . . . . TRUE 6 161575246 G 0.49 Subclonal
Patient 2, Organoids early p. POU6F2 p.Gly132Val missense_variant 0.276 0 87 45 . . . . . TRUE 7 39247103 T 1 Clonal
Patient 2, Organoids early p. COPS6 p.Phe168Leu missense_variant 0.583 0 48 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Organoids early p. CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 1 0 41 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Organoids early p. MGAM p.Ser1292Ser synonymous_variant 0.0294118 0 34 49 . . . . . TRUE 7 141759328 T 0.12 Subclonal
Patient 2, Organoids early p. MGAM p.Ser2188Ser synonymous_variant 0.037 0 164 74 . . . . . TRUE 7 141785689 T 0.15 Subclonal
Patient 2, Organoids early p. NUGGC p.Thr176Thr synonymous_variant 0.343 0 35 24 . . . . . TRUE 8 27925214 T 1 Clonal
Patient 2, Organoids early p. WRN p.Ala1179Ser missense_variant 0.14 0 101 28 TRUE . . . . TRUE 8 31004955 T 0.55 Subclonal
Patient 2, Organoids early p. NSMAF p.Glu12* stop_gained 0.622 0 45 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Organoids early p. CSMD3 p.Asp293Asn missense_variant 0.214 0 182 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Organoids early p. ADCY8 p.His239Asn missense_variant 0.0070922 0 141 26 . . . . . FALSE 8 132051865 T 0.07 Subclonal
Patient 2, Organoids early p. CNTLN p.Lys862Thr missense_variant 1 0 44 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Organoids early p. TRMT10B p.Thr195Thr synonymous_variant 1 0 106 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Organoids early p. C9orf64 p.Ile114Met missense_variant 0.975 0 40 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Organoids early p. SLC28A3 p.Glu500* stop_gained 0.239 0 176 109 . . . . . TRUE 9 86900409 A 0.95 Clonal
Patient 2, Organoids early p. TSC1 p.Gln767* stop_gained 1 0 193 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Organoids early p. PRKCQ p.Asn462Asn synonymous_variant 0.673 0 269 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Organoids early p. MASTL p.Arg793fs frameshift_variant 0.077951 0 449 91 . . . . . FALSE 10 27469988 G 0.7 Subclonal
Patient 2, Organoids early p. HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 1 0 54 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Organoids early p. SFXN3 p.Val222Val synonymous_variant 1 0 31 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Organoids early p. EPS8L2 p.Asp172Tyr missense_variant 0.697 0 66 84 . . . . . TRUE 11 720735 T 1 Clonal
Patient 2, Organoids early p. HPX p.Ser288Gly missense_variant 0.682 0 44 60 . . . . . TRUE 11 6453221 C 1 Clonal
Patient 2, Organoids early p. DCHS1 p.Leu644Gln missense_variant 0.794 0 170 168 . . . . . TRUE 11 6655404 T 1 Clonal
Patient 2, Organoids early p. NELL1 p.Val349Leu missense_variant 0.25 0 44 23 . . . . . TRUE 11 20949989 C 1 Clonal
Patient 2, Organoids early p. KIAA1549L p.Gly1602Gly synonymous_variant 0.69 0 29 17 . . . . . TRUE 11 33667501 A 1 Clonal
Patient 2, Organoids early p. OR8K5 p.Pro283Ser missense_variant 0.219 0 96 18 . . . . . FALSE 11 55926947 A 1 Clonal
Patient 2, Organoids early p. OR9Q1 p.Thr278Ala missense_variant 0.412 0 102 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Organoids early p. MS4A12 p.Pro255Pro synonymous_variant 0.357 0 221 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Organoids early p. LRP5 p.His965Asp missense_variant 0.225 0 457 407 . . . . . FALSE 11 68183861 G 1 Clonal
Patient 2, Organoids early p. SYTL2 p.Glu1611Val missense_variant 0.418 0 79 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Organoids early p. ARHGEF12 p.Leu630Phe missense_variant 0.457 0 210 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Organoids early p. TAS2R30 p.Val125Leu missense_variant 0.157 0 102 35 . . . . . TRUE 12 11286471 G 0.63 Subclonal
Patient 2, Organoids early p. HDAC7 p.Pro472Leu missense_variant 0.792 0.013 72 76 . . . . . TRUE 12 48188637 A 1 Clonal
Patient 2, Organoids early p. KMT2D p.Met1530Val missense_variant 0.776 0 157 145 TRUE TRUE TRUE . . TRUE 12 49439953 C 1 Clonal
Patient 2, Organoids early p. C12orf42 p.Gly270Arg missense_variant 0.198 0 96 30 . . . . . TRUE 12 103696161 T 0.99 Clonal
Patient 2, Organoids early p. SVOP p.Asp79Asn missense_variant 0.164 0 63 29 . . . . . TRUE 12 109366201 T 0.79 Clonal
Patient 2, Organoids early p. ANKLE2 p.Gly46Gly synonymous_variant 0.385 0 13 13 . . . . . TRUE 12 133338247 T 1 Clonal
Patient 2, Organoids early p. KPNA3 p.Leu323Leu synonymous_variant 0.388 0 103 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Organoids early p. SALL2 p.Pro365Leu missense_variant 0.625 0 96 95 . . . . . TRUE 14 21992768 A 1 Clonal
Patient 2, Organoids early p. TRAV36DV7 p.Gly103Arg missense_variant 0.078 0 51 23 . . . . . TRUE 14 22695116 A 0.31 Subclonal
Patient 2, Organoids early p. SRSF5 p.Ser90Gly missense_variant 0.517 0 145 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Organoids early p. GOLGA5 p.Ala522Asp missense_variant 0.439 0.012 198 86 TRUE . . . . FALSE 14 93286126 A 1 Clonal
Patient 2, Organoids early p. DPH6 p.Leu45Gln missense_variant 1 0 53 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Organoids early p. SRRM2 p.Trp513* stop_gained 0.442 0 86 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Organoids early p. C16orf89 p.Leu128Leu synonymous_variant 0.541 0 74 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Organoids early p. ZNF843 p.Glu264Glu synonymous_variant 0.146 0 41 21 . . . . . FALSE 16 31447379 T 0.73 Clonal
Patient 2, Organoids early p. CDH11 p.Glu391Asp missense_variant 0.111 0 54 17 TRUE . . . . FALSE 16 65016031 A 0.56 Subclonal
Patient 2, Organoids early p. DPEP3 p.Arg3Trp missense_variant 0.321 0 28 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Organoids early p. ZNF469 p.Thr3815Met missense_variant 0.205 0 88 83 . . . . . FALSE 16 88505322 T 1 Clonal
Patient 2, Organoids early p. TP53 p.Arg209fs frameshift_variant 0.92381 0 105 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Organoids early p. RARA p.Asp449Asp synonymous_variant 0.142857 0 70 48 TRUE . . . . TRUE 17 38512388 T 0.71 Clonal
Patient 2, Organoids early p. KRTAP4-11 p.Arg51Lys missense_variant 0.0952381 0 105 38 . . . . . TRUE 17 39274416 T 0.48 Subclonal
Patient 2, Organoids early p. HOXB5 p.Arg224Leu missense_variant 0.189 0 95 74 . . . . . TRUE 17 46669710 A 0.95 Clonal
Patient 2, Organoids early p. AKAP1 p.Leu832Val missense_variant 0.205 0 44 32 . . . . . TRUE 17 55194282 G 1 Clonal
Patient 2, Organoids early p. USH1G p.Thr100Lys missense_variant 0.182 0 198 165 . . . . . TRUE 17 72916632 T 0.91 Clonal
Patient 2, Organoids early p. DDC8 p.Gln416* stop_gained 0.254 0 142 100 . . . . . TRUE 17 76887340 A 1 Clonal
Patient 2, Organoids early p. FASN p.Leu1826fs frameshift_variant 0.190476 0 168 142 . . . . . TRUE 17 80041170 G 0.95 Clonal
Patient 2, Organoids early p. GALNT1 p.Arg426Cys missense_variant 0.429 0 21 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Organoids early p. FHOD3 p.Leu261Leu synonymous_variant 0.383 0 115 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Organoids early p. FHOD3 p.Arg1568His missense_variant 0.503 0 183 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Organoids early p. SMAD7 p.Pro215Leu missense_variant 0.47 0 66 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Organoids early p. DOT1L p.Ile1251Ile synonymous_variant 1 0.007519 125 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Organoids early p. ZNF414 p.Leu257Phe missense_variant 0.226 0 31 32 . . . . . TRUE 19 8576604 G 0.68 Clonal
Patient 2, Organoids early p. ADAMTS10 p.Val904Val synonymous_variant 0.582 0.011 79 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Organoids early p. MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.255 0 47 48 . . . . . TRUE 19 9015384 G 0.77 Clonal
Patient 2, Organoids early p. ZNF561 p.Arg441Pro missense_variant 1 0 125 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Organoids early p. RAVER1 p.Ala477Ala synonymous_variant 1 0 8 16 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Organoids early p. CAPN12 p.His686Arg missense_variant 1 0 23 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Organoids early p. ERCC1 p.Gly133Gly synonymous_variant 1 0 101 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Organoids early p. RTN2 p.Ser211Ser synonymous_variant 0.362 0 105 153 . . . . . TRUE 19 45997605 C 1 Clonal
Patient 2, Organoids early p. GPR4 p.Pro359Pro synonymous_variant 0.00980392 0 102 128 . . . . . TRUE 19 46094048 T 0.03 Subclonal
Patient 2, Organoids early p. PLCB4 p.Val86Phe missense_variant 0.714 0 84 30 . . . . . TRUE 20 9319571 T 1 Clonal
Patient 2, Organoids early p. MYH7B p.Ser797* stop_gained 0.356 0 90 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Organoids early p. CNKSR2 p.Glu480Gly missense_variant 0.052 0 77 18 . . . . . TRUE X 21581401 G Did not evaluate
Patient 2, Organoids early p. PPP1R3F p.Asn345Asn synonymous_variant 1 0 28 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Organoids early p. FGF13 p.Glu54Lys missense_variant 1 0 45 15 . . . . . TRUE X 137939731 T Did not evaluate
Patient 2, Organoids late p. C1orf159 p.Thr26Met missense_variant 0.391 0 46 61 . . . . . FALSE 1 1026359 A 1 Clonal
Patient 2, Organoids late p. ACTL8 p.Val6Ile missense_variant 0.094 0 64 70 . . . . . FALSE 1 18149519 A 0.29 Subclonal
Patient 2, Organoids late p. TMCO4 p.Ala211Ser missense_variant 0.583 0 36 27 . . . . . FALSE 1 20073075 A 1 Clonal
Patient 2, Organoids late p. HIVEP3 p.Met265fs frameshift_variant 0.357143 0 98 91 . . . . . FALSE 1 42049671 C 1 Clonal
Patient 2, Organoids late p. LEPRE1 p.Asp253Val missense_variant 0.549 0 175 147 . . . . . FALSE 1 43224922 A 1 Clonal
Patient 2, Organoids late p. KIF2C p.Arg258Thr missense_variant 0.2 0 20 24 . . . . . FALSE 1 45221614 C 0.62 Subclonal
Patient 2, Organoids late p. HPDL p.Gly61Arg missense_variant 0.16 0 94 84 . . . . . FALSE 1 45793001 A 0.49 Subclonal
Patient 2, Organoids late p. ELTD1 p.Ile35Ile synonymous_variant 0.514 0 37 13 . . . . . FALSE 1 79470822 A 1 Clonal
Patient 2, Organoids late p. LRRC8C p.Phe667Phe synonymous_variant 0.405 0.019 116 53 . . . . . FALSE 1 90180130 C 1 Clonal
Patient 2, Organoids late p. GJA5 p.Lys233del disruptive_inframe_deletion 0.0888889 0 315 82 . . . . . FALSE 1 147230646 A 0.81 Clonal
Patient 2, Organoids late p. CA14 p.Ser215Trp missense_variant 0.115 0 252 112 . . . . . FALSE 1 150235522 G 1 Clonal
Patient 2, Organoids late p. APOA2 p.Met34fs frameshift_variant 0.0527638 0 398 188 . . . . . FALSE 1 161193173 T 0.48 Subclonal
Patient 2, Organoids late p. GJC2 p.Leu353Pro missense_variant 0.227 0 22 22 . . . . . TRUE 1 228346517 C 0.93 Clonal
Patient 2, Organoids late p. OTX1 p.His260Gln missense_variant 0.177 0 198 86 . . . . . FALSE 2 63283166 G 0.9 Clonal
Patient 2, Organoids late p. PROM2 p.Leu119Leu synonymous_variant 0.195 0 77 68 . . . . . FALSE 2 95941738 T 0.99 Clonal
Patient 2, Organoids late p. CYP27C1 p.Pro243Pro synonymous_variant 0.186 0 70 64 . . . . . FALSE 2 127951434 G 0.94 Clonal
Patient 2, Organoids late p. NEB p.Ile3069Thr missense_variant 0.324 0 438 222 . . . . . TRUE 2 152490376 G 1 Clonal
Patient 2, Organoids late p. NBEAL1 p.Trp1775Cys missense_variant 0.09 0 89 21 . . . . . FALSE 2 204013821 T 0.46 Subclonal
Patient 2, Organoids late p. FASTKD2 p.Asn663Ser missense_variant 0.336 0 143 46 . . . . . FALSE 2 207655385 G 1 Clonal
Patient 2, Organoids late p. PIKFYVE p.Asn383Asn synonymous_variant 0.311 0 132 37 . . . . . FALSE 2 209165759 T 1 Clonal
Patient 2, Organoids late p. NCL p.Asp200_Asp201del disruptive_inframe_deletion 0.166667 0 150 40 . . . . . FALSE 2 232326258 C 0.85 Clonal
Patient 2, Organoids late p. COL6A3 p.Ser220Ser synonymous_variant 0.201 0 334 126 . . . . . FALSE 2 238303279 T 1 Clonal
Patient 2, Organoids late p. SNED1 p.Ala316Val missense_variant 0.607 0 183 92 . . . . . FALSE 2 241976672 T 1 Clonal
Patient 2, Organoids late p. ATG4B p.Arg201Arg synonymous_variant 0.732 0 149 108 . . . . . FALSE 2 242606124 A 1 Clonal
Patient 2, Organoids late p. C3orf20 p.Ile46Leu missense_variant 0.049 0 122 60 . . . . . FALSE 3 14724356 C 0.2 Subclonal
Patient 2, Organoids late p. SGOL1 p.Asp380Asp synonymous_variant 0.073 0 137 57 . . . . . FALSE 3 20215883 A 0.3 Subclonal
Patient 2, Organoids late p. KIAA1143 p.Gln136Lys missense_variant 0.215 0 65 30 . . . . . FALSE 3 44794892 T 0.88 Clonal
Patient 2, Organoids late p. TMF1 p.Cys318Ser missense_variant 0.543 0 35 24 . . . . . FALSE 3 69096903 G 1 Clonal
Patient 2, Organoids late p. PPP4R2 p.Ser146Arg missense_variant 0.182 0 22 9 . . . . . FALSE 3 73112842 A 0.56 Subclonal
Patient 2, Organoids late p. SPICE1 p.Leu419fs frameshift_variant 0.292035 0 113 61 . . . . . FALSE 3 113184532 G 0.9 Clonal
Patient 2, Organoids late p. ITGB5 p.Asp640His missense_variant&splice_region_variant 0.591 0 22 31 . . . . . FALSE 3 124487959 G 1 Clonal
Patient 2, Organoids late p. MSL2 p.Arg344Lys missense_variant 0.351 0 111 46 . . . . . FALSE 3 135870692 T 1 Clonal
Patient 2, Organoids late p. PHC3 p.Trp937* stop_gained 0.162 0 143 19 . . . . . FALSE 3 169820290 T 0.82 Clonal
Patient 2, Organoids late p. EPHB3 p.Gln509Lys missense_variant 0.159 0 63 64 . . . . . FALSE 3 184295491 A 0.81 Clonal
Patient 2, Organoids late p. TMEM41A p.Phe44Phe synonymous_variant 0.409 0 22 22 . . . . . FALSE 3 185214757 A 1 Clonal
Patient 2, Organoids late p. ADH1A p.Glu253Glu synonymous_variant 0.037 0 134 84 . . . . . TRUE 4 100203572 T 0.08 Subclonal
Patient 2, Organoids late p. DNAJB14 p.Tyr38Cys missense_variant 0.578 0 45 29 . . . . . TRUE 4 100867616 C 1 Clonal
Patient 2, Organoids late p. ADAMTS16 p.Val68Val synonymous_variant 0.056 0 107 63 . . . . . TRUE 5 5146271 G 0.23 Subclonal
Patient 2, Organoids late p. BDP1 p.Ala932fs frameshift_variant 0.701031 0 97 56 . . . . . TRUE 5 70805704 T 1 Clonal
Patient 2, Organoids late p. SLC22A4 p.Leu347_Leu348del disruptive_inframe_deletion 0.258621 0 58 72 . . . . . TRUE 5 131667533 T 0.8 Clonal
Patient 2, Organoids late p. CFB p.Ile744Val missense_variant 0.791 0 110 115 . . . . . FALSE 6 31915584 G 1 Clonal
Patient 2, Organoids late p. DNAH8 p.Ser1436Arg missense_variant 0.103 0 58 15 . . . . . FALSE 6 38802396 G 0.53 Subclonal
Patient 2, Organoids late p. RIMS1 p.Lys718Asn missense_variant 0.149 0 87 16 . . . . . FALSE 6 72957743 T 0.76 Clonal
Patient 2, Organoids late p. ASCC3 c.6075+2T>G splice_donor_variant&intron_variant 0.188 0 48 9 . . . . . FALSE 6 100964054 C 0.95 Clonal
Patient 2, Organoids late p. KIAA1919 p.Gln415Pro missense_variant 0.186 0 118 65 . . . . . FALSE 6 111588009 C 0.95 Clonal
Patient 2, Organoids late p. AGPAT4 p.Glu149Gln missense_variant 0.213 0 221 189 . . . . . FALSE 6 161575246 G 1 Clonal
Patient 2, Organoids late p. SDIM1 p.Arg56Gly missense_variant 0.045 0 89 64 . . . . . FALSE 6 166307988 C 0.23 Subclonal
Patient 2, Organoids late p. POU6F2 p.Gly132Val missense_variant 0.26 0 97 45 . . . . . TRUE 7 39247103 T 1 Clonal
Patient 2, Organoids late p. COPS6 p.Phe168Leu missense_variant 0.488 0 43 54 . . . . . TRUE 7 99688542 A 1 Clonal
Patient 2, Organoids late p. CREB3L2 p.Lys325Glu missense_variant&splice_region_variant 1 0 40 26 TRUE . . . . TRUE 7 137588706 C 1 Clonal
Patient 2, Organoids late p. MGAM p.Ser1292Ser synonymous_variant 0.175 0 40 38 . . . . . TRUE 7 141759328 T 0.71 Clonal
Patient 2, Organoids late p. MGAM p.Ser2188Ser synonymous_variant 0.083 0 168 74 . . . . . TRUE 7 141785689 T 0.34 Subclonal
Patient 2, Organoids late p. NOS3 p.Ala181Thr missense_variant 0.333 0.026 30 38 . . . . . TRUE 7 150693972 A 1 Clonal
Patient 2, Organoids late p. NUGGC p.Thr176Thr synonymous_variant 0.154 0 39 24 . . . . . FALSE 8 27925214 T 0.63 Subclonal
Patient 2, Organoids late p. WRN p.Ala1179Ser missense_variant 0.304 0 92 28 TRUE . . . . FALSE 8 31004955 T 1 Clonal
Patient 2, Organoids late p. NSMAF p.Glu12* stop_gained 0.395 0 39 23 . . . . . FALSE 8 59571872 A 1 Clonal
Patient 2, Organoids late p. CA8 p.Pro63Pro synonymous_variant 0.056 0 269 79 . . . . . FALSE 8 61192351 A 0.34 Subclonal
Patient 2, Organoids late p. CSMD3 p.Asp293Asn missense_variant 0.232 0 194 25 . . . . . FALSE 8 114111025 T 1 Clonal
Patient 2, Organoids late p. ADCY8 p.His239Asn missense_variant 0.093 0 172 22 . . . . . FALSE 8 132051865 T 1 Clonal
Patient 2, Organoids late p. CNTLN p.Lys862Thr missense_variant 1 0 53 21 . . . . . TRUE 9 17395037 C 1 Clonal
Patient 2, Organoids late p. TRMT10B p.Thr195Thr synonymous_variant 1 0 116 71 . . . . . TRUE 9 37769949 C 1 Clonal
Patient 2, Organoids late p. C9orf64 p.Ile114Met missense_variant 0.978 0 46 32 . . . . . TRUE 9 86570551 C 1 Clonal
Patient 2, Organoids late p. TSC1 p.Gln767* stop_gained 0.99 0 202 173 TRUE . TRUE . . TRUE 9 135778084 A 1 Clonal
Patient 2, Organoids late p. PRKCQ p.Asn462Asn synonymous_variant 0.734 0 244 79 . . . . . FALSE 10 6506334 A 1 Clonal
Patient 2, Organoids late p. MASTL p.Arg793fs frameshift_variant 0.0522193 0 383 91 . . . . . FALSE 10 27469988 G 0.42 Subclonal
Patient 2, Organoids late p. HK1 c.2481-1G>A splice_acceptor_variant&intron_variant 1 0 55 73 . . . . . TRUE 10 71158350 A 1 Clonal
Patient 2, Organoids late p. SFXN3 p.Val222Val synonymous_variant 0.967 0 30 50 . . . . . TRUE 10 102796893 T 1 Clonal
Patient 2, Organoids late p. EPS8L2 p.Asp172Tyr missense_variant 0.742 0 62 84 . . . . . FALSE 11 720735 T 1 Clonal
Patient 2, Organoids late p. HPX p.Ser288Gly missense_variant 0.814 0 43 60 . . . . . FALSE 11 6453221 C 1 Clonal
Patient 2, Organoids late p. DCHS1 p.Leu644Gln missense_variant 0.656 0 160 168 . . . . . FALSE 11 6655404 T 1 Clonal
Patient 2, Organoids late p. NELL1 p.Val349Leu missense_variant 0.2 0 50 23 . . . . . FALSE 11 20949989 C 0.82 Clonal
Patient 2, Organoids late p. KIAA1549L p.Gly1602Gly synonymous_variant 0.522 0 23 17 . . . . . FALSE 11 33667501 A 1 Clonal
Patient 2, Organoids late p. OR8K5 p.Pro283Ser missense_variant 0.185185 0 108 22 . . . . . FALSE 11 55926947 A 0.76 Clonal
Patient 2, Organoids late p. OR9Q1 p.Thr278Ala missense_variant 0.43 0 79 40 . . . . . FALSE 11 57947748 G 1 Clonal
Patient 2, Organoids late p. MS4A12 p.Pro255Pro synonymous_variant 0.445 0 209 82 . . . . . FALSE 11 60274558 A 1 Clonal
Patient 2, Organoids late p. LRP5 p.His965Asp missense_variant 0.208 0 448 407 . . . . . FALSE 11 68183861 G 0.85 Clonal
Patient 2, Organoids late p. SYTL2 p.Glu1611Val missense_variant 0.484 0 63 26 . . . . . FALSE 11 85411617 A 1 Clonal
Patient 2, Organoids late p. ARHGEF12 p.Leu630Phe missense_variant 0.584 0 166 76 TRUE . . . . FALSE 11 120322267 T 1 Clonal
Patient 2, Organoids late p. TAS2R30 p.Val125Leu missense_variant 0.272 0 103 35 . . . . . TRUE 12 11286471 G 0.84 Clonal
Patient 2, Organoids late p. HDAC7 p.Pro472Leu missense_variant 0.792 0.013 77 76 . . . . . TRUE 12 48188637 A 1 Clonal
Patient 2, Organoids late p. KMT2D p.Met1530Val missense_variant 0.769 0 134 145 TRUE TRUE TRUE . . TRUE 12 49439953 C 1 Clonal
Patient 2, Organoids late p. C12orf42 p.Gly270Arg missense_variant 0.205 0 78 30 . . . . . TRUE 12 103696161 T 0.84 Clonal
Patient 2, Organoids late p. SVOP p.Asp79Asn missense_variant 0.237 0 59 29 . . . . . TRUE 12 109366201 T 0.97 Clonal
Patient 2, Organoids late p. ANKLE2 p.Gly46Gly synonymous_variant 0.166667 0 18 17 . . . . . TRUE 12 133338247 T 0.68 Clonal
Patient 2, Organoids late p. KPNA3 p.Leu323Leu synonymous_variant 0.5 0 94 36 . . . . . TRUE 13 50283771 A 1 Clonal
Patient 2, Organoids late p. MYCBP2 p.Met3453Val missense_variant 0.087 0 126 29 . . . . . TRUE 13 77667310 C 0.36 Subclonal
Patient 2, Organoids late p. MBNL2 p.Lys178Asn missense_variant 0.143 0 21 11 . . . . . TRUE 13 97995464 T 0.58 Subclonal
Patient 2, Organoids late p. SALL2 p.Pro365Leu missense_variant 0.767 0 91 95 . . . . . FALSE 14 21992768 A 1 Clonal
Patient 2, Organoids late p. AKAP6 p.Arg509* stop_gained 0.00806452 0 124 41 . . . . . FALSE 14 33015384 T 0.03 Subclonal
Patient 2, Organoids late p. SRSF5 p.Ser90Gly missense_variant 0.6 0 115 72 . . . . . FALSE 14 70235585 G 1 Clonal
Patient 2, Organoids late p. GOLGA5 p.Ala522Asp missense_variant 0.288 0.012 156 86 TRUE . . . . FALSE 14 93286126 A 0.89 Clonal
Patient 2, Organoids late p. DPH6 p.Leu45Gln missense_variant 1 0 67 22 . . . . . TRUE 15 35830653 T 1 Clonal
Patient 2, Organoids late p. PLA2G4E p.Cys505Phe missense_variant 0.2 0 25 21 . . . . . TRUE 15 42282390 A 0.82 Clonal
Patient 2, Organoids late p. SRRM2 p.Trp513* stop_gained 0.529 0 87 84 . . . . . FALSE 16 2812068 A 1 Clonal
Patient 2, Organoids late p. SLX4 p.Pro198Gln missense_variant 0.085 0.004926 176 203 . . . . . FALSE 16 3656642 T 0.35 Subclonal
Patient 2, Organoids late p. C16orf71 p.Glu92Gln missense_variant 0.281 0 57 49 . . . . . FALSE 16 4787945 C 1 Clonal
Patient 2, Organoids late p. C16orf89 p.Leu128Leu synonymous_variant 0.412 0 51 46 . . . . . FALSE 16 5112516 A 1 Clonal
Patient 2, Organoids late p. CDH11 p.Glu391Asp missense_variant 0.191 0 68 17 TRUE . . . . FALSE 16 65016031 A 0.97 Clonal
Patient 2, Organoids late p. DPEP3 p.Arg3Trp missense_variant 0.55 0 20 25 . . . . . FALSE 16 68014352 A 1 Clonal
Patient 2, Organoids late p. ZNF469 p.Thr3815Met missense_variant 0.132 0 76 83 . . . . . FALSE 16 88505322 T 0.67 Subclonal
Patient 2, Organoids late p. TP53 p.Arg209fs frameshift_variant 0.931373 0 102 81 TRUE TRUE TRUE TRUE . TRUE 17 7578221 T 1 Clonal
Patient 2, Organoids late p. MFAP4 p.Pro33Leu missense_variant 0.181 0 116 74 . . . . . TRUE 17 19290135 A 0.74 Subclonal
Patient 2, Organoids late p. RARA p.Asp449Asp synonymous_variant 0.25 0 32 40 TRUE . . . . TRUE 17 38512388 T 1 Clonal
Patient 2, Organoids late p. KRTAP4-11 p.Arg51Lys missense_variant 0.063 0 80 31 . . . . . TRUE 17 39274416 T 0.32 Subclonal
Patient 2, Organoids late p. HOXB5 p.Arg224Leu missense_variant 0.173 0 81 74 . . . . . TRUE 17 46669710 A 0.88 Clonal
Patient 2, Organoids late p. AKAP1 p.Leu832Val missense_variant 0.255 0 51 32 . . . . . TRUE 17 55194282 G 1 Clonal
Patient 2, Organoids late p. USH1G p.Thr100Lys missense_variant 0.147 0 231 165 . . . . . TRUE 17 72916632 T 0.75 Subclonal
Patient 2, Organoids late p. DDC8 p.Gln416* stop_gained 0.123 0 138 100 . . . . . TRUE 17 76887340 A 0.63 Subclonal
Patient 2, Organoids late p. FASN p.Leu1826fs frameshift_variant 0.19898 0 196 142 . . . . . TRUE 17 80041170 G 1 Clonal
Patient 2, Organoids late p. GALNT1 p.Arg426Cys missense_variant 0.6 0 15 12 . . . . . FALSE 18 33272261 T 1 Clonal
Patient 2, Organoids late p. FHOD3 p.Leu261Leu synonymous_variant 0.61 0 82 61 . . . . . FALSE 18 34182699 T 1 Clonal
Patient 2, Organoids late p. FHOD3 p.Arg1568His missense_variant 0.601 0 143 94 . . . . . FALSE 18 34349306 A 1 Clonal
Patient 2, Organoids late p. SMAD7 p.Pro215Leu missense_variant 0.536 0 28 49 . . . . . FALSE 18 46474777 A 1 Clonal
Patient 2, Organoids late p. DOT1L p.Ile1251Ile synonymous_variant 1 0.007519 95 134 . . . . . TRUE 19 2226273 T 1 Clonal
Patient 2, Organoids late p. ZNF414 p.Leu257Phe missense_variant 0.4 0 25 32 . . . . . TRUE 19 8576604 G 1 Clonal
Patient 2, Organoids late p. ADAMTS10 p.Val904Val synonymous_variant 0.667 0.011 69 94 . . . . . TRUE 19 8650493 T 1 Clonal
Patient 2, Organoids late p. MUC16 p.Leu12735Pro missense_variant&splice_region_variant 0.38 0 50 48 . . . . . TRUE 19 9015384 G 1 Clonal
Patient 2, Organoids late p. ZNF561 p.Arg441Pro missense_variant 0.985 0 133 110 . . . . . TRUE 19 9721015 G 1 Clonal
Patient 2, Organoids late p. RAVER1 p.Ala477Ala synonymous_variant 1 0 9 16 . . . . . TRUE 19 10431817 A 1 Clonal
Patient 2, Organoids late p. CAPN12 p.His686Arg missense_variant 1 0 25 33 . . . . . TRUE 19 39221764 C 1 Clonal
Patient 2, Organoids late p. MARK4 p.Gly258Gly synonymous_variant 0.064 0 48 75 . . . . . TRUE 19 45774954 A 0.19 Subclonal
Patient 2, Organoids late p. ERCC1 p.Gly133Gly synonymous_variant 1 0 118 147 . . . . . TRUE 19 45923608 A 1 Clonal
Patient 2, Organoids late p. RTN2 p.Ser211Ser synonymous_variant 0.373 0 118 153 . . . . . TRUE 19 45997605 C 1 Clonal
Patient 2, Organoids late p. GPR4 p.Pro359Pro synonymous_variant 0.38 0 92 106 . . . . . TRUE 19 46094048 T 1 Clonal
Patient 2, Organoids late p. PLCB4 p.Val86Phe missense_variant 0.75 0 76 30 . . . . . FALSE 20 9319571 T 1 Clonal
Patient 2, Organoids late p. MYH7B p.Ser797* stop_gained 0.417 0 103 90 . . . . . FALSE 20 33580985 A 1 Clonal
Patient 2, Organoids late p. SMTN p.Gln325Lys missense_variant 0.164 0 128 183 . . . . . FALSE 22 31486982 A 0.51 Subclonal
Patient 2, Organoids late p. SCML2 p.Thr408Ser missense_variant 0.058 0 69 12 . . . . . TRUE X 18276215 A Did not evaluate
Patient 2, Organoids late p. PPP1R3F p.Asn345Asn synonymous_variant 1 0 29 23 . . . . . TRUE X 49137899 T Did not evaluate
Patient 2, Organoids late p. HEPH p.Ala382Ser missense_variant 0.087 0 104 30 . . . . . TRUE X 65409699 T Did not evaluate











p-value term ID t name
4.4900E-09 GO:0048285 organelle fission
4.5000E-08 GO:0000280 nuclear division
5.5700E-07 GO:0007049 cell cycle
2.5600E-06 GO:0022402 cell cycle process
4.2100E-04 GO:0000278 mitotic cell cycle
4.8600E-02 GO:1903047 mitotic cell cycle process
3.7800E-08 GO:0051321 meiotic cell cycle
1.0700E-09 GO:1903046 meiotic cell cycle process
2.7300E-09 GO:0140013 meiotic nuclear division
1.1400E-06 GO:0007127 meiosis I
1.4800E-02 GO:0007140 male meiotic nuclear division
5.6000E-05 GO:0070192 chromosome organization involved in meiotic cell cycle
3.4900E-03 GO:0007059 chromosome segregation
1.7800E-03 GO:0098813 nuclear chromosome segregation
8.9800E-04 GO:0045132 meiotic chromosome segregation
2.0100E-02 GO:0045143 homologous chromosome segregation
3.7100E-02 GO:0007129 synapsis
5.4900E-04 GO:0006259 DNA metabolic process
2.8900E-03 GO:0006310 DNA recombination
4.2700E-02 GO:0035825 homologous recombination
4.2700E-02 GO:0007131 reciprocal meiotic recombination
2.3200E-02 GO:0000725 recombinational repair
2.8000E-02 GO:0006260 DNA replication
3.2500E-03 GO:0006261 DNA-dependent DNA replication
6.8300E-03 GO:0006302 double-strand break repair
2.1200E-02 GO:0000724 double-strand break repair via homologous recombination
4.9000E-02 GO:0033260 nuclear DNA replication
4.0200E-02 GO:1902969 mitotic DNA replication
3.8600E-02 GO:0007292 female gamete generation
9.6700E-03 GO:0000793 condensed chromosome
1.9800E-02 GO:0097159 organic cyclic compound binding
3.7700E-02 GO:0016887 ATPase activity
1.1900E-02 GO:0003677 DNA binding
1.5200E-02 GO:1901363 heterocyclic compound binding
4.3500E-02 KEGG:03440 Homologous recombination
3.2900E-05 REAC:176187 Activation of ATR in response to replication stress
3.4700E-03 REAC:68962 Activation of the pre-replicative complex
2.0900E-02 REAC:69306 DNA Replication
2.5100E-03 REAC:1640170 Cell Cycle
3.1400E-02 REAC:69278 Cell Cycle, Mitotic
6.1000E-03 REAC:69620 Cell Cycle Checkpoints
p-value term ID t name
4.7700E-02 GO:0070563 negative regulation of vitamin D receptor signaling pathway
2.1700E-02 KEGG:03320 PPAR signaling pathway
Upregulated
Downregulated
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